



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/10		A1	(11) International Publication Number: WO 97/29187 (43) International Publication Date: 14 August 1997 (14.08.97)
<p>(21) International Application Number: PCT/US97/01094</p> <p>(22) International Filing Date: 21 January 1997 (21.01.97)</p> <p>(30) Priority Data: 08/599,171 9 February 1996 (09.02.96) US 08/646,590 8 May 1996 (08.05.96) US</p> <p>(71) Applicant (for all designated States except US): RECOMBINANT BIOCATALYSIS, INC. [US/US]; 505 Coast Boulevard South, La Jolla, CA 92037-4616 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): WARREN, Patrick, V. [US/US]; 3507 Sheffield Avenue, Philadelphia, PA 19163 (US). SWANSON, Ronald, V. [US/US]; Apartment A, 309 Lemon Street, Media, PA 19063 (US).</p> <p>(74) Agents: HERRON, Charles, J. et al.; Carella, Byme, Bain, Gilfillan, Cecchi, Stewart, & Olstein, 6 Becker Farm Road, Roseland, NJ 07068 (US).</p>		<p>(81) Designated States: AU, CA, IL, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: TRANSAMINASES AND AMINOTRANSFERASES</p> <p>(57) Abstract</p> <p>Thermostable transaminase and aminotransferase enzymes derived from various <i>ammonifex</i>, <i>aquifex</i> and <i>pyrobaculum</i> organisms are disclosed. The enzymes are produced from native or recombinant host cells and can be utilized in the pharmaceutical, agricultural and other industries.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finnland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

TRANSAMINASES AND AMINOTRANSFERASES

This application is a continuation-in-part of copending U.S. serial no. 08/646,590 filed May 8, 1996 which is a continuation-in-part of copending U.S. serial no. 08/599,171 filed on February 9, 1996.

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production and isolation of such polynucleotides and polypeptides. More particularly, the polynucleotides and polypeptides of the present invention have been putatively identified as transaminases and/or aminotransferases. Aminotransferases are enzymes that catalyze the transfer of amino groups from α -amino to α -keto acids. They are also called transaminases.

The α -amino groups of the 20 L-amino acids commonly found in proteins are removed during the oxidative degradation of the amino acids. The removal of the α -amino groups, the first step in the catabolism of most of the L-amino acids, is promoted by aminotransferases (or transaminases). In these transamination reactions, the α -amino group is transferred to the α -carbon atom of α -ketoglutarate, leaving behind the

corresponding α -keto acid analog of the amino acid. There is no net deamination (*i.e.*, loss of amino groups) in such reactions because the α -ketoglutarate becomes aminated as the α -amino acid is deaminated. The effect of transamination reactions is to collect the amino groups from many different amino acids in the form of only one, namely, L-glutamate. The glutamate channels amino groups either into biosynthetic pathways or into a final sequence of reactions by which nitrogenous waste products are formed and then excreted.

Cells contain several different aminotransferases, many specific for α -ketoglutarate as the amino group acceptor. The aminotransferases differ in their specificity for the other substrate, the L-amino acid that donates the amino group, and are named for the amino group donor. The reactions catalyzed by the aminotransferases are freely reversible, having an equilibrium constant of about 1.0 ($\Delta G^0 = 0$ kJ/mol).

Aminotransferases are classic examples of enzymes catalyzing bimolecular ping-pong reactions. In such reactions the first substrate must leave the active site before the second substrate can bind. Thus the incoming amino acid binds to the active site, donates its amino group to pyridoxal phosphate, and departs in the form of an α -keto acid. Then the incoming α -keto acid is bound, accepts the amino group from pyridoxamine phosphate, and departs in the form of an amino acid.

The measurement of alanine aminotransferase and aspartate aminotransferase levels in blood serum is an important diagnostic procedure in medicine, used as an indicator of heart damage and to monitor recovery from the damage.

The polynucleotides and polypeptides of the present invention have been identified as transaminases and/or aminotransferases as a result of their enzymatic activity.

In accordance with one aspect of the present invention, there are provided novel enzymes, as well as active fragments, analogs and derivatives thereof.

In accordance with another aspect of the present invention, there are provided isolated nucleic acid molecules encoding the enzymes of the present invention including mRNAs, cDNAs, genomic DNAs as well as active analogs and fragments of such enzymes.

In accordance with another aspect of the present invention there are provided isolated nucleic acid molecules encoding mature polypeptides expressed by the DNA contained in ATCC Deposit No. _____.

In accordance with yet a further aspect of the present invention, there is provided a process for producing such polypeptides by recombinant techniques comprising culturing recombinant prokaryotic and/or eukaryotic host cells, containing a nucleic acid sequence of the present invention, under conditions promoting expression of said enzymes and subsequent recovery of said enzymes.

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing such enzymes, or polynucleotides encoding such enzymes for transferring an amino group from an α -amino acid to an α -keto acid. Most transaminases use L-amino acids as substrates, but as described below, it is also possible to convert the transaminases of the invention to use D-amino acids as substrates, thereby increasing their array of uses to include, for example, manufacture of synthetic pyrethroids and as components of β -lactam antibiotics. The transaminases of the invention are stable at high temperatures and in organic solvents and, thus, are superior for use with L- and/or D-amino acids for production of optically pure chiral compounds used in pharmaceutical, agricultural and other chemical industries.

In accordance with yet a further aspect of the present invention, there are also provided nucleic acid probes comprising nucleic acid molecules of sufficient length to hybridize to a nucleic acid sequence of the present invention.

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing such enzymes, or polynucleotides encoding such enzymes, for *in vitro* purposes related to scientific research, for example, to generate probes for identifying similar sequences which might encode similar enzymes from other organisms by using certain regions, *i.e.*, conserved sequence regions, of the nucleotide sequence.

These and other aspects of the present invention should be apparent to those skilled in the art from the teachings herein.

The following drawings are illustrative of embodiments of the invention and are not meant to limit the scope of the invention as encompassed by the claims.

Figure 1 is an illustration of the full-length DNA (SEQ ID NO:17) and corresponding deduced amino acid sequence (SEQ ID NO:25) of *Aquifex* aspartate transaminase A of the present invention. Sequencing was performed using a 378 automated DNA sequencer (Applied Biosystems, Inc.) for all sequences of the present invention.

Figure 2 is an illustration of the full-length DNA (SEQ ID NO:18) and corresponding deduced amino acid sequence (SEQ ID NO:26) of *Aquifex* aspartate aminotransferase B.

Figure 3 is an illustration of the full-length DNA (SEQ ID NO:19) and corresponding deduced amino acid sequence (SEQ ID NO:27) of *Aquifex* adenosyl-8-amino-7-oxononanoate aminotransferase.

Figure 4 is an illustration of the full-length DNA (SEQ ID NO:20) and corresponding deduced amino acid sequence (SEQ ID NO:28) of *Aquifex acetylornithine aminotransferase*.

Figure 5 is an illustration of the full-length DNA (SEQ ID NO:21) and corresponding deduced amino acid sequence (SEQ ID NO:29) of *Ammonifex degensii* aspartate aminotransferase.

Figure 6 is an illustration of the full-length DNA (SEQ ID NO:22) and corresponding deduced amino acid sequence (SEQ ID NO:30) of *Aquifex glucosamine:fructose-6-phosphate aminotransferase*.

Figure 7 is an illustration of the full-length DNA (SEQ ID NO:23) and corresponding deduced amino acid sequence (SEQ ID NO:31) of *Aquifex histidinol-phosphate aminotransferase*.

Figure 8 is an illustration of the full-length DNA (SEQ ID NO:24) and corresponding deduced amino acid sequence (SEQ ID NO:32) of *Pyrobaculum aerophilum* branched chain aminotransferase.

Figure 9 is an illustration of the full-length DNA (SEQ ID NO:35) and corresponding deduced amino acid sequence (SEQ ID NO:36) of *Ammonifex degensii* histidinol phosphate aminotransferase.

Figure 10 is an illustration of the full-length DNA (SEQ ID NO:39) and corresponding deduced amino acid sequence (SEQ ID NO:40) of *Aquifex* aspartate aminotransferase.

Figure 11 is a diagrammatic illustration of the assay used to assess aminotransferase activity of the proteins using glutamate dehydrogenase.

The term "gene" means the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons).

A coding sequence is "operably linked to" another coding sequence when RNA polymerase will transcribe the two coding sequences into a single mRNA, which is then translated into a single polypeptide having amino acids derived from both coding sequences. The coding sequences need not be contiguous to one another so long as the expressed sequences ultimately process to produce the desired protein.

"Recombinant" enzymes refer to enzymes produced by recombinant DNA techniques; *i.e.*, produced from cells transformed by an exogenous DNA construct encoding the desired enzyme. "Synthetic" enzymes are those prepared by chemical synthesis.

A DNA "coding sequence of" or a "nucleotide sequence encoding" a particular enzyme, is a DNA sequence which is transcribed and translated into an enzyme when placed under the control of appropriate regulatory sequences.

In accordance with an aspect of the present invention, there are provided isolated nucleic acids (polynucleotides) which encode for the mature enzymes having the deduced amino acid sequences of Figures 1-8 (SEQ ID NOS:17-32).

In accordance with another aspect of the present invention, there are provided isolated polynucleotides encoding the enzymes of the present invention. The deposited material is a mixture of genomic clones comprising DNA encoding an enzyme of the present invention. Each genomic clone comprising the respective DNA has been inserted into a pQE vector (Qiagen, Inc., Chatsworth, CA). The deposit has been deposited with the American Type Culture Collection, 12301 Parklawn Drive,

Rockville, Maryland 20852, USA, on December 13, 1995 and assigned ATCC Deposit No. _____.

The deposit(s) have been made under the terms of the Budapest Treaty on the International Recognition of the deposit of micro-organisms for purposes of patent procedure. The strains will be irrevocably and without restriction or condition released to the public upon the issuance of a patent. These deposits are provided merely as convenience to those of skill in the art and are not an admission that a deposit would be required under 35 U.S.C. §112. The sequences of the polynucleotides contained in the deposited materials, as well as the amino acid sequences of the polypeptides encoded thereby, are controlling in the event of any conflict with any description of sequences herein. A license may be required to make, use or sell the deposited materials, and no such license is hereby granted.

The polynucleotides of this invention were originally recovered from genomic DNA libraries derived from the following organisms:

Aquifex VF5 is a Eubacteria which was isolated in Vulcano, Italy. It is a gram-negative, rod-shaped, strictly chemolithoautotrophic, marine organism which grows optimally at 85-90°C ($T_{max}=95^{\circ}\text{C}$) at pH 6.8 in a high salt culture medium with O_2 as a substrate, and $\text{H}_2/\text{CO}_2+0.5\% \text{ O}_2$ in gas phase.

Ammonifex degensii KC4 is a new Eubacterial organism isolated in Java, Indonesia. This Gram negative chemolithoautotroph has three respiration systems. The bacterium can utilize nitrate, sulfate, and sulfur. The organism grows optimally at 70°C, and pH 7.0, in a low salt culture medium with 0.2% nitrate as a substrate and H_2/CO_2 in gas phase.

Pyrobaculum aerophilum IM2 is a thermophilic sulfur archaea (Crenarchaeota) isolated in Ischia Maronti, Italy. It is a rod-shaped organism that grows optimally at

100°C at pH 7.0 in a low salt culture medium with nitrate, yeast extract, peptone, and O₂ as substrates and N₂/CO₂, O₂ in gas phase.

Accordingly, the polynucleotides and enzymes encoded thereby are identified by the organism from which they were isolated, and are sometimes hereinafter referred to as "VF5/ATA" (Figure 1 and SEQ ID NOS:17 and 25), "VF5/AAB" (Figure 2 and SEQ ID NOS:18 and 26), "VF5/A87A" (Figure 3 and SEQ ID NOS:19 and 27), "VF5/AOA" (Figure 4 and SEQ ID NOS:20 and 28), "KC4/AA" (Figure 5 and SEQ ID NOS:21 and 29), "VF5/GF6PA" (Figure 6 and SEQ ID NOS:22 and 30), "VF5/HPA" (Figure 7 and SEQ ID NOS:23 and 31), "IM2/BCA" (Figure 8 and SEQ ID NOS:24 and 32), "KC4/HPA" (Figure 9 and SEQ ID NOS. 35 and 36) and "VF5/AA" (Figure 10 and SEQ ID NOS. 39 and 40).

The polynucleotides and polypeptides of the present invention show identity at the nucleotide and protein level to known genes and proteins encoded thereby as shown in Table 1.

Table 1

Enzyme	Gene w/closest Homology (Organism)	Protein Similarity (%)	Protein Identity (%)	DNA Identity (%)
VF5/ATA	<i>Bacillus subtilis</i>	57.5	38.3	50.1
VF5/AAB	<i>Sulfolobus solfataricus</i>	62.5	33.0	50.1
VF5/A87A	<i>Bacillus sphaericus BioA</i>	67.4	42.9	51
VF5/AOA	<i>Bacillus subtilis argD</i>	70.6	48.7	52.0
KC4/AA	<i>Bacillus YM-2 aspC</i>	72.6	52.7	52.0
VF5/GF6PA	<i>Rhizobium Leguminosarum NodM</i>	66.3	47.7	51.0
VF5/HPA	<i>Bacillus subtilis HisH/E. coli HisC (same gene)</i>	55.7	32.6	45.3
IM2/BCA	<i>E. coli iluE</i>	63.7	43.6	49.7
KC4/HPA	<i>Bacillus subtilis</i>	65.1	44.1	
VF5/AA	<i>Bacillus subtilis</i>	71.6	52.7	

All the clones identified in Table 1 encode polypeptides which have transaminase or aminotransferase activity.

One means for isolating the nucleic acid molecules encoding the enzymes of the present invention is to probe a gene library with a natural or artificially designed probe using art recognized procedures (see, for example: Current Protocols in Molecular Biology, Ausubel F.M. *et al.* (EDS.) Green Publishing Company Assoc. and John Wiley Interscience, New York, 1989, 1992). It is appreciated by one skilled in the art that the polynucleotides of SEQ ID NOS:17-24, 35 and 39 or fragments thereof (comprising at least 12 contiguous nucleotides), are particularly useful probes. Other particularly useful probes for this purpose are hybridizable fragments of the sequences

of SEQ ID NOS:1-9, 33-34 and 37-38 (*i.e.*, comprising at least 12 contiguous nucleotides).

With respect to nucleic acid sequences which hybridize to specific nucleic acid sequences disclosed herein, hybridization may be carried out under conditions of reduced stringency, medium stringency or even stringent conditions. As an example of oligonucleotide hybridization, a polymer membrane containing immobilized denatured nucleic acids is first prehybridized for 30 minutes at 45°C in a solution consisting of 0.9 M NaCl, 50 mM NaH₂PO₄, pH 7.0, 5.0 mM Na₂EDTA, 0.5% SDS, 10X Denhardt's, and 0.5 mg/mL polyriboadenylic acid. Approximately 2 X 10⁷ cpm (specific activity 4-9 X 10⁸ cpm/ug) of ³²P end-labeled oligonucleotide probe are then added to the solution. After 12-16 hours of incubation, the membrane is washed for 30 minutes at room temperature in 1X SET (150 mM NaCl, 20 mM Tris hydrochloride, pH 7.8, 1 mM Na₂EDTA) containing 0.5% SDS, followed by a 30 minute wash in fresh 1X-SET at T_m -10°C (T_m is minus 10°C) for the oligo-nucleotide probe. The membrane is then exposed to auto-radiographic film for detection of hybridization signals.

Stringent conditions means hybridization will occur only if there is at least 90% identity, preferably at least 95% identity and most preferably at least 97% identity between the sequences. *See J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory (1989)* which is hereby incorporated by reference in its entirety.

As used herein, a first DNA (RNA) sequence is at least 70% and preferably at least 80% identical to another DNA (RNA) sequence if there is at least 70% and preferably at least a 80% or 90% identity, respectively, between the bases of the first sequence and the bases of the another sequence, when properly aligned with each other, for example when aligned by BLASTN.

The present invention relates to polynucleotides which differ from the reference polynucleotide such that the changes are silent changes, for example the change does not or the changes do not alter the amino acid sequence encoded by the polynucleotide. The present invention also relates to nucleotide changes which result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference polynucleotide. In a preferred aspect of the invention these polypeptides retain the same biological action as the polypeptide encoded by the reference polynucleotide.

The polynucleotides of this invention were recovered from genomic gene libraries from the organisms listed in Table 1. Gene libraries were generated in the Lambda ZAP II cloning vector (Stratagene Cloning Systems). Mass excisions were performed on these libraries to generate libraries in the pBluescript phagemid. Libraries were generated and excisions were performed according to the protocols/methods hereinafter described.

The polynucleotides of the present invention may be in the form of RNA or DNA which DNA includes cDNA, genomic DNA, and synthetic DNA. The DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand. The coding sequences which encodes the mature enzymes may be identical to the coding sequences shown in Figures 1-8 (SEQ ID NOS:17-24) or may be a different coding sequence which coding sequence, as a result of the redundancy or degeneracy of the genetic code, encodes the same mature enzymes as the DNA of Figures 1-10 (SEQ ID NOS:17-24, 35 and 39).

The polynucleotides which encode for the mature enzymes of Figures 1-10 (SEQ ID NOS:25-32, 36 and 40) may include, but is not limited to: only the coding sequence for the mature enzyme; the coding sequence for the mature enzyme and additional coding sequence such as a leader sequence or a proprotein sequence; the coding sequence for the mature enzyme (and optionally additional coding sequence) and non-

coding sequence, such as introns or non-coding sequence 5' and/or 3' of the coding sequence for the mature enzyme.

Thus, the term "polynucleotide encoding an enzyme (protein)" encompasses a polynucleotide which includes only coding sequence for the enzyme as well as a polynucleotide which includes additional coding and/or non-coding sequence.

The present invention further relates to variants of the hereinabove described polynucleotides which encode for fragments, analogs and derivatives of the enzymes having the deduced amino acid sequences of Figures 1-10 (SEQ ID NOS:25-32, 36 and 40). The variant of the polynucleotide may be a naturally occurring allelic variant of the polynucleotide or a non-naturally occurring variant of the polynucleotide.

Thus, the present invention includes polynucleotides (SEQ ID NOS:17-24, 35 and 39) encoding the same mature enzymes as shown in Figures 1-10 as well as variants of such polynucleotides (SEQ ID NOS:17-24, 35 and 39) which variants encode for a fragment, derivative or analog of the enzymes of Figures 1-10. Such nucleotide variants include deletion variants, substitution variants and addition or insertion variants.

As hereinabove indicated, the polynucleotides may have a coding sequence which is a naturally occurring allelic variant of the coding sequences shown in Figures 1-10 (SEQ ID NOS:17-24, 35 and 39). As known in the art, an allelic variant is an alternate form of a polynucleotide sequence which may have a substitution, deletion or addition of one or more nucleotides, which does not substantially alter the function of the encoded enzyme. Also, using directed and other evolution strategies, one may make very minor changes in DNA sequence which can result in major changes in function.

Fragments of the full length gene of the present invention may be used as hybridization probes for a cDNA or a genomic library to isolate the full length DNA and to isolate other DNAs which have a high sequence similarity to the gene or similar

biological activity. Probes of this type preferably have at least 10, preferably at least 15, and even more preferably at least 30 bases and may contain, for example, at least 50 or more bases. The probe may also be used to identify a DNA clone corresponding to a full length transcript and a genomic clone or clones that contain the complete gene including regulatory and promotor regions, exons and introns. An example of a screen comprises isolating the coding region of the gene by using the known DNA sequence to synthesize an oligonucleotide probe. Labeled oligonucleotides having a sequence complementary or identical to that of the gene or portion of the gene sequences of the present invention are used to screen a library of genomic DNA to determine which members of the library the probe hybridizes to.

It is also appreciated that such probes can be and are preferably labeled with an analytically detectable reagent to facilitate identification of the probe. Useful reagents include but are not limited to radioactivity, fluorescent dyes or enzymes capable of catalyzing the formation of a detectable product. The probes are thus useful to isolate complementary copies of DNA from other sources or to screen such sources for related sequences.

The present invention further relates to polynucleotides which hybridize to the hereinabove-described sequences if there is at least 70%, preferably at least 90%, and more preferably at least 95% identity between the sequences. The present invention particularly relates to polynucleotides which hybridize under stringent conditions to the hereinabove-described polynucleotides. As herein used, the term "stringent conditions" means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences. The polynucleotides which hybridize to the hereinabove described polynucleotides in a preferred embodiment encode enzymes which either retain substantially the same biological function or activity as the mature enzyme encoded by the DNA of Figures 1-10 (SEQ ID NOS:17-24, 35 and 39).

Alternatively, the polynucleotide may have at least 15 bases, preferably at least 30 bases, and more preferably at least 50 bases which hybridize to any part of a polynucleotide of the present invention and which has an identity thereto, as hereinabove described, and which may or may not retain activity. For example, such polynucleotides may be employed as probes for the polynucleotides of SEQ ID NOS:17-24, 35 and 39 for example, for recovery of the polynucleotide or as a diagnostic probe or as a PCR primer.

Thus, the present invention is directed to polynucleotides having at least a 70% identity, preferably at least 90% identity and more preferably at least a 95% identity to a polynucleotide which encodes the enzymes of SEQ ID NOS:25-32, 36 and 40 as well as fragments thereof, which fragments have at least 15 bases, preferably at least 30 bases and most preferably at least 50 bases, which fragments are at least 90% identical, preferably at least 95% identical and most preferably at least 97% identical under stringent conditions to any portion of a polynucleotide of the present invention.

The present invention further relates to enzymes which have the deduced amino acid sequences of Figures 1-10 (SEQ ID NOS:17-24, 35 and 39) as well as fragments, analogs and derivatives of such enzyme.

The terms "fragment," "derivative" and "analog" when referring to the enzymes of Figures 1-10 (SEQ ID NOS:25-32, 36 and 40) means enzymes which retain essentially the same biological function or activity as such enzymes. Thus, an analog includes a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature enzyme.

The enzymes of the present invention may be a recombinant enzyme, a natural enzyme or a synthetic enzyme, preferably a recombinant enzyme.

The fragment, derivative or analog of the enzymes of Figures 1-10 (SEQ ID NOS:25-32, 36 and 40) may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature enzyme is fused with another compound, such as a compound to increase the half-life of the enzyme (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature enzyme, such as a leader or secretory sequence or a sequence which is employed for purification of the mature enzyme or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

The enzymes and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.

The term "isolated" means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or enzyme present in a living animal is not isolated, but the same polynucleotide or enzyme, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or enzymes could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.

The enzymes of the present invention include the enzymes of SEQ ID NOS:25-32, 36 and 40 (in particular the mature enzyme) as well as enzymes which have at least 70% similarity (preferably at least 70% identity) to the enzymes of SEQ ID NOS:25-32, 36 and 40 and more preferably at least 90% similarity (more preferably at least 90% identity) to the enzymes of SEQ ID NOS:25-32, 36 and 40 and still more preferably at least 95% similarity (still more preferably at least 95% identity) to the enzymes of SEQ

ID NOS:25-32, 36 and 40 and also include portions of such enzymes with such portion of the enzyme generally containing at least 30 amino acids and more preferably at least 50 amino acids.

As known in the art "similarity" between two enzymes is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one enzyme to the sequence of a second enzyme.

A variant, *i.e.* a "fragment", "analog" or "derivative" polypeptide, and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions, fusions and truncations, which may be present in any combination.

Among preferred variants are those that vary from a reference by conservative amino acid substitutions. Such substitutions are those that substitute a given amino acid in a polypeptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of the hydroxyl residues Ser and Thr, exchange of the acidic residues Asp and Glu, substitution between the amide residues Asn and Gln, exchange of the basic residues Lys and Arg and replacements among the aromatic residues Phe, Tyr.

Most highly preferred are variants which retain the same biological function and activity as the reference polypeptide from which it varies.

Fragments or portions of the enzymes of the present invention may be employed for producing the corresponding full-length enzyme by peptide synthesis; therefore, the fragments may be employed as intermediates for producing the full-length enzymes. Fragments or portions of the polynucleotides of the present invention may be used to synthesize full-length polynucleotides of the present invention.

The present invention also relates to vectors which include polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of enzymes of the invention by recombinant techniques.

Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector such as an expression vector. The vector may be, for example, in the form of a plasmid, a phage, *etc.* The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes of the present invention. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

The polynucleotides of the present invention may be employed for producing enzymes by recombinant techniques. Thus, for example, the polynucleotide may be included in any one of a variety of expression vectors for expressing an enzyme. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, *e.g.*, derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in the host.

The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.

The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. As representative examples of such promoters, there may be mentioned: LTR or SV40

promoter, the *E. coli*. *lac* or *trp*, the phage lambda P_L promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression.

In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in *E. coli*.

The vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein.

As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as *E. coli*, *Streptomyces*, *Bacillus subtilis*; fungal cells, such as yeast; insect cells such as *Drosophila S2* and *Spodoptera Sf9*; animal cells such as CHO, COS or Bowes melanoma; adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.

More particularly, the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example; Bacterial: pQE70,

pQE60, pQE-9 (Qiagen), pBluescript II KS, pTrc99a, pKK223-3, pDR540, pRIT2T (Pharmacia); Eukaryotic: pXT1, pSG5 (Stratagene) pSVK3, pBPV, pMSG, pSVL SV40 (Pharmacia). However, any other plasmid or vector may be used as long as they are replicable and viable in the host.

Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P_R, P_L and trp. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.

In a further embodiment, the present invention relates to host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., Battey, J., *Basic Methods in Molecular Biology*, (1986)).

The constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence. Alternatively, the enzymes of the invention can be synthetically produced by conventional peptide synthesizers.

Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook *et al.*, *Molecular Cloning*:

A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), the disclosure of which is hereby incorporated by reference.

Transcription of the DNA encoding the enzymes of the present invention by higher eukaryotes is increased by inserting an enhancer sequence into the vector. Enhancers are *cis*-acting elements of DNA, usually about from 10 to 300 bp that act on a promoter to increase its transcription. Examples include the SV40 enhancer on the late side of the replication origin bp 100 to 270, a cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, *e.g.*, the ampicillin resistance gene of *E. coli* and *S. cerevisiae* TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), α -factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated enzyme. Optionally, the heterologous sequence can encode a fusion enzyme including an N-terminal identification peptide imparting desired characteristics, *e.g.*, stabilization or simplified purification of expressed recombinant product.

Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hosts for transformation include *E.*

coli, *Bacillus subtilis*, *Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, although others may also be employed as a matter of choice.

As a representative but nonlimiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEM1 (Promega Biotec, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed.

Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.

Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, such methods are well known to those skilled in the art.

Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, *Cell*, 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome

binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

The enzyme can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.

The enzymes of the present invention may be a naturally purified product, or a product of chemical synthetic procedures, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect and mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the enzymes of the present invention may be glycosylated or may be non-glycosylated. Enzymes of the invention may or may not also include an initial methionine amino acid residue.

Transaminases are a group of key enzymes in the metabolism of amino acids and amino sugars and are found in all organisms from microbes to mammals. In the transamination reaction, an amino group is transferred from an amino acid to an α -keto acid. Pyridoxal phosphate is required as a co-factor to mediate the transfer of the amino group without liberation of ammonia.

Amino acids currently have applications as additives to animal feed, human nutritional supplements, components in infusion solutions, and synthetic intermediates for manufacture of pharmaceuticals and agricultural products. For example, L-glutamic

acid is best known as a flavor enhancer for human food. L-lysine and L-methionine are large volume additives to animal feed and human supplements. L-tryptophan and L-threonine have similar potential applications. L-phenylalanine and L-aspartic acid have very important market potential as key components in the manufacture of the low-calorie sweetener aspartame, and other promising low-calorie sweeteners have compositions containing certain amino acids as well. Infusion solutions require a large range of amino acids including those essential ones in human diets.

Transaminases are highly stereoselective, and most use L-amino acids as substrates. Using the approach disclosed in a commonly assigned, copending provisional application Serial No. 60/008,316, filed on December 7, 1995 and entitled "Combinatorial Enzyme Development," the disclosure of which is incorporated herein by reference in its entirety, one can convert the transaminases of the invention to use D-amino acids as substrates. Such conversion makes possible a broader array of transaminase applications. For instance, D-valine can be used in the manufacture of synthetic pyrethroids. D-phenylglycine and its derivatives can be useful as components of β -lactam antibiotics. Further, the thermostable transaminases have superior stability at higher temperatures and in organic solvents. Thus, they are better suited to utilize either L- and/or D-amino acids for production of optically pure chiral compounds used in pharmaceutical, agricultural, and other chemical manufactures.

There are a number of reasons to employ transaminases in industrial-scale production of amino acids and their derivatives.

- 1) Transaminases can catalyze stereoselective synthesis of D- or L-amino acids from their corresponding α -keto acids. Therefore no L- or D-isomers are produced, and no resolution is required.
- 2) Transaminases have uniformly high catalytic rates, capable of converting up to 400 μ moles of substrates per minute per mg enzyme.

3) Many required α -keto acids can be conveniently prepared by chemical synthesis at low cost.

4) The capital investment for an immobilized enzyme process using transaminases is much lower than for a large scale fermentation process, and productivity of the bioreactor is often an order of magnitude higher.

5) The technology is generally applicable to a broad range of D- or L-amino acids because transaminases exist with varying specificities. Such broad scope allows a number of different L- or D-amino acids to be produced with the same equipment and often the same biocatalyst.

Antibodies generated against the enzymes corresponding to a sequence of the present invention can be obtained by direct injection of the enzymes into an animal or by administering the enzymes to an animal, preferably a nonhuman. The antibody so obtained will then bind the enzymes itself. In this manner, even a sequence encoding only a fragment of the enzymes can be used to generate antibodies binding the whole native enzymes. Such antibodies can then be used to isolate the enzyme from cells expressing that enzyme.

For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler and Milstein, *Nature*, 256:495-497, 1975), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* 4:72, 1983), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole *et al.*, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96, 1985).

Techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce single chain antibodies to immunogenic enzyme

products of this invention. Also, transgenic mice may be used to express humanized antibodies to immunogenic enzyme products of this invention.

Antibodies generated against an enzyme of the present invention may be used in screening for similar enzymes from other organisms and samples. Such screening techniques are known in the art, for example, one such screening assay is described in Sambrook and Maniatis, Molecular Cloning: A Laboratory Manual (2d Ed.), vol. 2:Section 8.49, Cold Spring Harbor Laboratory, 1989, which is hereby incorporated by reference in its entirety.

The present invention will be further described with reference to the following examples; however, it is to be understood that the present invention is not limited to such examples. All parts or amounts, unless otherwise specified, are by weight.

In order to facilitate understanding of the following examples certain frequently occurring methods and/or terms will be described.

"Plasmids" are designated by a lower case "p" preceded and/or followed by capital letters and/or numbers. The starting plasmids herein are either commercially available, publicly available on an unrestricted basis, or can be constructed from available plasmids in accord with published procedures. In addition, equivalent plasmids to those described are known in the art and will be apparent to the ordinarily skilled artisan.

"Digestion" of DNA refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements were used as would be known to the ordinarily skilled artisan. For analytical purposes, typically 1 μ g of plasmid or DNA fragment is used with about 2 units of enzyme in about 20 μ l of buffer solution. For the purpose of isolating DNA

fragments for plasmid construction, typically 5 to 50 μ g of DNA are digested with 20 to 250 units of enzyme in a larger volume. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer. Incubation times of about 1 hour at 37°C are ordinarily used, but may vary in accordance with the supplier's instructions. After digestion the reaction is electrophoresed directly on a polyacrylamide gel to isolate the desired fragment.

Size separation of the cleaved fragments is performed using 8 percent polyacrylamide gel described by Goeddel *et al.*, *Nucleic Acids Res.*, 8:4057 (1980).

"Oligonucleotides" refers to either a single stranded polydeoxynucleotide or two complementary polydeoxynucleotide strands which may be chemically synthesized. Such synthetic oligonucleotides have no 5' phosphate and thus will not ligate to another oligonucleotide without adding a phosphate with an ATP in the presence of a kinase. A synthetic oligonucleotide will ligate to a fragment that has not been dephosphorylated.

"Ligation" refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments (Maniatis, T., *et al.*, *Id.*, p. 146). Unless otherwise provided, ligation may be accomplished using known buffers and conditions with 10 units of T4 DNA ligase ("ligase") per 0.5 μ g of approximately equimolar amounts of the DNA fragments to be ligated.

Unless otherwise stated, transformation was performed as described in Sambrook and Maniatis, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1989.

Example 1**Bacterial Expression and Purification of Transaminases and Aminotransferases**

DNA encoding the enzymes of the present invention, SEQ ID NOS:25 through 32, 36 and 40 were initially amplified from a pBluescript vector containing the DNA by the PCR technique using the primers noted herein. The amplified sequences were then inserted into the respective PQE vector listed beneath the primer sequences, and the enzyme was expressed according to the protocols set forth herein. The genomic DNA has also been used as a template for the PCR amplification, *i.e.*, once a positive clone has been identified and primer sequences determined using the cDNA, it was then possible to return to the genomic DNA and directly amplify the desired sequence(s) there. The 5' and 3' primer sequences and the vector for the respective genes are as follows:

Aquifex Aspartate Transaminase A

aspA501 5' CCGAGAAATTCAATTAAAGAGGAGAAATTAACTATGATTGAAGACCCCTATGGAC (SEQ. ID NO:1)

aspA301 3' CGAAGATCTTAGCAGTTCTCAGGTTTC (SEQ. ID NO:2)

vector: pQET1

Aquifex Aspartate Aminotransferase B

aspB501 5' CCGAGAAATTCAATTAAAGAGGAGAAATTAACTATGGACAGGCTTGAAAAAGTA (SEQ ID NO:3)

aspB301 3' CGGAAGATCTTCAGCTAAGCTTCTCAAGAA (SEQ ID NO:4)

vector: pQET1

Aquifex Adenosyl-8-amino-7-oxononanoate Aminotransferase

ameth501 5' CCGACAATTGATTAAAGAGGAGAAATTAACTATGTGGATTAGACCCCTAAA (SEQ ID NO:5)

ameth301 3' CGGAGGATCCCTACACCTCTTTCAAGCT (SEQ ID NO:6)

vector: pQET12

Aquifex Acetylornithine Aminotransferase

aorn 501 5' CCGACAATTGATTAAAGAGGAGAAATTAACTATGACATACTTAATGAACAAT (SEQ ID NO:7)

aorn 301 3' CGGAAGATCTTATGAGAAGTCCCTTCAG (SEQ ID NO:8)

vector: pQET12

Ammonifex degensii Aspartate Aminotransferase

adasp 501 5' CCGAGAATTCAATTAAAGAGGAGAAATTAACTATGCGAAACTGGCCGAGCGG (SEQ ID NO:9)

adasp 301 3' CGGAGGATCCTTAAAGTGCCTCGATCAA (SEQ ID NO:10)

vector: pQET12

Aquifex Glucosamine:Fructose-6-phosphate Aminotransferase

glut 501 5' CCGACAATTGATTAAAGAGGAGAAATTAACTATGTGCGGGATAGTCGGATAC (SEQ ID NO:11)

glut 301 3' CGGAAGATCTTATTCCACCGTGACCGTTT (SEQ ID NO:12)

vector: pQET1

Aquifex Histidine-phosphate Aminotransferase

his 501 5' CCGACAATTGATTAAAGAGGAGAAATTAACTATGATAACCCAGAGGATTAAG (SEQ ID NO:13)

his 301 3' CGGAAGATCTTAAAGAGAGCTTGAAAGGGA (SEQ ID NO:14)

vector: pQET1

Pyrobaculum aerophilum Branched Chain Aminotransferase

bcat 501 5' CCGAGAATTCAATTAAAGAGGAGAAATTAACTATGAAGCCGTACGCTAAATAT (SEQ ID NO:15)

bcat 301 3' CGGAAGATCTCTAATACACAGGAGTGATCCA (SEQ ID NO:16)

vector: pQET1

Ammonifex degensii hp aminotransferase

5' -CCGAGAATTCAATTAAAGAGGAGAAATTAACTATGGCAGTCAAAGTGCAGCCT

3' -CGGAGGATCCTTATCCAAAGCTTCCAGGAAG

vector: pQET1

*Aquifex aspartate aminotransferase*5' CCGAGAATTCAATTAAAGAGGAGAAATTAACTATGAGAAAAGGACTTGCAAGT3' CGGAGGATCCTTAGATCTCTCAAGGGCTT

vector: pQET1

The restriction enzyme sites indicated correspond to the restriction enzyme sites on the bacterial expression vector indicated for the respective gene (Qiagen, Inc. Chatsworth, CA). The pQE vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter operator (P/O), a ribosome binding site (RBS), a 6-His tag and restriction enzyme sites.

The pQE vector was digested with the restriction enzymes indicated. The amplified sequences were ligated into the respective pQE vector and inserted in frame with the sequence encoding for the RBS. The ligation mixture was then used to transform the *E. coli* strain M15/pREP4 (Qiagen, Inc.) by electroporation. M15/pREP4 contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants were identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies were selected. Plasmid DNA was isolated and confirmed by restriction analysis. Clones containing the desired constructs were grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture was used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells were grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG ("Isopropyl-B-D-thiogalacto pyranoside") was then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression. Cells were grown an extra 3 to 4 hours. Cells were then harvested by centrifugation.

The primer sequences set out above may also be employed to isolate the target gene from the deposited material by hybridization techniques described above.

Example 2**Isolation of a Selected Clone from the Deposited Genomic Clones**

The two oligonucleotide primers corresponding to the gene of interest are used to amplify the gene from the deposited material. A polymerase chain reaction is carried out in 25 μ l of reaction mixture with 0.1 μ g of the DNA of the gene of interest. The reaction mixture is 1.5-5 mM MgCl₂, 0.01% (w/v) gelatin, 20 μ M each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 1.25 Unit of Taq polymerase. Thirty cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with the Perkin-Elmer Cetus 9600 thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the gene of interest by subcloning and sequencing the DNA product.

Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, within the scope of the appended claims, the invention may be practiced otherwise than as particularly described.

FIGURE 6

ATG TGC GGG ATA GTC GGA TAC GTA GGG AGG GAT TTA GCC CTT CCT ATA Met Cys Gly Ile Val Gly Tyr Val Gly Arg Asp Leu Ala Leu Pro Ile 5 10 15	48
GTC CTC GGA GCT CTT GAG AGA CTC GAA TAC AGG GGT TAC GAC TCC GCG Val Leu Gly Ala Leu Glu Arg Leu Glu Tyr Arg Gly Tyr Asp Ser Ala 20 25 30	96
GGA GTT GCC CTT ATA GAA GAC GGG AAA CTC ATA GTT GAA AAG AAG AAG Gly Val Ala Leu Ile Glu Asp Gly Lys Leu Ile Val Glu Lys Lys Lys 35 40 45	144
GGA AAG ATA AGG GAA CTC GTT AAA GCG CTA TGG GGA AAG GAT TAC AAG Gly Lys Ile Arg Glu Leu Val Lys Ala Leu Trp Gly Lys Asp Tyr Lys 50 55 60	192
GCT AAA ACG GGT ATA GGT CAC ACA CGC TGG GCA ACC CAC GGA AAG CCC Ala Lys Thr Gly Ile Gly His Thr Arg Trp Ala Thr His Gly Lys Pro 65 70 75 80	240
ACG GAC GAG AAC GCC CAC CCC CAC ACC GAC GAA AAA GGT GAG TTT GCA Thr Asp Glu Asn Ala His Pro His Thr Asp Glu Lys Gly Glu Phe Ala 85 90 95	288
GTA GTT CAC AAC GGG ATA ATA GAA AAC TAC TTA GAA CTA AAA GAG GAA Val Val His Asn Gly Ile Ile Glu Asn Tyr Leu Glu Leu Lys Glu Glu 100 105 110	336
CTA AAG AAG GAA GGT GTA AAG TTC AGG TCC GAA ACA GAC ACA GAA GTT Leu Lys Glu Gly Val Lys Phe Arg Ser Glu Thr Asp Thr Glu Val 115 120 125	384
ATA GCC CAC CTC ATA GCG AAG AAC TAC AGG GGG GAC TTA CTG GAG GCC Ile Ala His Leu Ile Ala Lys Asn Tyr Arg Gly Asp Leu Leu Glu Ala 130 135 140	432
GTT TTA AAA ACC GTA AAG AAA TTA AAG GGT GCT TTT GCC TTT GCG GTT Val Leu Lys Thr Val Lys Lys Leu Lys Gly Ala Phe Ala Phe Ala Val 145 150 155 160	480
ATA ACG GTT CAC GAA CCA AAC AGA CTA ATA GGA GTG AAG CAG GGG AGT Ile Thr Val His Glu Pro Asn Arg Leu Ile Gly Val Lys Gln Gly Ser 165 170 175	528
CCT TTA ATC GTC GGA CTC GGA GAA GGA AAC TTC CTC GCT TCA GAT Pro Leu Ile Val Gly Leu Gly Glu Gly Glu Asn Phe Leu Ala Ser Asp 180 185 190	576
ATT CCC GCA ATA CTT CCT TAC ACG AAA AAG ATT ATT GTT CTT GAT GAC Ile Pro Ala Ile Leu Pro Tyr Thr Lys Lys Ile Ile Val Leu Asp Asp 195 200 205	624
GGG GAA ATA GCG GAC CTG ACT CCC GAC ACT GTG AAC ATT TAC AAC TTT Gly Glu Ile Ala Asp Leu Thr Pro Asp Thr Val Asn Ile Tyr Asn Phe 210 215 220	672
GAG GGA GAG CCC GTT TCA AAG GAA GTA ATG ATT ACG CCC TGG GAT CTT Glu Gly Glu Pro Val Ser Lys Glu Val Met Ile Thr Pro Trp Asp Leu 225 230 235 240	720

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANTS:

WARREN, Patrick V.

SWANSON, Ronald V.

(ii) TITLE OF INVENTION:

TRANSAMINASES AND AMINOTRANSFERASES

(iii) NUMBER OF SEQUENCES: 40

(iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: CARELLA, BYRNE, BAIN, GILFILLAN, CECCHI, STEWART & OLSTEIN
- (B) STREET: 6 BECKER FARM ROAD
- (C) CITY: ROSELAND
- (D) STATE: NEW JERSEY
- (E) COUNTRY: USA
- (F) ZIP: 07068

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: 3.5 INCH DISKETTE
- (B) COMPUTER: IBM PS/2
- (C) OPERATING SYSTEM: MS-DOS
- (D) SOFTWARE: WORD PERFECT 5.1

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER: Unassigned
- (B) FILING DATE: Concurrently
- (C) CLASSIFICATION: Unassigned

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- (C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: HERRON, CHARLES J.
- (B) REGISTRATION NUMBER: 28,019
- (C) REFERENCE/DOCKET NUMBER: 331400-38

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: 201-994-1700
- (B) TELEFAX: 201-994-1744

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 52 NUCLEOTIDES
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CCGAGAATTC ATAAAGAGG AGAAATTAAC TATGATTGAA GACCCTATGG AC

52

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 31 NUCLEOTIDES
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CGGAAGATCT TTAAGCACTT CTCTCAGGTT C

31

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 52 NUCLEOTIDES
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CCGAGAATTC ATAAAGAGG AGAAATTAAC TATGGACAGG CTTGAAAAG TA

52

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 31 NUCLEOTIDES
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CGGAAGATCT TCAGCTAACG TTCTCTAAGA A

31

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 52 NUCLEOTIDES
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CCGACAATTG ATAAAGAGG AGAAATTAAC TATGTGGAA TTAGACCCTA AA

52

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 31 NUCLEOTIDES
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CGGAGGATCC CTACACCTGT TTTTCAAGCT C

31

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 52 NUCLEOTIDES
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CCGACAATTG ATAAAGAGG AGAAATTAAC TATGACATAC TTAATGAACA AT

52

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 31 NUCLEOTIDES
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CGGAAGATCT TTATGAGAAG TCCCTTTCAA G

31

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 52 NUCLEOTIDES
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CCGAGAATTC ATAAAGAGG AGAAATTAAC TATGCGGAAA CTGGCCGAGC GG

52

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 31 NUCLEOTIDES
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CGGAGGATCC TTAAAGTGCC GCTTCGATCA A

31

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 52 NUCLEOTIDES
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CCGACAATTG ATAAAGAGG AGAAATTAAC TATGTGCGGG ATAGTCGGAT AC

52

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 31 NUCLEOTIDES
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CGGAAGATCT TTATTCCACC GTGACCGTTT T

31

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 52 NUCLEOTIDES
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CCGACAATTG ATAAAGAGG AGAAATTAAC TATGATACCC CAGAGGATTA AG

52

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 31 NUCLEOTIDES
(B) TYPE: NUCLEIC ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CGGAAGATCT TTAAAGAGAG CTTGAAAGGG A

31

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 52 NUCLEOTIDES
(B) TYPE: NUCLEIC ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CCGAGAATTG ATAAAGAGG AGAAATTAAC TATGAAGCCG TACGCTAAAT AT

52

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 31 NUCLEOTIDES
(B) TYPE: NUCLEIC ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CGGAAGATCT CTAATACACA GGAGTGATCC A

31

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 1245 NUCLEOTIDES
(B) TYPE: NUCLEIC ACID
(C) STRANDEDNESS: SINGLE
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: GENOMIC DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

ATG ATT GAA GAC CCT ATG GAC TGG GCT TTT CCG AGG ATA AAG AGA CTG Met Ile Glu Asp Pro Met Asp Trp Ala Phe Pro Arg Ile Lys Arg Leu	48
5 10 15	
CCT CAG TAT GTC TTC TCT CTC GTT AAC GAA CTC AAG TAC AAG CTA AGG Pro Gln Tyr Val Phe Ser Leu Val Asn Glu Leu Lys Tyr Lys Leu Arg	96
20 25 30	
CGT GAA GGC GAA GAT GTA GTG GAT CTT GGT ATG GGC AAT CCT AAC ATG Arg Glu Gly Glu Asp Val Val Asp Leu Gly Met Gly Asn Pro Asn Met	144
35 40 45	
CCT CCA GCA AAG CAC ATA ATA GAT AAA CTC TGC GAA GTG GCT CAA AAG Pro Pro Ala Lys His Ile Ile Asp Lys Leu Cys Glu Val Ala Gln Lys	192
50 55 60	
CCG AAC GTT CAC GGA TAT TCT GCG TCA AGG GGC ATA CCA AGA CTG AGA Pro Asn Val His Gly Tyr Ser Ala Ser Arg Gly Ile Pro Arg Leu Arg	240
65 70 75 80	
AAG GCT ATA TGT AAC TTC TAC GAA GAA AGG TAC GGA GTG AAA CTC GAC Lys Ala Ile Cys Asn Phe Tyr Glu Glu Arg Tyr Gly Val Lys Leu Asp	288
85 90 95	
CCT GAG AGG GAG GCT ATA CTA ACA ATC GGT GCA AAG GAA GGG TAT TCT Pro Glu Arg Glu Ala Ile Leu Thr Ile Gly Ala Lys Glu Gly Tyr Ser	336
100 105 110	
CAT TTG ATG CTT GCG ATG ATA TCT CCG GGT GAT ACG GTA ATA GTT CCT His Leu Met Leu Ala Met Ile Ser Pro Gly Asp Thr Val Ile Val Pro	384
115 120 125	
AAT CCC ACC TAT CCT ATT CAC TAT TAC GCT CCC ATA ATT GCA GGA GGG Asn Pro Thr Tyr Pro Ile His Tyr Tyr Ala Pro Ile Ile Ala Gly Gly	432
130 135 140	
GAA GTT CAC TCA ATA CCC CTT AAC TTC TCG GAC GAT CAA GAT CAT CAG Glu Val His Ser Ile Pro Leu Asn Phe Ser Asp Asp Gln Asp His Gln	480
145 150 155 160	
GAA GAG TTT TTA AGG AGG CTT TAC GAG ATA GTA AAA ACC GCG ATG CCA Glu Glu Phe Leu Arg Arg Leu Tyr Glu Ile Val Lys Thr Ala Met Pro	528
165 170 175	
AAA CCC AAG GCT GTC ATA AGC TTT CCT CAC AAT CCA ACG ACC ATA Lys Pro Lys Ala Val Val Ile Ser Phe Pro His Asn Pro Thr Thr Ile	576
180 185 190	
ACG GTA GAA AAG GAC TTT TTT AAA GAA ATA GTT AAG TTT GCA AAG GAA Thr Val Glu Lys Asp Phe Phe Lys Glu Ile Val Lys Phe Ala Lys Glu	624
195 200 205	
CAC GGT CTC TGG ATA ATA CAC GAT TTT GCG TAT GCG GAT ATA GCC TTT His Gly Leu Trp Ile Ile His Asp Phe Ala Tyr Ala Asp Ile Ala Phe	672
210 215 220	

GAC GGT TAC AAG CCC CCC TCA ATA CTC GAA ATA GAA GGT GCT AAA GAC Asp Gly Tyr Lys Pro Pro Ser Ile Leu Glu Ile Glu Gly Ala Lys Asp 225 230 235 240	720
GTT GCG GTT GAG CTC TAC TCC ATG TCA AAG GGC TTT TCA ATG GCG GGC Val Ala Val Glu Leu Tyr Ser Met Ser Lys Gly Phe Ser Met Ala Gly 245 250 255	768
TGG AGG GTA GCC TTT GTC GTT GGA AAC GAA ATA CTC ATA AAA AAC CTT Trp Arg Val Ala Phe Val Val Gly Asn Glu Ile Leu Ile Lys Asn Leu 260 265 270	816
GCA CAC CTC AAA AGC TAC TTG GAT TAC GGT ATA TTT ACT CCC ATA CAG Ala His Leu Lys Ser Tyr Leu Asp Tyr Gly Ile Phe Thr Pro Ile Gln 275 280 285	864
GTG GCC TCT ATT ATC GCA TTA GAG AGC CCC TAC GAA ATC GTG GAA AAA Val Ala Ser Ile Ile Ala Leu Glu Ser Pro Tyr Glu Ile Val Glu Lys 290 295 300	912
ACC GCA AAG GTT TAC CAA AAA AGA AGA GAC GTT CTG GTG GAA GGG TTA Thr Ala Lys Val Tyr Gln Lys Arg Arg Asp Val Leu Val Glu Gly Leu 305 310 315 320	960
AAC AGG CTC GGC TGG AAA GTA AAA AAA CCT AAG GCT ACC ATG TTC GTC Asn Arg Leu Gly Trp Lys Val Lys Lys Pro Lys Ala Thr Met Phe Val 325 330 335	1008
TGG GCA AAG ATT CCC GAA TGG ATA AAT ATG AAC TCT CTG GAC TTT TCC Trp Ala Lys Ile Pro Glu Trp Ile Asn Met Asn Ser Leu Asp Phe Ser 340 345 350	1056
TTG TTC CTC CTA AAA GAG GCG AAG GTT GCG GTA TCC CCG GGT GTG GGC Leu Phe Leu Leu Lys Glu Ala Lys Val Ala Val Ser Pro Gly Val Gly 355 360 365	1104
TTT GGT CAG TAC GGA GAG GGG TAC GTA AGG TTT GCA CTT GTA GAA AAT Phe Gly Gln Tyr Gly Glu Gly Tyr Val Arg Phe Ala Leu Val Glu Asn 370 375 380	1152
GAA CAC AGG ATC AGA CAG GCT ATA AGG GGA ATA AGG AAA GCC TTC AGA Glu His Arg Ile Arg Gln Ala Ile Arg Gly Ile Arg Lys Ala Phe Arg 385 390 395 400	1200
AAA CTC CAG AAG GAG AGG AAA CTT GAA CCT GAG AGA AGT GCT TAA Lys Leu Gln Lys Glu Arg Lys Leu Glu Pro Glu Arg Ser Ala End 405 410 414	1245

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 1122 NUCLEOTIDES
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: GENOMIC DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

ATG GAC AGG CTT GAA AAA GTA TCA CCC TTC ATA GTA ATG GAT ATC CTA Met Asp Arg Leu Glu Lys Val Ser Pro Phe Ile Val Met Asp Ile Leu 5 10 15	48
GCT CAG GCC CAG AAG TAC GAA GAC GTA GTA CAC ATG GAG ATA GGA GAG Ala Gln Ala Gln Lys Tyr Glu Asp Val Val His Met Glu Ile Gly Glu 20 25 30	96
CCC GAT TTA GAA CCG TCT CCC AAG GTA ATG GAA GCT CTG GAA CGT GCG Pro Asp Leu Glu Pro Ser Pro Lys Val Met Glu Ala Leu Glu Arg Ala 35 40 45	144
GTG AAG GAA AAG ACG TTC TTC TAC ACC CCT GCT CTG GGA CTC TGG GAA Val Lys Glu Lys Thr Phe Phe Tyr Thr Pro Ala Leu Gly Leu Trp Glu 50 55 60	192
CTC AGG GAA AGG ATA TCG GAG TTT TAC AGG AAA AAG TAC AGC GTT GAA Leu Arg Glu Arg Ile Ser Glu Phe Tyr Arg Lys Lys Tyr Ser Val Glu 65 70 75 80	240
GTT TCT CCA GAG AGA GTC ATC GTA ACT ACC GGA ACT TCG GGA GCG TTT Val Ser Pro Glu Arg Val Ile Val Thr Thr Gly Thr Ser Gly Ala Phe 85 90 95	288
CTC GTA GCC TAC GCC GTA ACA CTA AAT GCG GGA GAG AAG ATA ATC CTC Leu Val Ala Tyr Ala Val Thr Leu Asn Ala Gly Glu Lys Ile Ile Leu 100 105 110	336
CCA GAC CCC TCT TAC CCC TGT TAC AAA AAC TTT GCC TAC CTC TTA GAC Pro Asp Pro Ser Tyr Pro Cys Tyr Lys Asn Phe Ala Tyr Leu Leu Asp 115 120 125	384
GCT CAG CCG GTT TTC GTA AAC GTT GAC AAG GAA ACG AAT TAC GAA GTA Ala Gln Pro Val Phe Val Asn Val Asp Lys Glu Thr Asn Tyr Glu Val 130 135 140	432
AGG AAA GAG ATG ATA GAA GAC ATT GAT GCG AAA GCC CTT CAC ATT TCC Arg Lys Glu Met Ile Glu Asp Ile Asp Ala Lys Ala Leu His Ile Ser 145 150 155 160	480
TCG CCT CAA AAC CCT ACG GGC ACA CTC TAC TCA CCT GAA ACC CTG AAG Ser Pro Gln Asn Pro Thr Gly Thr Leu Tyr Ser Pro Glu Thr Leu Lys 165 170 175	528
GAA CTT GCG GAG TAC TGC GAA GAG AAG GGT ATG TAC TTC ATA TCC GAC Glu Leu Ala Glu Tyr Cys Glu Glu Lys Gly Met Tyr Phe Ile Ser Asp 180 185 190	576
GAG ATT TAC CAC GGA CTC GTT TAC GAA GGT AGG GAG CAC ACA GCA CTT Glu Ile Tyr His Gly Leu Val Tyr Glu Gly Arg Glu His Thr Ala Leu 195 200 205	624
GAG TTC TCT GAC AGG GCT ATT GTC ATA AAC GGG TTT TCT AAG TAC TTC Glu Phe Ser Asp Arg Ala Ile Val Ile Asn Gly Phe Ser Lys Tyr Phe 210 215 220	672
TGT ATG CCA GGT TTC AGG ATA GGG TGG ATG ATA GTT CCG GAA GAA CTC Cys Met Pro Gly Phe Arg Ile Gly Trp Met Ile Val Pro Glu Glu Leu 225 230 235 240	720

GTG AGA AAG GCG GAA ATA GTA ATT CAG AAC GTA TTT ATA TCT GCC CCG Val Arg Lys Ala Glu Ile Val Ile Gln Asn Val Phe Ile Ser Ala Pro 245 250 255	768
ACG CTC AGT CAG TAC GCC GCC CTT GAG GCT TTT GAT TAC GAG TAT TTG Thr Leu Ser Gln Tyr Ala Ala Leu Glu Ala Phe Asp Tyr Glu Tyr Leu 260 265 270	816
GAG AAG GTA AGA AAA ACC TTT GAA GAG AGG AGG AAC TTC CTT TAT GGG Glu Lys Val Arg Lys Thr Phe Glu Glu Arg Arg Asn Phe Leu Tyr Gly 275 280 285	864
GAA CTG AAA AAA CTC TTC AAG ATA GAC GCG AAA CCT CAG GGA GCT TTT Glu Leu Lys Lys Leu Phe Lys Ile Asp Ala Lys Pro Gln Gly Ala Phe 290 295 300	912
TAC GTA TGG GCA AAC ATA AGT GAT TAC TCC ACA GAT AGC TAC GAA TTT Tyr Val Trp Ala Asn Ile Ser Asp Tyr Ser Thr Asp Ser Tyr Glu Phe 305 310 315 320	960
GCT TTA AAA CTT TTA AGG GAG GCG AGG GTG GCG GTA ACG CCC GGG GTG Ala Leu Lys Leu Arg Glu Ala Arg Val Ala Val Thr Pro Gly Val 325 330 335	1008
GAC TTT GGA AAA AAC AAA ACG AAG GAG TAT ATA AGG TTT GCT TAT ACG Asp Phe Gly Lys Asn Lys Thr Lys Glu Tyr Ile Arg Phe Ala Tyr Thr 340 345 350	1056
AGA AAG ATA GAA GAA CTT AAG GAG GGC GTT GAA AGG ATA AAG AAG TTC Arg Lys Ile Glu Glu Leu Lys Glu Gly Val Glu Arg Ile Lys Lys Phe 355 360 365	1104
TTA GAG AAG CTT AGC TGA Leu Glu Lys Leu Ser End 370	1122

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 1359 NUCLEOTIDES
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: GENOMIC DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

ATG TGG GAA TTA GAC CCT AAA ACG CTC GAA AAG TGG GAC AAG GAG TAC Met Trp Glu Leu Asp Pro Lys Thr Leu Glu Lys Trp Asp Lys Glu Tyr 5 10 15	48
TTC TGG CAT CCA TTT ACC CAG ATG AAA GTC TAC AGA GAA GAA GAA AAC Phe Trp His Pro Phe Thr Gln Met Lys Val Tyr Arg Glu Glu Glu Asn 20 25 30	96
CTG ATA TTT GAA CGC GGA GAA GGC GTT TAC CTG TGG GAC ATA TAC GGC Leu Ile Phe Glu Arg Gly Glu Val Tyr Leu Trp Asp Ile Tyr Gly 35 40 45	144

AGG AAG TAT ATA GAT GCC ATA TCT TCC CTC TGG TGC AAC GTC CAC GGA Arg Lys Tyr Ile Asp Ala Ile Ser Ser Leu Trp Cys Asn Val His Gly 50 55 60	192
CAT AAC CAC CCT AAA CTG AAC AAC GCA GTT ATG AAA CAG CTC TGT AAG His Asn His Pro Lys Leu Asn Ala Val Met Lys Gln Leu Cys Lys 65 70 75 80	240
GTA GCT CAC ACA ACT ACT CTG GGA AGT TCC AAC GTT CCC GCC ATA CTC Val Ala His Thr Thr Leu Gly Ser Ser Asn Val Pro Ala Ile Leu 85 90 95	288
CTT GCA AAG AAG CTT GTA GAA ATT TCT CCT GAA GGA TTA AAC AAG GTC Leu Ala Lys Lys Leu Val Glu Ile Ser Pro Glu Gly Leu Asn Lys Val 100 105 110	336
TTT TAC TCC GAA GAC GGT GCG GAA GCA GTA GAG ATA GCG ATA AAG ATG Phe Tyr Ser Glu Asp Gly Ala Glu Ala Val Glu Ile Ala Ile Lys Met 115 120 125	384
GCT TAT CAC TAC TGG AAG AAC AAG GGA GTT AAA GGG AAA AAC GTT TTC Ala Tyr His Tyr Trp Lys Asn Lys Gly Val Lys Gly Lys Asn Val Phe 130 135 140	432
ATA ACG CTT TCC GAA GCC TAC CAC GGG GAT ACT GTA GGA GCG GTT AGC Ile Thr Leu Ser Glu Ala Tyr His Gly Asp Thr Val Gly Ala Val Ser 145 150 155 160	480
GTA GGG GGT ATA GAA CTC TTC CAC GGA ACT TAT AAA GAT CTC CTT TTC Val Gly Ile Glu Leu Phe His Gly Thr Tyr Lys Asp Leu Leu Phe 165 170 175	528
AAG ACT ATA AAA CTC CCA TCT CCT TAC CTG TAC TGC AAG GAA AAG TAC Lys Thr Ile Lys Leu Pro Ser Pro Tyr Leu Tyr Cys Lys Glu Lys Tyr 180 185 190	576
GGG GAA CTC TGC CCT GAG TGC ACG GCA GAT TTA TTA AAA CAA CTG GAA Gly Glu Leu Cys Pro Glu Cys Thr Ala Asp Leu Leu Lys Gln Leu Glu 195 200 205	624
GAT ATC CTG AAG TCG CGG GAA GAT ATC GTT GCG GTC ATT ATG GAA GCG Asp Ile Leu Lys Ser Arg Glu Asp Ile Val Ala Val Ile Met Glu Ala 210 215 220	672
GGA ATT CAG GCA GCC GCG GGA ATG CTC CCC TTC CCT CCG GGA TTT TTG Gly Ile Gln Ala Ala Ala Gly Met Leu Pro Phe Pro Pro Gly Phe Leu 225 230 235 240	720
AAA GGC GTA AGG GAG CTT ACG AAG AAA TAC GAC ACT TTA ATG ATA GTT Lys Gly Val Arg Glu Leu Thr Lys Lys Tyr Asp Thr Leu Met Ile Val 245 250 255	768
GAC GAG GTT GCC ACG GGA TTT GGC AGG ACG GGA ACG ATG TTT TAC TGT Asp Glu Val Ala Thr Gly Phe Gly Arg Thr Gly Thr Met Phe Tyr Cys 260 265 270	816
GAG CAG GAA GGA GTC AGT CCG GAC TTT ATG TGT CTA GGT AAG GGT ATA Glu Gln Glu Gly Val Ser Pro Asp Phe Met Cys Leu Gly Lys Gly Ile 275 280 285	864

ACC GGA GGG TAC CTC CCG CTT GCT GCG ACA CTC ACA ACG GAC GAG GTG	912
Thr Gly Gly Tyr Leu Pro Leu Ala Ala Thr Leu Thr Thr Asp Glu Val	
290 295 300	
TTC AAT GCC TTT TTA GGT GAG TTC GGG GAG GCA AAG CAC TTT TAC CAC	960
Phe Asn Ala Phe Leu Gly Glu Phe Gly Glu Ala Lys His Phe Tyr His	
305 310 315 320	
GGG CAC ACC TAC ACT GGA AAT AAC CTC GCC TGT TCC GTT GCA CTC GCA	1008
Gly His Thr Tyr Thr Gly Asn Asn Leu Ala Cys Ser Val Ala Leu Ala	
325 330 335	
AAC TTA GAA GTT TTT GAG GAA GAA AGA ACT TTA GAG AAG CTC CAA CCA	1056
Asn Leu Glu Val Phe Glu Glu Glu Arg Thr Leu Glu Lys Leu Gln Pro	
340 345 350	
AAG ATA AAG CTT TTA AAG GAA AGG CTT CAG GAG TTC TGG GAA CTC AAG	1104
Lys Ile Lys Leu Leu Lys Glu Arg Leu Gln Glu Phe Trp Glu Leu Lys	
355 360 365	
CAC GTT GGA GAT GTT AGA CAG CTA GGT TTT ATG GCT GGA ATA GAG CTG	1152
His Val Gly Asp Val Arg Gln Leu Gly Phe Met Ala Gly Ile Glu Leu	
370 375 380	
GTG AAG GAC AAA GAA AAG GGA GAA CCT TTC CCT TAC GGT GAA AGG ACG	1200
Val Lys Asp Lys Glu Lys Gly Glu Pro Phe Pro Tyr Gly Glu Arg Thr	
385 390 395 400	
GGA TTT AAG GTG GCT TAC AAG TGC AGG GAA AAA GGG GTG TTT TTG AGA	1245
Gly Phe Lys Val Ala Tyr Lys Cys Arg Glu Lys Gly Val Phe Leu Arg	
405 410 415	
CCG CTC GGA GAC GTT ATG GTA TTG ATG ATG CCT CTT GTA ATA GAG GAA	1293
Pro Leu Gly Asp Val Met Val Leu Met Met Pro Leu Val Ile Glu Glu	
420 425 430	
GAC GAA ATG AAC TAC GTT ATT GAT ACA CTT AAA TGG GCA ATT AAA GAG	1341
Asp Glu Met Asn Tyr Val Ile Asp Thr Leu Lys Trp Ala Ile Lys Glu	
435 440 445	
CTT GAA AAA GAG GTG TAG	1359
Leu Glu Lys Glu Val End	
450	

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 1032 NUCLEOTIDES
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: GENOMIC DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

ATG ACA TAC TTA ATG AAC AAT TAC GCA AGG TTG CCC GTA AAG TTT GTA	48
Met Thr Tyr Leu Met Asn Asn Tyr Ala Arg Leu Pro Val Lys Phe Val	
5 10 15	

AGG GGA AAA GGT GTT TAC CTG TAC GAT GAG GAA GGA AAG GAG TAT CTT Arg Gly Lys Gly Val Tyr Leu Tyr Asp Glu Glu Gly Lys Glu Tyr Leu 20 25 30	96
GAC TTT GTC TCC GGT ATA GGC GTC AAC TCC CTC GGT CAC GCT TAC CCA Asp Phe Val Ser Gly Ile Gly Val Asn Ser Leu Gly His Ala Tyr Pro 35 40 45	144
AAA CTC ACA GAA GCT CTA AAA GAA CAG GTT GAG AAA CTC CTC CAC GTT Lys Leu Thr Glu Ala Leu Lys Glu Gln Val Glu Lys Leu Leu His Val 50 55 60	192
TCA AAT CTT TAC GAA AAC CCG TGG CAG GAA CTG GCT CAC AAA CTT Ser Asn Leu Tyr Glu Asn Pro Trp Gln Glu Leu Ala His Lys Leu 65 70 75 80	240
GTA AAA CAC TTC TGG ACA GAA GGG AAG GTA TTT TTC GCA AAC AGC GGA Val Lys His Phe Trp Thr Glu Gly Lys Val Phe Phe Ala Asn Ser Gly 85 90 95	288
ACG GAA AGT GTA GAG GCG GCT ATA AAG CTC GCA AGG AAG TAC TGG AGG Thr Glu Ser Val Glu Ala Ala Ile Lys Leu Ala Arg Lys Tyr Trp Arg 100 105 110	336
GAT AAA GGA AAG AAC AAG TGG AAG TTT ATA TCC TTT GAA AAC TCT TTC Asp Lys Gly Lys Asn Lys Trp Lys Phe Ile Ser Phe Glu Asn Ser Phe 115 120 125	384
CAC GGG AGA ACC TAC GGT AGC CTC TCC GCA ACG GGA CAG CCA AAG TTC His Gly Arg Thr Tyr Gly Ser Leu Ser Ala Thr Gly Gln Pro Lys Phe 130 135 140	432
CAC AAA GGC TTT GAA CCT CTA GTT CCT GGA TTT TCT TAC GCA AAG CTG His Lys Gly Phe Glu Pro Leu Val Pro Gly Phe Ser Tyr Ala Lys Leu 145 150 155 160	480
AAC GAT ATA GAC AGC GTT TAC AAA CTC CTA GAC GAG GAA ACC GCG GGG Asn Asp Ile Asp Ser Val Tyr Lys Leu Asp Glu Glu Thr Ala Gly 165 170 175	528
ATA ATT ATT GAA GTT ATA CAA GGA GAG GGC GGA GTA AAC GAG GCG AGT Ile Ile Ile Glu Val Ile Gln Gly Glu Gly Gly Val Asn Glu Ala Ser 180 185 190	576
GAG GAT TTT CTA AGT AAA CTC CAG GAA ATT TGT AAA GAA AAA GAT GTG Glu Asp Phe Leu Ser Lys Leu Gln Glu Ile Cys Lys Glu Lys Asp Val 195 200 205	624
CTC TTA ATT ATA GAC GAA GTG CAA ACG GGA ATA GGA AGG ACC GGG GAA Leu Leu Ile Ile Asp Glu Val Gln Thr Gly Ile Gly Arg Thr Gly Glu 210 215 220	672
TTC TAC GCA TAT CAA CAC TTC AAT CTA AAA CCG GAC GTA ATT GCG CTT Phe Tyr Ala Tyr Gln His Phe Asn Leu Lys Pro Asp Val Ile Ala Leu 225 230 235 240	720
GCG AAG GGA CTC GGA GGA GGT GTG CCA ATA GGT GCC ATC CTT GCA AGG Ala Lys Gly Leu Gly Gly Val Pro Ile Gly Ala Ile Leu Ala Arg 245 250 255	768

GAA GAA GTG GCC CAG AGC TTT ACT CCC GGC TCC CAC GGC TCT ACC TTC Glu Glu Val Ala Gln Ser Phe Thr Pro Gly Ser His Gly Ser Thr Phe 260 265 270	816
GGA GGA AAC CCC TTA GCC TGC AGG GCG GGA ACA GTG GTA GTA GAT GAA Gly Gly Asn Pro Leu Ala Cys Arg Ala Gly Thr Val Val Val Asp Glu 275 280 285	864
GTT GAA AAA CTC CTG CCT CAC GTA AGG GAA GTG GGG AAT TAC TTC AAA Val Glu Lys Leu Leu Pro His Val Arg Glu Val Gly Asn Tyr Phe Lys 290 295 300	912
GAA AAA CTG AAG GAA CTC GGC AAA GGA AAG GTA AAG GGA AGA GGA TTG Glu Lys Leu Lys Glu Leu Gly Lys Gly Lys Val Lys Gly Arg Gly Leu 305 310 315 320	960
ATG CTC GGT CTT GAA CTT GAA AGA GAG TGT AAA GAT TAC GTT CTC AAG Met Leu Gly Leu Glu Leu Arg Glu Cys Lys Asp Tyr Val Leu Lys 325 330 335	1008
GCT CTT GAA AGG GAC TTC TCA TAA Ala Leu Glu Arg Asp Phe Ser End 340	1032

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 1197 NUCLEOTIDES
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: GENOMIC DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

ATG CGG AAA CTG GCC GAG CGG GCG CAG AAA CTG AGC CCC TCT CCC ACC Met Arg Lys Leu Ala Glu Arg Ala Gln Lys Leu Ser Pro Ser Pro Thr 5 10 15	48
CTC TCG GTG GAC ACC AAG GCC AAG GAG CTT TTG CGG CAG GGG GAA AGG Leu Ser Val Asp Thr Lys Ala Lys Glu Leu Leu Arg Gln Gly Glu Arg 20 25 30	96
GTC ATC AAT TTC GGG GCG GGG GAG CCG GAC TTC GAT ACA CCG GAA CAC Val Ile Asn Phe Gly Ala Gly Glu Pro Asp Phe Asp Thr Pro Glu His 35 40 45	144
ATC AAG GAA GCG GCG AAG CGA GCT TTA GAT CAG GGC TTC ACC AAG TAC Ile Lys Glu Ala Ala Lys Arg Ala Leu Asp Gln Gly Phe Thr Lys Tyr 50 55 60	192
ACG CCG GTG GCT GGG ATC TTA CCT CTT CGG GAG GCC ATA TGC GAG AAG Thr Pro Val Ala Gly Ile Leu Pro Leu Arg Glu Ala Ile Cys Glu Lys 65 70 75 80	240
CTT TAC CGC GAC AAT CAA CTG GAA TAC AGC CCG AAT GAG ATC GTG GTC Leu Tyr Arg Asp Asn Gln Leu Glu Tyr Ser Pro Asn Glu Ile Val Val 85 90 95	288

TCC TGT GGC GCC AAG CAT TCT ATT TTC AAC GCT CTG CAG GTC CTC CTG Ser Cys Gly Ala Lys His Ser Ile Phe Asn Ala Leu Gln Val Leu Leu 100 105 110	336
GAC CCG GGG GAC GAG GTG ATA ATC CCC GTC CCC TAC TGG ACT TCC TAT Asp Pro Gly Asp Glu Val Ile Ile Pro Val Pro Tyr Trp Thr Ser Tyr 115 120 125	384
CCG GAG CAG GTG AAG CTG GCG GGA GGG GTG CCG GTT TTC GTC CCC ACC Pro Glu Gln Val Lys Leu Ala Gly Gly Val Pro Val Phe Val Pro Thr 130 135 140	432
TCT CCC GAG AAC GAC TTC AAG CTC AGG CCG GAA GAT CTA CGT GCG GCT Ser Pro Glu Asn Asp Phe Lys Leu Arg Pro Glu Asp Leu Arg Ala Ala 145 150 155 160	480
GTA ACC CCG CGC ACC CGC CTT TTG ATC CTC AAT TCC CCG GCC AAC CCC Val Thr Pro Arg Thr Arg Leu Leu Ile Leu Asn Ser Pro Ala Asn Pro 165 170 175	528
ACA GGC ACC GTT TAC CGC CGG GAG GAA CTT ATC GGC TTA GCG GAG GTA Thr Gly Thr Val Tyr Arg Arg Glu Glu Leu Ile Gly Leu Ala Glu Val 180 185 190	576
GCC CTG GAG GCC GAC CTA TGG ATC TTG TCG GAC GAG ATC TAC GAA AAG Ala Leu Glu Ala Asp Leu Trp Ile Leu Ser Asp Glu Ile Tyr Glu Lys 195 200 205	624
CTG ATC TAC GAC GGG ATG GAG CAC GTG AGC ATA GCC GCG CTC GAC CCG Leu Ile Tyr Asp Gly Met Glu His Val Ser Ile Ala Ala Leu Asp Pro 210 215 220	672
GAG GTC AAA AAG CGC ACG ATT GTG GTA AAC GGT GTT TCC AAG GCT TAC Glu Val Lys Lys Arg Thr Ile Val Val Asn Gly Val Ser Lys Ala Tyr 225 230 235 240	720
GCC ATG ACC GGT TGG CGC ATA GGT TAT GCT GCC GCT CCC CGG CCG ATA Ala Met Thr Gly Trp Arg Ile Gly Tyr Ala Ala Ala Pro Arg Pro Ile 245 250 255	768
GCC CAG GCC ATG ACC AAC CTC CAA AGC CAC AGT ACC TCT AAC CCC ACT Ala Gln Ala Met Thr Asn Leu Gln Ser His Ser Thr Ser Asn Pro Thr 260 265 270	816
TCC GTA GCC CAG GCG GCG CTG GCC GCT CTG AAG GGG CCA CAA GAG Ser Val Ala Gln Ala Ala Leu Ala Ala Leu Lys Gly Pro Gln Glu 275 280 285	864
CCG GTG GAG AAC ATG CGC CGG GCT TTT CAA AAG CGG CGG GAT TTC ATC Pro Val Glu Asn Met Arg Arg Ala Phe Gln Lys Arg Arg Asp Phe Ile 290 295 300	912
TGG CAG TAC CTA AAC TCC TTA CCC GGA GTG CGC TGC CCC AAA CCT TTA Trp Gln Tyr Leu Asn Ser Leu Pro Gly Val Arg Cys Pro Lys Pro Leu 305 310 315 320	960
GGG GCC TTT TAC GTC TTT CCA GAA GTT GAG CGG GCT TTT GGG CCG CCG Gly Ala Phe Tyr Val Phe Pro Glu Val Glu Arg Ala Phe Gly Pro Pro 325 330 335	1008

TCT AAA AGG ACG GGA AAT ACT ACC GCT AGC GAC CTG GCC CTT TTC CTC Ser Lys Arg Thr Gly Asn Thr Thr Ala Ser Asp Leu Ala Leu Phe Leu 340 345 350	1056
CTG GAA GAG ATA AAA GTG GCC ACC GTG GCT GGG GCT GCC TTT GGG GAC Leu Glu Glu Ile Lys Val Ala Thr Val Ala Gly Ala Ala Phe Gly Asp 355 360 365	1104
GAT CGC TAC CTG CGC TTT TCC TAC GCC CTG CGG CTG GAA GAT ATC GAA Asp Arg Tyr Leu Arg Phe Ser Tyr Ala Leu Arg Leu Glu Asp Ile Glu 370 375 380	1152
GAG GGG ATG CAA CGG TTT AAA GAA TTG ATC GAA GCG GCA CTT TAA Glu Gly Met Gln Arg Phe Lys Glu Leu Ile Glu Ala Ala Leu End 385 390 395	1197

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 1779 NUCLEOTIDES
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: GENOMIC DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

ATG TGC GGG ATA GTC GGA TAC GTA GGG AGG GAT TTA GCC CTT CCT ATA Met Cys Gly Ile Val Gly Tyr Val Gly Arg Asp Leu Ala Leu Pro Ile 5 10 15	48
GTC CTC GGA GCT CTT GAG AGA CTC GAA TAC AGG GGT TAC GAC TCC GCG Val Leu Gly Ala Leu Glu Arg Leu Glu Tyr Arg Gly Tyr Asp Ser Ala 20 25 30	96
GGA GTT GCC CTT ATA GAA GAC GGG AAA CTC ATA GTT GAA AAG AAG AAG Gly Val Ala Leu Ile Glu Asp Gly Lys Leu Ile Val Glu Lys Lys Lys 35 40 45	144
GGA AAG ATA AGG GAA CTC GTT AAA GCG CTA TGG GGA AAG GAT TAC AAG Gly Lys Ile Arg Glu Leu Val Lys Ala Leu Trp Gly Lys Asp Tyr Lys 50 55 60	192
GCT AAA ACG GGT ATA GGT CAC ACA CGC TGG GCA ACC CAC GGA AAG CCC Ala Lys Thr Gly Ile Gly His Thr Arg Trp Ala Thr His Gly Lys Pro 65 70 75 80	240
ACG GAC GAG AAC GCC CAC CCC CAC ACC GAC GAA AAA GGT GAG TTT GCA Thr Asp Glu Asn Ala His Pro His Thr Asp Glu Lys Gly Glu Phe Ala 85 90 95	288
GTA GTT CAC AAC GGG ATA ATA GAA AAC TAC TTA GAA CTA AAA GAG GAA Val Val His Asn Gly Ile Ile Glu Asn Tyr Leu Glu Leu Lys Glu Glu 100 105 110	336
CTA AAG AAG GAA GGT GTA AAG TTC AGG TCC GAA ACA GAC ACA GAA GTT Leu Lys Lys Glu Gly Val Lys Phe Arg Ser Glu Thr Asp Thr Glu Val 115 120 125	384

ATA GCC CAC CTC ATA GCG AAG AAC TAC AGG GGG GAC TTA CTG GAG GCC Ile Ala His Leu Ile Ala Lys Asn Tyr Arg Gly Asp Leu Leu Glu Ala 130 135 140	432
GTT TTA AAA ACC GTA AAG AAA TTA AAG GGT GCT TTT GCC TTT GCG GTT Val Leu Lys Thr Val Lys Lys Leu Lys Gly Ala Phe Ala Phe Ala Val 145 150 155 160	480
ATA ACG GTT CAC GAA CCA AAC AGA CTA ATA GGA GTG AAG CAG GGG AGT Ile Thr Val His Glu Pro Asn Arg Leu Ile Gly Val Lys Gln Gly Ser 165 170 175	528
CCT TTA ATC GTC GGA CTC GGA GAA GGA AAC TTC CTC GCT TCA GAT Pro Leu Ile Val Gly Leu Gly Glu Asn Phe Leu Ala Ser Asp 180 185 190	576
ATT CCC GCA ATA CTT CCT TAC ACG AAA AAG ATT ATT GTT CTT GAT GAC Ile Pro Ala Ile Leu Pro Tyr Thr Lys Lys Ile Ile Val Leu Asp Asp 195 200 205	624
GGG GAA ATA GCG GAC CTG ACT CCC GAC ACT GTG AAC ATT TAC AAC TTT Gly Glu Ile Ala Asp Leu Thr Pro Asp Thr Val Asn Ile Tyr Asn Phe 210 215 220	672
GAG GGA GAG CCC GTT TCA AAG GAA GTA ATG ATT ACG CCC TGG GAT CTT Glu Gly Glu Pro Val Ser Lys Glu Val Met Ile Thr Pro Trp Asp Leu 225 230 235 240	720
GTT TCT GCG GAA AAG GGT GGT TTT AAA CAC TTC ATG CTA AAA GAG ATA Val Ser Ala Glu Lys Gly Gly Phe Lys His Phe Met Leu Lys Glu Ile 245 250 255	768
TAC GAA CAG CCC AAA GCC ATA AAC GAC ACA CTC AAG GGT TTC CTC TCA Tyr Glu Gln Pro Lys Ala Ile Asn Asp Thr Leu Lys Gly Phe Leu Ser 260 265 270	816
ACC GAA GAC GCA ATA CCC TTT AAG TTA AAA GAC TTC AGA AGG GTT TTA Thr Glu Asp Ala Ile Pro Phe Lys Leu Lys Asp Phe Arg Arg Val Leu 275 280 285	864
ATA ATA GCG TGC GGG ACC TCT TAC CAC GCG GGC TTC GTC GGA AAG TAC Ile Ile Ala Cys Gly Thr Ser Tyr His Ala Gly Phe Val Gly Lys Tyr 290 295 300	912
TGG ATA GAG AGA TTT GCA GGT GTT CCC ACA GAG GTA ATT TAC GCT TCG Trp Ile Glu Arg Phe Ala Gly Val Pro Thr Glu Val Ile Tyr Ala Ser 305 310 315 320	960
GAA TTC AGG TAT GCG GAC GTT CCC GTT TCG GAC AAG GAT ATC GTT ATC Glu Phe Arg Tyr Ala Asp Val Pro Val Ser Asp Lys Asp Ile Val Ile 325 330 335	1008
GGA ATT TCC CAG TCA GGA GAG ACC GCT GAC ACA AAG TTT GCC CTT CAG Gly Ile Ser Gln Ser Gly Glu Thr Ala Asp Thr Lys Phe Ala Leu Gln 340 345 350	1056
TCC GCA AAG GAA AAG GGA GCC TTT ACC GTG GGA CTC GTA AAC GTA GTG Ser Ala Lys Glu Lys Gly Ala Phe Thr Val Gly Leu Val Asn Val Val 355 360 365	1104

GGA AGT GCC ATA GAC AGG GAG TCG GAC TTT TCC CTT CAC ACA CAT GCG Gly Ser Ala Ile Asp Arg Glu Ser Asp Phe Ser Leu His Thr His Ala 370 375 380	1152
GGA CCC GAA ATA GGC GTG GCG GCT ACA AAG ACC TTC ACC GCA CAG TTC Gly Pro Glu Ile Gly Val Ala Ala Thr Lys Thr Phe Thr Ala Gln Phe 385 390 395 400	1200
ACC GCA CTC TAC GCC CTT TCG GTA AGG GAA AGT GAG GAG AGG GAA AAT Thr Ala Leu Tyr Ala Leu Ser Val Arg Glu Ser Glu Glu Arg Glu Asn 405 410 415	1248
CTA ATA AGA CTC CTT GAA AAG GTT CCA TCA CTC GTT GAA CAA ACA CTG Leu Ile Arg Leu Leu Glu Lys Val Pro Ser Leu Val Glu Gln Thr Leu 420 425 430	1296
AAC ACC GCA GAA GAA GTG GAG AAG GTA GCG GAA AAG TAC ATG AAA AAG Asn Thr Ala Glu Glu Val Glu Lys Val Ala Glu Lys Tyr Met Lys Lys 435 440 445	1344
AAA AAC ATG CTT TAC CTC GGA AGG TAC TTA AAT TAC CCC ATA GCG CTG Lys Asn Met Leu Tyr Leu Gly Arg Tyr Leu Asn Tyr Pro Ile Ala Leu 450 455 460	1392
GAG GGA GCT CTT AAA CTT AAA GAA ATT TCT TAC ATA CAC GCG GAA GGT Glu Gly Ala Leu Lys Leu Lys Glu Ile Ser Tyr Ile His Ala Glu Gly 465 470 475 480	1440
TAT CCC GCA GGG GAG ATG AAG CAC GGT CCC ATA GCC CTC ATA GAC GAA Tyr Pro Ala Gly Glu Met Lys His Gly Pro Ile Ala Leu Ile Asp Glu 485 490 495	1488
AAC ATG CCG GTT GTG GTA ATC GCA CCG AAA GAC AGG GTT TAC GAG AAG Asn Met Pro Val Val Val Ile Ala Pro Lys Asp Arg Val Tyr Glu Lys 500 505 510	1536
ATA CTC TCA AAC GTA GAA GAG GTT CTC GCA AGA AAG GGA AGG GTT ATT Ile Leu Ser Asn Val Glu Glu Val Leu Ala Arg Lys Gly Arg Val Ile 515 520 525	1584
TCT GTA GGC TTT AAA GGA GAC GAA ACT CTC AAA AGC AAA TCC GAG AGC Ser Val Gly Phe Lys Gly Asp Glu Thr Leu Lys Ser Lys Ser Glu Ser 530 535 540	1632
GTT ATG GAA ATC CCG AAG GCA GAA GAA CCG ATA ACT CCT TTC TTG ACG Val Met Glu Ile Pro Lys Ala Glu Glu Pro Ile Thr Pro Phe Leu Thr 545 550 555 560	1680
GTA ATA CCC CTG CAA CTC TTT GCC TAC TTT ATA GCG AGC AAA CTG GGA Val Ile Pro Leu Gln Leu Phe Ala Tyr Phe Ile Ala Ser Lys Leu Gly 565 570 575	1728
CTG GAT GTG GAT CAG CCG AGA AAT CTC GCC AAA ACG GTC ACG GTG GAA Leu Asp Val Asp Gln Pro Arg Asn Leu Ala Lys Thr Val Thr Val Glu 580 585 590	1776
TAA End	1779

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 1065 NUCLEOTIDES
 (B) TYPE: NUCLEIC ACID
 (C) STRANDEDNESS: SINGLE
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: GENOMIC DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

ATG ATA CCC CAG AGG ATT AAG GAA CTT GAA GCT TAC AAG ACG GAG GTC Met Ile Pro Gln Arg Ile Lys Glu Leu Glu Ala Tyr Lys Thr Glu Val 5 10 15	48
ACT CCC GCC TCC GTC AGG CTT TCC TCT AAC GAA TTC CCC TAC GAC TTT Thr Pro Ala Ser Val Arg Leu Ser Ser Asn Glu Phe Pro Tyr Asp Phe 20 25 30	96
CCC GAG GAG ATA AAA CAA AGG GCC TTA GAA GAA TTA AAA AAG GTT CCC Pro Glu Glu Ile Lys Gln Arg Ala Leu Glu Glu Leu Lys Val Pro 35 40 45	144
TTG AAC AAA TAC CCA GAC CCC GAA GCG AAA GAG TTA AAA GCG GTT CTT Leu Asn Lys Tyr Pro Asp Pro Glu Ala Lys Glu Leu Lys Ala Val Leu 50 55 60	192
GCG GAT TTT TTC GGC GTT AAG GAA GAA AAT TTA GTT CTC GGT AAC GGT Ala Asp Phe Phe Gly Val Lys Glu Glu Asn Leu Val Leu Gly Asn Gly 65 70 75 80	240
TCG GAC GAA CTC ATA TAC CTC TCA ATA GCT ATA GGT GAA CTT TAC Ser Asp Glu Leu Ile Tyr Tyr Leu Ser Ile Ala Ile Gly Glu Leu Tyr 85 90 95	288
ATA CCC GTT TAC ATA CCT GTT CCC ACC TTT CCC ATG TAC GAG ATA AGT Ile Pro Val Tyr Ile Pro Val Pro Thr Phe Pro Met Tyr Glu Ile Ser 100 105 110	336
GCG AAA GTT CTC GGA AGA CCC CTC GTA AAG GTT CAA CTG GAC GAA AAC Ala Lys Val Leu Gly Arg Pro Leu Val Lys Val Gln Leu Asp Glu Asn 115 120 125	384
TTT GAT ATA GAC TTA GAA AGA AGT ATT GAA TTA ATA GAG AAA GAA AAA Phe Asp Ile Asp Leu Glu Arg Ser Ile Glu Leu Ile Glu Lys Glu Lys 130 135 140	432
CCC GTT CTC GGG TAC TTT GCT TAC CCA AAC AAC CCC ACG GGA AAC CTC Pro Val Leu Gly Tyr Phe Ala Tyr Pro Asn Asn Pro Thr Gly Asn Leu 145 150 155 160	480
TTT TCC AGG GGA AAG ATT GAG GAG ATA AGA AAC AGG GGT GTT TTC TGT Phe Ser Arg Gly Lys Ile Glu Glu Ile Arg Asn Arg Gly Val Phe Cys 165 170 175	528
GTA ATA GAC GAA GCC TAC TAT CAT TAC TCC GGA GAA ACC TTT CTG GAA Val Ile Asp Glu Ala Tyr Tyr His Tyr Ser Gly Glu Thr Phe Leu Glu 180 185 190	576

GAC GCG CTC AAA AGG GAA GAT ACG GTA GTT TTG AGG ACA CTT TCA AAA Asp Ala Leu Lys Arg Glu Asp Thr Val Val Leu Arg Thr Leu Ser Lys 195 200 205	624
ATC GGT ATG GCG AGT TTA AGG GTA GGG ATT TTA ATA GGG AAG GGG GAA Ile Gly Met Ala Ser Leu Arg Val Gly Ile Leu Ile Gly Lys Gly Glu 210 215 220	672
ATC GTC TCA GAA ATT AAC AAG GTG AGA CTC CCC TTC AAC GTG ACC TAC Ile Val Ser Glu Ile Asn Lys Val Arg Leu Pro Phe Asn Val Thr Tyr 225 230 235 240	720
CCC TCT CAG GTG ATG GCA AAA GTT CTC CTC ACG GAG GGA AGA GAA TTC Pro Ser Gln Val Met Ala Lys Val Leu Leu Thr Glu Gly Arg Glu Phe 245 250 255	768
CTA ATG GAA AAG ATA CAG GAG GTT GTA ACA GAG CGA GAA AGG ATG TAC Leu Met Glu Lys Ile Gln Glu Val Val Thr Glu Arg Glu Arg Met Tyr 260 265 270	816
GAC GAA ATG AAG AAA ATA GAA GGA GTT GAG GTT TTT CCG AGT AAG GCT Asp Glu Met Lys Lys Ile Glu Gly Val Glu Val Phe Pro Ser Lys Ala 275 280 285	864
AAC TTC TTG CTT TTC AGA ACG CCT TAC CCC GCC CAC GAG GTT TAT CAG Asn Phe Leu Leu Phe Arg Thr Pro Tyr Pro Ala His Glu Val Tyr Gln 290 295 300	912
GAG CTA CTG AAA AGG GAT GTC CTC GTC AGG AAC GTA TCT TAC ATG GAA Glu Leu Leu Lys Arg Asp Val Leu Val Arg Asn Val Ser Tyr Met Glu 305 310 315 320	960
GGA CTC CAA AAG TGC CTC AGG GTA AGC GTA GGG AAA CCG GAA GAA AAC Gly Leu Gln Lys Cys Leu Arg Val Ser Val Gly Lys Pro Glu Glu Asn 325 330 335	1008
AAC AAG TTT CTG GAA GCA CTG GAG GAG AGT ATA AAA TCC CTT TCA AGC Asn Lys Phe Leu Glu Ala Leu Glu Ser Ile Lys Ser Leu Ser Ser 340 345 350	1056
TCT CTT TAA Ser Leu End	1065

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 912 NUCLEOTIDES
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

- (ii) MOLECULE TYPE: GENOMIC DNA

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

ATG AAG CCG TAC GCT AAA TAT ATC TGG CTT GAC GGC AGA ATA CTT AAG
Met Lys Pro Tyr Ala Lys Tyr Ile Trp Leu Asp Gly Arg Ile Leu Lys
5 10 15

48

TGG GAA GAC GCG AAA ATA CAC GTG TTG ACT CAC GCG CTT CAC TAC GGA Trp Glu Asp Ala Lys Ile His Val Leu Thr His Ala Leu His Tyr Gly 20 25 30	96
ACC TCT ATA TTC GAG GGA ATA AGA GGG TAT TGG AAC GGC GAT AAT TTG Thr Ser Ile Phe Glu Gly Ile Arg Gly Tyr Trp Asn Gly Asp Asn Leu 35 40 45	144
CTC GTC TTT AGG TTA GAA GAA CAC ATC GAC CGC ATG TAC AGA TCG GCT Leu Val Phe Arg Leu Glu Glu His Ile Asp Arg Met Tyr Arg Ser Ala 50 55 60	192
AAG ATA CTA GGC ATA AAT ATT CCG TAT ACA AGA GAG GAA GTC CGC CAA Lys Ile Leu Gly Ile Asn Ile Pro Tyr Thr Arg Glu Glu Val Arg Gln 65 70 75 80	240
GCT GTA CTA GAG ACC ATA AAG GCT AAT AAC TTC CGA GAG GAT GTC TAC Ala Val Leu Glu Thr Ile Lys Ala Asn Asn Phe Arg Glu Asp Val Tyr 85 90 95	288
ATA AGA CCT GTG GCG TTT GTC GCC TCG CAG ACG GTG ACG CTT GAC ATA Ile Arg Pro Val Ala Phe Val Ala Ser Gln Thr Val Thr Leu Asp Ile 100 105 110	336
AGA AAT TTG GAA GTC TCC CTC GCG GTT ATT GTA TTC CCA TTT GGC AAA Arg Asn Leu Glu Val Ser Leu Ala Val Ile Val Phe Pro Phe Gly Lys 115 120 125	384
TAC CTC TCG CCC AAC GGC ATT AAG GCA ACG ATT GTA AGC TGG CGT AGA Tyr Leu Ser Pro Asn Gly Ile Lys Ala Thr Ile Val Ser Trp Arg Arg 130 135 140	432
GTA CAT AAT ACA ATG CTC CCT GTG ATG GCA AAA ATC GGC GGT ATA TAT Val His Asn Thr Met Leu Pro Val Met Ala Lys Ile Gly Gly Ile Tyr 145 150 155 160	480
GTA AAC TCT GTA CTT GCG CTT GTA GAG GCT AGA AGC AGG GGA TTT GAC Val Asn Ser Val Leu Ala Leu Val Glu Ala Arg Ser Arg Gly Phe Asp 165 170 175	528
GAG GCT TTA TTA ATG GAC GTT AAC GGT TAT GTT GTT GAG GGT TCT GGA Glu Ala Leu Leu Met Asp Val Asn Gly Tyr Val Val Glu Gly Ser Gly 180 185 190	576
GAG AAT ATT TTC ATT GTC AGA GGT GGA AGG CTT TTC ACG CCG CCA GTA Glu Asn Ile Phe Ile Val Arg Gly Arg Leu Phe Thr Pro Pro Val 195 200 205	624
CAC GAA TCT ATC CTC GAG GGA ATT ACG AGG GAT ACG GTA ATA AAG CTC His Glu Ser Ile Leu Glu Gly Ile Thr Arg Asp Thr Val Ile Lys Leu 210 215 220	672
AGC GGG GAT GTG GGA CTT CGG GTG GAG GAA AAG CCT ATT ACG AGG GAG Ser Gly Asp Val Gly Leu Arg Val Glu Glu Lys Pro Ile Thr Arg Glu 225 230 235 240	720
GAG GTG TAT ACA GCC GAC GAG GTG TTT TTA GTA GGA ACC GCC GCA GAG Glu Val Tyr Thr Ala Asp Glu Val Phe Leu Val Gly Thr Ala Ala Glu 245 250 255	768

ATA ACG CCA GTG GTG GAG GTT GAC GGC AGA ACA ATC GGC ACA GGC AAG Ile Thr Pro Val Val Glu Val Asp Gly Arg Thr Ile Gly Thr Gly Lys 260 265 270	816
CCG GGC CCC ATT ACG ACA AAA ATA GCT GAG CTG TAC TCA AAC GTC GTG Pro Gly Pro Ile Thr Thr Lys Ile Ala Glu Leu Tyr Ser Asn Val Val 275 280 285	864
AGA GGC AAA GTA GAG AAA TAC TTA AAT TGG ATC ACT CCT GTG TAT TAG	912
Arg Gly Lys Val Glu Lys Tyr Leu Asn Trp Ile Thr Pro Val Tyr End 290 295 300	

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 414 AMINO ACIDS
 (B) TYPE: AMINO ACID
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Met Ile Glu Asp Pro Met Asp Trp Ala Phe Pro Arg Ile Lys Arg Leu 5 10 15
Pro Gln Tyr Val Phe Ser Leu Val Asn Glu Leu Lys Tyr Lys Leu Arg 20 25 30
Arg Glu Gly Glu Asp Val Val Asp Leu Gly Met Gly Asn Pro Asn Met 35 40 45
Pro Pro Ala Lys His Ile Ile Asp Lys Leu Cys Glu Val Ala Gln Lys 50 55 60
Pro Asn Val His Gly Tyr Ser Ala Ser Arg Gly Ile Pro Arg Leu Arg 65 70 75 80
Lys Ala Ile Cys Asn Phe Tyr Glu Glu Arg Tyr Gly Val Lys Leu Asp 85 90 95
Pro Glu Arg Glu Ala Ile Leu Thr Ile Gly Ala Lys Glu Gly Tyr Ser 100 105 110
His Leu Met Leu Ala Met Ile Ser Pro Gly Asp Thr Val Ile Val Pro 115 120 125
Asn Pro Thr Tyr Pro Ile His Tyr Ala Pro Ile Ile Ala Gly Gly 130 135 140
Glu Val His Ser Ile Pro Leu Asn Phe Ser Asp Asp Gln Asp His Gln 145 150 155 160
Glu Glu Phe Leu Arg Arg Leu Tyr Glu Ile Val Lys Thr Ala Met Pro 165 170 175
Lys Pro Lys Ala Val Val Ile Ser Phe Pro His Asn Pro Thr Thr Ile 180 185 190

Thr Val Glu Lys Asp Phe Phe Lys Glu Ile Val Lys Phe Ala Lys Glu
 195 200 205
 His Gly Leu Trp Ile Ile His Asp Phe Ala Tyr Ala Asp Ile Ala Phe
 210 215 220
 Asp Gly Tyr Lys Pro Pro Ser Ile Leu Glu Ile Glu Gly Ala Lys Asp
 225 230 235 240
 Val Ala Val Glu Leu Tyr Ser Met Ser Lys Gly Phe Ser Met Ala Gly
 245 250 255
 Trp Arg Val Ala Phe Val Val Gly Asn Glu Ile Leu Ile Lys Asn Leu
 260 265 270
 Ala His Leu Lys Ser Tyr Leu Asp Tyr Gly Ile Phe Thr Pro Ile Gln
 275 280 285
 Val Ala Ser Ile Ile Ala Leu Glu Ser Pro Tyr Glu Ile Val Glu Lys
 290 295 300
 Thr Ala Lys Val Tyr Gln Lys Arg Arg Asp Val Leu Val Glu Gly Leu
 305 310 315 320
 Asn Arg Leu Gly Trp Lys Val Lys Lys Pro Lys Ala Thr Met Phe Val
 325 330 335
 Trp Ala Lys Ile Pro Glu Trp Ile Asn Met Asn Ser Leu Asp Phe Ser
 340 345 350
 Leu Phe Leu Leu Lys Glu Ala Lys Val Ala Val Ser Pro Gly Val Gly
 355 360 365
 Phe Gly Gln Tyr Gly Glu Gly Tyr Val Arg Phe Ala Leu Val Glu Asn
 370 375 380
 Glu His Arg Ile Arg Gln Ala Ile Arg Gly Ile Arg Lys Ala Phe Arg
 385 390 395 400
 Lys Leu Gln Lys Glu Arg Lys Leu Glu Pro Glu Arg Ser Ala End
 405 410 414

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 373 AMINO ACIDS
 (B) TYPE: AMINO ACID
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Met Asp Arg Leu Glu Lys Val Ser Pro Phe Ile Val Met Asp Ile Leu
 5 10 15
 Ala Gln Ala Gln Lys Tyr Glu Asp Val Val His Met Glu Ile Gly Glu
 20 25 30

Pro Asp Leu Glu Pro Ser Pro Lys Val Met Glu Ala Leu Glu Arg Ala
 35 40 45
 Val Lys Glu Lys Thr Phe Phe Tyr Thr Pro Ala Leu Gly Leu Trp Glu
 50 55 60
 Leu Arg Glu Arg Ile Ser Glu Phe Tyr Arg Lys Lys Tyr Ser Val Glu
 65 70 75 80
 Val Ser Pro Glu Arg Val Ile Val Thr Thr Gly Thr Ser Gly Ala Phe
 85 90 95
 Leu Val Ala Tyr Ala Val Thr Leu Asn Ala Gly Glu Lys Ile Ile Leu
 100 105 110
 Pro Asp Pro Ser Tyr Pro Cys Tyr Lys Asn Phe Ala Tyr Leu Leu Asp
 115 120 125
 Ala Gln Pro Val Phe Val Asn Val Asp Lys Glu Thr Asn Tyr Glu Val
 130 135 140
 Arg Lys Glu Met Ile Glu Asp Ile Asp Ala Lys Ala Leu His Ile Ser
 145 150 155 160
 Ser Pro Gln Asn Pro Thr Gly Thr Leu Tyr Ser Pro Glu Thr Leu Lys
 165 170 175
 Glu Leu Ala Glu Tyr Cys Glu Glu Lys Gly Met Tyr Phe Ile Ser Asp
 180 185 190
 Glu Ile Tyr His Gly Leu Val Tyr Glu Gly Arg Glu His Thr Ala Leu
 195 200 205
 Glu Phe Ser Asp Arg Ala Ile Val Ile Asn Gly Phe Ser Lys Tyr Phe
 210 215 220
 Cys Met Pro Gly Phe Arg Ile Gly Trp Met Ile Val Pro Glu Glu Leu
 225 230 235 240
 Val Arg Lys Ala Glu Ile Val Ile Gln Asn Val Phe Ile Ser Ala Pro
 245 250 255
 Thr Leu Ser Gln Tyr Ala Ala Leu Glu Ala Phe Asp Tyr Glu Tyr Leu
 260 265 270
 Glu Lys Val Arg Lys Thr Phe Glu Glu Arg Arg Asn Phe Leu Tyr Gly
 275 280 285
 Glu Leu Lys Lys Leu Phe Lys Ile Asp Ala Lys Pro Gln Gly Ala Phe
 290 295 300
 Tyr Val Trp Ala Asn Ile Ser Asp Tyr Ser Thr Asp Ser Tyr Glu Phe
 305 310 315 320
 Ala Leu Lys Leu Leu Arg Glu Ala Arg Val Ala Val Thr Pro Gly Val
 325 330 335
 Asp Phe Gly Lys Asn Lys Thr Lys Glu Tyr Ile Arg Phe Ala Tyr Thr
 340 345 350

Arg Lys Ile Glu Glu Leu Lys Glu Gly Val Glu Arg Ile Lys Lys Phe
 355 360 365
 Leu Glu Lys Leu Ser
 370

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 453 AMINO ACIDS
 (B) TYPE: AMINO ACID
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Met Trp Glu Leu Asp Pro Lys Thr Leu Glu Lys Trp Asp Lys Glu Tyr
 5 10 15

Phe Trp His Pro Phe Thr Gln Met Lys Val Tyr Arg Glu Glu Asn
 20 25 30

Leu Ile Phe Glu Arg Gly Glu Gly Val Tyr Leu Trp Asp Ile Tyr Gly
 35 40 45

Arg Lys Tyr Ile Asp Ala Ile Ser Ser Leu Trp Cys Asn Val His Gly
 50 55 60

His Asn His Pro Lys Leu Asn Asn Ala Val Met Lys Gln Leu Cys Lys
 65 70 75 80

Val Ala His Thr Thr Leu Gly Ser Ser Asn Val Pro Ala Ile Leu
 85 90 95

Leu Ala Lys Lys Leu Val Glu Ile Ser Pro Glu Gly Leu Asn Lys Val
 100 105 110

Phe Tyr Ser Glu Asp Gly Ala Glu Ala Val Glu Ile Ala Ile Lys Met
 115 120 125

Ala Tyr His Tyr Trp Lys Asn Lys Gly Val Lys Gly Lys Asn Val Phe
 130 135 140

Ile Thr Leu Ser Glu Ala Tyr His Gly Asp Thr Val Gly Ala Val Ser
 145 150 155 160

Val Gly Gly Ile Glu Leu Phe His Gly Thr Tyr Lys Asp Leu Leu Phe
 165 170 175

Lys Thr Ile Lys Leu Pro Ser Pro Tyr Leu Tyr Cys Lys Glu Lys Tyr
 180 185 190

Gly Glu Leu Cys Pro Glu Cys Thr Ala Asp Leu Leu Lys Gln Leu Glu
 195 200 205

Asp Ile Leu Lys Ser Arg Glu Asp Ile Val Ala Val Ile Met Glu Ala
 210 215 220
 Gly Ile Gln Ala Ala Ala Gly Met Leu Pro Phe Pro Pro Gly Phe Leu
 225 230 235 240
 Lys Gly Val Arg Glu Leu Thr Lys Tyr Asp Thr Leu Met Ile Val
 245 250 255
 Asp Glu Val Ala Thr Gly Phe Gly Arg Thr Gly Thr Met Phe Tyr Cys
 260 265 270
 Glu Gln Glu Gly Val Ser Pro Asp Phe Met Cys Leu Gly Lys Gly Ile
 275 280 285
 Thr Gly Gly Tyr Leu Pro Leu Ala Ala Thr Leu Thr Thr Asp Glu Val
 290 295 300
 Phe Asn Ala Phe Leu Gly Glu Phe Gly Glu Ala Lys His Phe Tyr His
 305 310 315 320
 Gly His Thr Tyr Thr Gly Asn Asn Leu Ala Cys Ser Val Ala Leu Ala
 325 330 335
 Asn Leu Glu Val Phe Glu Glu Glu Arg Thr Leu Glu Lys Leu Gln Pro
 340 345 350
 Lys Ile Lys Leu Leu Lys Glu Arg Leu Gln Glu Phe Trp Glu Leu Lys
 355 360 365
 His Val Gly Asp Val Arg Gln Leu Gly Phe Met Ala Gly Ile Glu Leu
 370 375 380
 Val Lys Asp Lys Glu Lys Gly Glu Pro Phe Pro Tyr Gly Glu Arg Thr
 385 390 395 400
 Gly Phe Lys Val Ala Tyr Lys Cys Arg Glu Lys Gly Val Phe Leu Arg
 405 410 415
 Pro Leu Gly Asp Val Met Val Leu Met Met Pro Leu Val Ile Glu Glu
 420 425 430
 Asp Glu Met Asn Tyr Val Ile Asp Thr Leu Lys Trp Ala Ile Lys Glu
 435 440 445
 Leu Glu Lys Glu Val
 450

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 343 AMINO ACIDS
 (B) TYPE: AMINO ACID
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Met Thr Tyr Leu Met Asn Asn Tyr Ala Arg Leu Pro Val Lys Phe Val
 5 10 15
 Arg Gly Lys Gly Val Tyr Leu Tyr Asp Glu Glu Gly Lys Glu Tyr Leu
 20 25 30
 Asp Phe Val Ser Gly Ile Gly Val Asn Ser Leu Gly His Ala Tyr Pro
 35 40 45
 Lys Leu Thr Glu Ala Leu Lys Glu Gln Val Glu Lys Leu Leu His Val
 50 55 60
 Ser Asn Leu Tyr Glu Asn Pro Trp Gln Glu Leu Ala His Lys Leu
 65 70 75 80
 Val Lys His Phe Trp Thr Glu Gly Lys Val Phe Phe Ala Asn Ser Gly
 85 90 95
 Thr Glu Ser Val Glu Ala Ala Ile Lys Leu Ala Arg Lys Tyr Trp Arg
 100 105 110
 Asp Lys Gly Lys Asn Lys Trp Lys Phe Ile Ser Phe Glu Asn Ser Phe
 115 120 125
 His Gly Arg Thr Tyr Gly Ser Leu Ser Ala Thr Gly Gln Pro Lys Phe
 130 135 140
 His Lys Gly Phe Glu Pro Leu Val Pro Gly Phe Ser Tyr Ala Lys Leu
 145 150 155 160
 Asn Asp Ile Asp Ser Val Tyr Lys Leu Leu Asp Glu Glu Thr Ala Gly
 165 170 175
 Ile Ile Ile Glu Val Ile Gln Gly Glu Gly Val Asn Glu Ala Ser
 180 185 190
 Glu Asp Phe Leu Ser Lys Leu Gln Glu Ile Cys Lys Glu Lys Asp Val
 195 200 205
 Leu Leu Ile Ile Asp Glu Val Gln Thr Gly Ile Gly Arg Thr Gly Glu
 210 215 220
 Phe Tyr Ala Tyr Gln His Phe Asn Leu Lys Pro Asp Val Ile Ala Leu
 225 230 235 240
 Ala Lys Gly Leu Gly Gly Val Pro Ile Gly Ala Ile Leu Ala Arg
 245 250 255
 Glu Glu Val Ala Gln Ser Phe Thr Pro Gly Ser His Gly Ser Thr Phe
 260 265 270
 Gly Gly Asn Pro Leu Ala Cys Arg Ala Gly Thr Val Val Val Asp Glu
 275 280 285
 Val Glu Lys Leu Leu Pro His Val Arg Glu Val Gly Asn Tyr Phe Lys
 290 295 300
 Glu Lys Leu Lys Glu Leu Gly Lys Val Lys Gly Arg Gly Leu
 305 310 315 320

Met Leu Gly Leu Glu Leu Glu Arg Glu Cys Lys Asp Tyr Val Leu Lys
 325 330 335

Ala Leu Glu Arg Asp Phe Ser
 340

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 398 AMINO ACIDS
 (B) TYPE: AMINO ACID
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Met Arg Lys Leu Ala Glu Arg Ala Gln Lys Leu Ser Pro Ser Pro Thr
 5 10 15

Leu Ser Val Asp Thr Lys Ala Lys Glu Leu Leu Arg Gln Gly Glu Arg
 20 25 30

Val Ile Asn Phe Gly Ala Gly Glu Pro Asp Phe Asp Thr Pro Glu His
 35 40 45

Ile Lys Glu Ala Ala Lys Arg Ala Leu Asp Gln Gly Phe Thr Lys Tyr
 50 55 60

Thr Pro Val Ala Gly Ile Leu Pro Leu Arg Glu Ala Ile Cys Glu Lys
 65 70 75 80

Leu Tyr Arg Asp Asn Gln Leu Glu Tyr Ser Pro Asn Glu Ile Val Val
 85 90 95

Ser Cys Gly Ala Lys His Ser Ile Phe Asn Ala Leu Gln Val Leu Leu
 100 105 110

Asp Pro Gly Asp Glu Val Ile Ile Pro Val Pro Tyr Trp Thr Ser Tyr
 115 120 125

Pro Glu Gln Val Lys Leu Ala Gly Gly Val Pro Val Phe Val Pro Thr
 130 135 140

Ser Pro Glu Asn Asp Phe Lys Leu Arg Pro Glu Asp Leu Arg Ala Ala
 145 150 155 160

Val Thr Pro Arg Thr Arg Leu Leu Ile Leu Asn Ser Pro Ala Asn Pro
 165 170 175

Thr Gly Thr Val Tyr Arg Arg Glu Glu Leu Ile Gly Leu Ala Glu Val
 180 185 190

Ala Leu Glu Ala Asp Leu Trp Ile Leu Ser Asp Glu Ile Tyr Glu Lys
 195 200 205

Leu Ile Tyr Asp Gly Met Glu His Val Ser Ile Ala Ala Leu Asp Pro
 210 215 220

Glu Val Lys Lys Arg Thr Ile Val Val Asn Gly Val Ser Lys Ala Tyr
 225 230 235 240

Ala Met Thr Gly Trp Arg Ile Gly Tyr Ala Ala Ala Pro Arg Pro Ile
 245 250 255

Ala Gln Ala Met Thr Asn Leu Gln Ser His Ser Thr Ser Asn Pro Thr
 260 265 270

Ser Val Ala Gln Ala Ala Leu Ala Ala Leu Lys Gly Pro Gln Glu
 275 280 285

Pro Val Glu Asn Met Arg Arg Ala Phe Gln Lys Arg Arg Asp Phe Ile
 290 295 300

Trp Gln Tyr Leu Asn Ser Leu Pro Gly Val Arg Cys Pro Lys Pro Leu
 305 310 315 320

Gly Ala Phe Tyr Val Phe Pro Glu Val Glu Arg Ala Phe Gly Pro Pro
 325 330 335

Ser Lys Arg Thr Gly Asn Thr Thr Ala Ser Asp Leu Ala Leu Phe Leu
 340 345 350

Leu Glu Glu Ile Lys Val Ala Thr Val Ala Gly Ala Ala Phe Gly Asp
 355 360 365

Asp Arg Tyr Leu Arg Phe Ser Tyr Ala Leu Arg Leu Glu Asp Ile Glu
 370 375 380

Glu Gly Met Gln Arg Phe Lys Glu Leu Ile Glu Ala Ala Leu
 385 390 395

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 592 AMINO ACIDS
 - (B) TYPE: AMINO ACID
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Met Cys Gly Ile Val Gly Tyr Val Gly Arg Asp Leu Ala Leu Pro Ile
 5 10 15

Val Leu Gly Ala Leu Glu Arg Leu Glu Tyr Arg Gly Tyr Asp Ser Ala
 20 25 30

Gly Val Ala Leu Ile Glu Asp Gly Lys Leu Ile Val Glu Lys Lys Lys
 35 40 45

Gly Lys Ile Arg Glu Leu Val Lys Ala Leu Trp Gly Lys Asp Tyr Lys
 50 55 60

Ala Lys Thr Gly Ile Gly His Thr Arg Trp Ala Thr His Gly Lys Pro
 65 70 75 80

Thr Asp Glu Asn Ala His Pro His Thr Asp Glu Lys Gly Glu Phe Ala
 85 90 95
 Val Val His Asn Gly Ile Ile Glu Asn Tyr Leu Glu Leu Lys Glu Glu
 100 105 110
 Leu Lys Lys Glu Gly Val Lys Phe Arg Ser Glu Thr Asp Thr Glu Val
 115 120 125
 Ile Ala His Leu Ile Ala Lys Asn Tyr Arg Gly Asp Leu Leu Glu Ala
 130 135 140
 Val Leu Lys Thr Val Lys Lys Leu Lys Gly Ala Phe Ala Phe Ala Val
 145 150 155 160
 Ile Thr Val His Glu Pro Asn Arg Leu Ile Gly Val Lys Gln Gly Ser
 165 170 175
 Pro Leu Ile Val Gly Leu Gly Glu Asn Phe Leu Ala Ser Asp
 180 185 190
 Ile Pro Ala Ile Leu Pro Tyr Thr Lys Lys Ile Ile Val Leu Asp Asp
 195 200 205
 Gly Glu Ile Ala Asp Leu Thr Pro Asp Thr Val Asn Ile Tyr Asn Phe
 210 215 220
 Glu Gly Glu Pro Val Ser Lys Glu Val Met Ile Thr Pro Trp Asp Leu
 225 230 235 240
 Val Ser Ala Glu Lys Gly Phe Lys His Phe Met Leu Lys Glu Ile
 245 250 255
 Tyr Glu Gln Pro Lys Ala Ile Asn Asp Thr Leu Lys Gly Phe Leu Ser
 260 265 270
 Thr Glu Asp Ala Ile Pro Phe Lys Leu Lys Asp Phe Arg Arg Val Leu
 275 280 285
 Ile Ile Ala Cys Gly Thr Ser Tyr His Ala Gly Phe Val Gly Lys Tyr
 290 295 300
 Trp Ile Glu Arg Phe Ala Gly Val Pro Thr Glu Val Ile Tyr Ala Ser
 305 310 315 320
 Glu Phe Arg Tyr Ala Asp Val Pro Val Ser Asp Lys Asp Ile Val Ile
 325 330 335
 Gly Ile Ser Gln Ser Gly Glu Thr Ala Asp Thr Lys Phe Ala Leu Gln
 340 345 350
 Ser Ala Lys Glu Lys Gly Ala Phe Thr Val Gly Leu Val Asn Val Val
 355 360 365
 Gly Ser Ala Ile Asp Arg Glu Ser Asp Phe Ser Leu His Thr His Ala
 370 375 380
 Gly Pro Glu Ile Gly Val Ala Ala Thr Lys Thr Phe Thr Ala Gln Phe
 385 390 395 400

Thr Ala Leu Tyr Ala Leu Ser Val Arg Glu Ser Glu Glu Arg Glu Asn
 405 410 415
 Leu Ile Arg Leu Leu Glu Lys Val Pro Ser Leu Val Glu Gln Thr Leu
 420 425 430
 Asn Thr Ala Glu Glu Val Glu Lys Val Ala Glu Lys Tyr Met Lys Lys
 435 440 445
 Lys Asn Met Leu Tyr Leu Gly Arg Tyr Leu Asn Tyr Pro Ile Ala Leu
 450 455 460
 Glu Gly Ala Leu Lys Leu Lys Glu Ile Ser Tyr Ile His Ala Glu Gly
 465 470 475 480
 Tyr Pro Ala Gly Glu Met Lys His Gly Pro Ile Ala Leu Ile Asp Glu
 485 490 495
 Asn Met Pro Val Val Val Ile Ala Pro Lys Asp Arg Val Tyr Glu Lys
 500 505 510
 Ile Leu Ser Asn Val Glu Glu Val Leu Ala Arg Lys Gly Arg Val Ile
 515 520 525
 Ser Val Gly Phe Lys Gly Asp Glu Thr Leu Lys Ser Lys Ser Glu Ser
 530 535 540
 Val Met Glu Ile Pro Lys Ala Glu Glu Pro Ile Thr Pro Phe Leu Thr
 545 550 555 560
 Val Ile Pro Leu Gln Leu Phe Ala Tyr Phe Ile Ala Ser Lys Leu Gly
 565 570 575
 Leu Asp Val Asp Gln Pro Arg Asn Leu Ala Lys Thr Val Thr Val Glu
 580 585 590

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 354 AMINO ACIDS
 - (B) TYPE: AMINO ACID
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Met Ile Pro Gln Arg Ile Lys Glu Leu Glu Ala Tyr Lys Thr Glu Val
 5 10 15
 Thr Pro Ala Ser Val Arg Leu Ser Ser Asn Glu Phe Pro Tyr Asp Phe
 20 25 30
 Pro Glu Glu Ile Lys Gln Arg Ala Leu Glu Glu Leu Lys Val Pro
 35 40 45
 Leu Asn Lys Tyr Pro Asp Pro Glu Ala Lys Glu Leu Lys Ala Val Leu
 50 55 60

Ala Asp Phe Phe Gly Val Lys Glu Glu Asn Leu Val Leu Gly Asn Gly
 65 70 75 80

Ser Asp Glu Leu Ile Tyr Tyr Leu Ser Ile Ala Ile Gly Glu Leu Tyr
 85 90 95

Ile Pro Val Tyr Ile Pro Val Pro Thr Phe Pro Met Tyr Glu Ile Ser
 100 105 110

Ala Lys Val Leu Gly Arg Pro Leu Val Lys Val Gln Leu Asp Glu Asn
 115 120 125

Phe Asp Ile Asp Leu Glu Arg Ser Ile Glu Leu Ile Glu Lys Glu Lys
 130 135 140

Pro Val Leu Gly Tyr Phe Ala Tyr Pro Asn Asn Pro Thr Gly Asn Leu
 145 150 155 160

Phe Ser Arg Gly Lys Ile Glu Glu Ile Arg Asn Arg Gly Val Phe Cys
 165 170 175

Val Ile Asp Glu Ala Tyr Tyr His Tyr Ser Gly Glu Thr Phe Leu Glu
 180 185 190

Asp Ala Leu Lys Arg Glu Asp Thr Val Val Leu Arg Thr Leu Ser Lys
 195 200 205

Ile Gly Met Ala Ser Leu Arg Val Gly Ile Leu Ile Gly Lys Gly Glu
 210 215 220

Ile Val Ser Glu Ile Asn Lys Val Arg Leu Pro Phe Asn Val Thr Tyr
 225 230 235 240

Pro Ser Gln Val Met Ala Lys Val Leu Leu Thr Glu Gly Arg Glu Phe
 245 250 255

Leu Met Glu Lys Ile Gln Glu Val Val Thr Glu Arg Glu Arg Met Tyr
 260 265 270

Asp Glu Met Lys Lys Ile Glu Gly Val Glu Val Phe Pro Ser Lys Ala
 275 280 285

Asn Phe Leu Leu Phe Arg Thr Pro Tyr Pro Ala His Glu Val Tyr Gln
 290 295 300

Glu Leu Leu Lys Arg Asp Val Leu Val Arg Asn Val Ser Tyr Met Glu
 305 310 315 320

Gly Leu Gln Lys Cys Leu Arg Val Ser Val Gly Lys Pro Glu Glu Asn
 325 330 335

Asn Lys Phe Leu Glu Ala Leu Glu Glu Ser Ile Lys Ser Leu Ser Ser
 340 345 350

Ser Leu

*

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 303 AMINO ACIDS
 (B) TYPE: AMINO ACID
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Met Lys Pro Tyr Ala Lys Tyr Ile Trp Leu Asp Gly Arg Ile Leu Lys
 5 10 15

Trp Glu Asp Ala Lys Ile His Val Leu Thr His Ala Leu His Tyr Gly
 20 25 30

Thr Ser Ile Phe Glu Gly Ile Arg Gly Tyr Trp Asn Gly Asp Asn Leu
 35 40 45

Leu Val Phe Arg Leu Glu Glu His Ile Asp Arg Met Tyr Arg Ser Ala
 50 55 60

Lys Ile Leu Gly Ile Asn Ile Pro Tyr Thr Arg Glu Glu Val Arg Gln
 65 70 75 80

Ala Val Leu Glu Thr Ile Lys Ala Asn Asn Phe Arg Glu Asp Val Tyr
 85 90 95

Ile Arg Pro Val Ala Phe Val Ala Ser Gln Thr Val Thr Leu Asp Ile
 100 105 110

Arg Asn Leu Glu Val Ser Leu Ala Val Ile Val Phe Pro Phe Gly Lys
 115 120 125

Tyr Leu Ser Pro Asn Gly Ile Lys Ala Thr Ile Val Ser Trp Arg Arg
 130 135 140

Val His Asn Thr Met Leu Pro Val Met Ala Lys Ile Gly Gly Ile Tyr
 145 150 155 160

Val Asn Ser Val Leu Ala Leu Val Glu Ala Arg Ser Arg Gly Phe Asp
 165 170 175

Glu Ala Leu Leu Met Asp Val Asn Gly Tyr Val Val Glu Gly Ser Gly
 180 185 190

Glu Asn Ile Phe Ile Val Arg Gly Gly Arg Leu Phe Thr Pro Pro Val
 195 200 205

His Glu Ser Ile Leu Glu Gly Ile Thr Arg Asp Thr Val Ile Lys Leu
 210 215 220

Ser Gly Asp Val Gly Leu Arg Val Glu Glu Lys Pro Ile Thr Arg Glu
 225 230 235 240

Glu Val Tyr Thr Ala Asp Glu Val Phe Leu Val Gly Thr Ala Ala Glu
 245 250 255

Ile Thr Pro Val Val Glu Val Asp Gly Arg Thr Ile Gly Thr Gly Lys
 260 265 270

Pro Gly Pro Ile Thr Thr Lys Ile Ala Glu Leu Tyr Ser Asn Val Val
 275 280 285

Arg Gly Lys Val Glu Lys Tyr Leu Asn Trp Ile Thr Pro Val Tyr
 290 295 300

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 52 NUCLEOTIDES
 (B) TYPE: NUCLEIC ACID
 (C) STRANDEDNESS: SINGLE
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

CCGAGAATTCTTAAAGAGG AGAAATTAAC TATGGCAGTC AAAAGTGCGGGC CT
 52

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 31 NUCLEOTIDES
 (B) TYPE: NUCLEIC ACID
 (C) STRANDEDNESS: SINGLE
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

CGGAGGATCC TTATCCAAAG CTTCCAGGAA G
 31

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 1,092 NUCLEOTIDES
 (B) TYPE: NUCLEIC ACID
 (C) STRANDEDNESS: SINGLE
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: GENOMIC DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

ATG GCA GTC AAA GTG CGG CCT GAG CTC AGC CAG GTG GAG ATC TAC CGT
 Met Ala Val Lys Val Arg Pro Glu Leu Ser Gln Val Glu Ile Tyr Arg
 5 10 15

48

CCC GGC AAA CCC ATC GAA GAG GTA AAG AAG GAG CTG GGG CTG GAG GAG Pro Gly Lys Pro Ile Glu Glu Val Lys Lys Glu Leu Gly Leu Glu Glu 20 25 30	96
GTA GTC AAG CTG GCC TCC AAC GAG AAC CCT CTG GGA CCT TCT CCC AAG Val Val Lys Leu Ala Ser Asn Glu Asn Pro Leu Gly Pro Ser Pro Lys 35 40 45	144
GCC GTG GCG GCG CTG GAG GGA CTG GAC CAC TGG CAC CTT TAC CCA GAA Ala Val Ala Ala Leu Glu Gly Leu Asp His Trp His Leu Tyr Pro Glu 50 55 60	192
GGC TCA AGC TAT GAG CTA CGG CAG GCG CTG GGT AAG AAA CTG GAG ATA Gly Ser Ser Tyr Glu Leu Arg Gln Ala Leu Gly Lys Lys Leu Glu Ile 65 70 75 80	240
GAC CCG GAC AGC ATC ATC GTG GGT TGC GGC TCA AGC GAA GTC ATC CAG Asp Pro Asp Ser Ile Ile Val Gly Cys Gly Ser Ser Glu Val Ile Gln 85 90 95	288
ATG CTC TCT TTG GCC CTG CTG GCG CCC GGC GAC GAG GTG GTC ATC CCT Met Leu Ser Leu Ala Leu Ala Pro Gly Asp Glu Val Val Ile Pro 100 105 110	336
GTG CCT ACC TTT CCC CGC TAT GAG CCC CTG GCA CGG CTC ATG GGG GCT Val Pro Thr Phe Pro Arg Tyr Glu Pro Leu Ala Arg Leu Met Gly Ala 115 120 125	384
AAT CCC GTA AAA GTT CCC TTG AAG GAC TAC CGC ATC GAT GTG GAG GCA Asn Pro Val Lys Val Pro Leu Lys Asp Tyr Arg Ile Asp Val Glu Ala 130 135 140	432
GTG GCC CGA GCC CTT TCC CCC CGT ACC AAG CTG GTC TAC CTA TGC AAC Val Ala Arg Ala Leu Ser Pro Arg Thr Lys Leu Val Tyr Leu Cys Asn 145 150 155 160	480
CCC AAC AAC CCC ACC GGG ACC ATC GTC ACC CGG GAG GAG GTG GAG TGG Pro Asn Asn Pro Thr Gly Thr Ile Val Thr Arg Glu Glu Val Glu Trp 165 170 175	528
TTC TTG GAA AAG GCG GGG GAG GGG GTT CTC ACC GTG CTG GAC GAG GCC Phe Leu Glu Lys Ala Gly Glu Gly Val Leu Thr Val Leu Asp Glu Ala 180 185 190	576
TAC TGC GAG TAC GTG ACC AGC CCC GCC TAC CCT GAT GGG CTC GAT TTC Tyr Cys Glu Tyr Val Thr Ser Pro Ala Tyr Pro Asp Gly Leu Asp Phe 195 200 205	624
CTG CGC CGG GGC TAC AAT GTG GTG GTG CTG CGC ACC TTC TCC AAG ATC Leu Arg Arg Gly Tyr Asn Val Val Val Leu Arg Thr Phe Ser Lys Ile 210 215 220	672
TAC GGG CTG GCC GGG CTG CGC ATA GGG TAC GGT GTG GCG GAC AGG GAG Tyr Gly Leu Ala Gly Leu Arg Ile Gly Tyr Gly Val Ala Asp Arg Glu 225 230 235 240	720
CTG GTG GCG GAA CTG CAC CGG GTG CGG GAG CCT TTC AAT GTC AGT TCC Leu Val Ala Glu Leu His Arg Val Arg Glu Pro Phe Asn Val Ser Ser 245 250 255	768
GCT GCT CAG ATA GCC GCC CTG GCC GCC CTG GAA GAC GAA GAG TTC GTG Ala Ala Gln Ile Ala Ala Leu Ala Leu Glu Asp Glu Glu Phe Val 260 265 270	816

GCG CTT TCG CGC CAG GTC AAC GAA GAA GGG AAG GTT TTT CTC TAC CGA Ala Leu Ser Arg Gln Val Asn Glu Glu Gly Lys Val Phe Leu Tyr Arg 275 280 285	864
GAA CTG GAG AGG CGG GGG ATC GCC TAC GTG CCC ACC GAG GCC AAC TTC Glu Leu Glu Arg Arg Gly Ile Ala Tyr Val Pro Thr Glu Ala Asn Phe 290 295 300	912
CTA CTC TTC GAT GCC GGT CGG GAC GAG CAG GAA GTA TTT CGC CGG ATG Leu Leu Phe Asp Ala Gly Arg Asp Glu Gln Glu Val Phe Arg Arg Met 305 310 315 320	960
CTG CGC CAG GGA GTG ATC ATC CGG GNC GGG GTG GGT TAT CCC ACC CAC Leu Arg Gln Gly Val Ile Ile Arg Xxx Gly Val Gly Tyr Pro Thr His 325 330 335	1008
TTA AGG GTG ACC ATC GGC ACC TTG GAA CAG AAC CAG CGC TTC CTG GAA Leu Arg Val Thr Ile Gly Thr Leu Glu Gln Asn Gln Arg Phe Leu Glu 340 345 350	1056
GCT TTG GAT AAG GCT CTA GAG CTT AGG GGG GTT TAA Ala Leu Asp Lys Ala Leu Glu Leu Arg Gly Val 355 360 363	1092

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: AMINO ACIDS
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Met Ala Val Lys Val Arg Pro Glu Leu Ser Gln Val Glu Ile Tyr Arg 5 10 15
Pro Gly Lys Pro Ile Glu Glu Val Lys Lys Glu Leu Gly Leu Glu Glu 20 25 30
Val Val Lys Leu Ala Ser Asn Glu Asn Pro Leu Gly Pro Ser Pro Lys 35 40 45
Ala Val Ala Ala Leu Glu Gly Leu Asp His Trp His Leu Tyr Pro Glu 50 55 60
Gly Ser Ser Tyr Glu Leu Arg Gln Ala Leu Gly Lys Lys Leu Glu Ile 65 70 75 80
Asp Pro Asp Ser Ile Ile Val Gly Cys Gly Ser Ser Glu Val Ile Gln 85 90 95
Met Leu Ser Leu Ala Leu Ala Pro Gly Asp Glu Val Val Ile Pro 100 105 110
Val Pro Thr Phe Pro Arg Tyr Glu Pro Leu Ala Arg Leu Met Gly Ala 115 120 125

Asn Pro Val Lys Val Pro Leu Lys Asp Tyr Arg Ile Asp Val Glu Ala
 130 135 140
 Val Ala Arg Ala Leu Ser Pro Arg Thr Lys Leu Val Tyr Leu Cys Asn
 145 150 155 160
 Pro Asn Asn Pro Thr Gly Thr Ile Val Thr Arg Glu Glu Val Glu Trp
 165 170 175
 Phe Leu Glu Lys Ala Gly Glu Gly Val Leu Thr Val Leu Asp Glu Ala
 180 185 190
 Tyr Cys Glu Tyr Val Thr Ser Pro Ala Tyr Pro Asp Gly Leu Asp Phe
 195 200 205
 Leu Arg Arg Gly Tyr Asn Val Val Val Leu Arg Thr Phe Ser Lys Ile
 210 215 220
 Tyr Gly Leu Ala Gly Leu Arg Ile Gly Tyr Gly Val Ala Asp Arg Glu
 225 230 235 240
 Leu Val Ala Glu Leu His Arg Val Arg Glu Pro Phe Asn Val Ser Ser
 245 250 255
 Ala Ala Gln Ile Ala Ala Leu Ala Leu Glu Asp Glu Glu Phe Val
 260 265 270
 Ala Leu Ser Arg Gln Val Asn Glu Glu Gly Lys Val Phe Leu Tyr Arg
 275 280 285
 Glu Leu Glu Arg Arg Gly Ile Ala Tyr Val Pro Thr Glu Ala Asn Phe
 290 295 300
 Leu Leu Phe Asp Ala Gly Arg Asp Glu Gln Glu Val Phe Arg Arg Met
 305 310 315 320
 Leu Arg Gln Gly Val Ile Ile Arg Xxx Gly Val Gly Tyr Pro Thr His
 325 330 335
 Leu Arg Val Thr Ile Gly Thr Leu Glu Gln Asn Gln Arg Phe Leu Glu
 340 345 350
 Ala Leu Asp Lys Ala Leu Glu Leu Arg Gly Val
 355 360 363

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 52 NUCLEOTIDES
 (B) TYPE: NUCLEIC ACID
 (C) STRANDEDNESS: SINGLE
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

CCGAGAATTC ATTAAGAGG AGAAATTAAC TATGAGAAAAA GGACTTGCAA GT

52

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 31 NUCLEOTIDES
 (B) TYPE: NUCLEIC ACID
 (C) STRANDEDNESS: SINGLE
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

CGGAGGATCC TTAGATCTCT TCAAGGGCTT T
 31

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 1,085 NUCLEOTIDES
 (B) TYPE: NUCLEIC ACID
 (C) STRANDEDNESS: SINGLE
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

ATG AGA AAA GGA CTT GCA AGT AGG GTA AGT CAC CTA AAA CCT TCC CCC Met Arg Lys Gly Leu Ala Ser Arg Val Ser His Leu Lys Pro Ser Pro 5 10 15	48
ACG CTG ACC ATA ACC GCA AAA GCA AAA GAA TTA AGG GCT AAA GGA GTG Thr Leu Thr Ile Thr Ala Lys Ala Lys Glu Leu Arg Ala Lys Gly Val 20 25 30	96
GAC GTT ATA GGT TTT GGA GCG GGA GAA CCT GAC TTC GAC ACA CCC GAC Asp Val Ile Gly Phe Gly Ala Gly Glu Pro Asp Phe Asp Thr Pro Asp 35 40 45	144
TTC ATA AAG GAA GCC TGT ATA AGG GCT TTA AGG GAA GGA AAG ACC AAG Phe Ile Lys Glu Ala Cys Ile Arg Ala Leu Arg Glu Gly Lys Thr Lys 50 55 60	192
TAC GCT CCC TCC GCG GGA ATA CCA GAG CTC AGA GAA GCT ATA GCT GAA Tyr Ala Pro Ser Ala Gly Ile Pro Glu Leu Arg Glu Ala Ile Ala Glu 65 70 75 80	240
AAA CTA CTG AAA GAA AAC AAA GTT GAG TAC AAA CCT TCA GAG ATA GTC Lys Leu Lys Glu Asn Lys Val Glu Tyr Lys Pro Ser Glu Ile Val 85 90 95	288
GTT TCC GCA GGA GCG AAA ATG GTT CTC TTC CTC ATA TTC ATG GCT ATA Val Ser Ala Gly Ala Lys Met Val Leu Phe Leu Ile Phe Met Ala Ile 100 105 110	336
CTG GAC GAA GGA GAC GAG GTT TTA CTA CCT AGC CCT TAC TGG GTA ACT Leu Asp Glu Gly Asp Glu Val Leu Leu Pro Ser Pro Tyr Trp Val Thr 115 120 125	384
TAC CCC GAA CAG ATA AGG TTC TTC GGA GGG GTT CCC GTT GAG GTT CCT Tyr Pro Glu Gln Ile Arg Phe Phe Gly Val Pro Val Glu Val Pro 130 135 140	432

CTA AAG AAA GAG AAA GGA TTT CAA TTA AGT CTG GAA GAT GTG AAA GAA Leu Lys Lys Glu Lys Gly Phe Gln Leu Ser Leu Glu Asp Val Lys Glu 145 150 155 160	480
AAG GTT ACG GAG AGA ACA AAA GCT ATA GTC ATA AAC TCT CCG AAC AAC Lys Val Thr Glu Arg Thr Lys Ala Ile Val Ile Asn Ser Pro Asn Asn 165 170 175	528
CCC ACT GGT GCT GTT TAC GAA GAG GAG GAA CTT AAG AAA ATA GCG GAG Pro Thr Gly Ala Val Tyr Glu Glu Glu Leu Lys Ile Ala Glu 180 185 190	576
TTT TGC GTG GAG AGG GGC ATT TTC ATA ATT TCC GAT GAG TGC TAT GAG Phe Cys Val Glu Arg Gly Ile Phe Ile Ile Ser Asp Glu Cys Tyr Glu 195 200 205	624
TAC TTC GTT TAC GGT GAT GCA AAA TTT GTT AGC CCT GCC TCT TTC TCG Tyr Phe Val Tyr Gly Asp Ala Lys Phe Val Ser Pro Ala Ser Phe Ser 210 215 220	672
GAT GAA GTA AAG AAC ATA ACC TTC ACG GTA AAC GCC TTT TCG AAG AGC Asp Glu Val Lys Asn Ile Thr Phe Thr Val Asn Ala Phe Ser Lys Ser 225 230 235 240	720
TAT TCC ATG ACT GGT TGG CGA ATA GGT TAT GTA GCG TGC CCC GAA GAG Tyr Ser Met Thr Gly Trp Arg Ile Gly Tyr Val Ala Cys Pro Glu Glu 245 250 255	768
TAC GCA AAA GTG ATA GCG AGT CTT AAC AGC CAG AGT GTT TCC AAC GTC Tyr Ala Lys Val Ile Ala Ser Leu Asn Ser Gln Ser Val Ser Asn Val 260 265 270	816
ACT ACC TTT GCC CAG TAT GGA GCT CTT GAG GCC TTG AAA AAT CCA AAG Thr Thr Phe Ala Gln Tyr Gly Ala Leu Glu Ala Leu Lys Asn Pro Lys 275 280 285	864
TCT AAA GAT TTT GTA AAC GAA ATG AGA AAT GCT TTT GAA AGG AGA AGG Ser Lys Asp Phe Val Asn Glu Met Arg Asn Ala Phe Glu Arg Arg Arg 290 295 300	912
GAT ACG GCT GTA GAA GAG CTT TCT AAA ATT CCA GGT ATG GAT GTG GTA Asp Thr Ala Val Glu Glu Leu Ser Lys Ile Pro Gly Met Asp Val Val 305 310 315 320	960
AAA CCC GAA GGT GCC TTT TAC ATA TTT CCG GAC TTC TCC GCT TAC GCT Lys Pro Glu Gly Ala Phe Tyr Ile Phe Pro Asp Phe Ser Ala Tyr Ala 325 330 335	1008
GAG AAA CTG GGT GGT GAT GTG AAA CTC TCG GAG TTC CTT CTG GAA AAG Glu Lys Leu Gly Gly Asp Val Lys Leu Ser Glu Phe Leu Leu Glu Lys 340 345 350	1056
GCT AAG GTT GCG GTG GTT CCC GGT TCG GCC TTC GGA GCT CCC GGA TTT Ala Lys Val Ala Val Val Pro Gly Ser Ala Phe Gly Ala Pro Gly Phe 355 360 365	1104
TTG AGG CTT TCT TAC GCC CTT TCC GAG GAA AGA CTC GTT GAG GGT ATA Leu Arg Leu Ser Tyr Ala Leu Ser Glu Glu Arg Leu Val Glu Gly Ile 370 375 380	1152
AGG AGA ATA AAG AAA GCC CTT GAA GAG ATC TAA Arg Arg Ile Lys Ala Leu Glu Glu Ile	1185

385

390

394

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 394 AMINO ACIDS
 (B) TYPE: AMINO ACID
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: polypeptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Met Arg Lys Gly Leu Ala Ser Arg Val Ser His Leu Lys Pro Ser Pro
 5 10 15

Thr Leu Thr Ile Thr Ala Lys Ala Lys Glu Leu Arg Ala Lys Gly Val
 20 25 30

Asp Val Ile Gly Phe Gly Ala Gly Glu Pro Asp Phe Asp Thr Pro Asp
 35 40 45

Phe Ile Lys Glu Ala Cys Ile Arg Ala Leu Arg Glu Gly Lys Thr Lys
 50 55 60

Tyr Ala Pro Ser Ala Gly Ile Pro Glu Leu Arg Glu Ala Ile Ala Glu
 65 70 75 80

Lys Leu Leu Lys Glu Asn Lys Val Glu Tyr Lys Pro Ser Glu Ile Val
 85 90 95

Val Ser Ala Gly Ala Lys Met Val Leu Phe Leu Ile Phe Met Ala Ile
 100 105 110

Leu Asp Glu Gly Asp Glu Val Leu Leu Pro Ser Pro Tyr Trp Val Thr
 115 120 125

Tyr Pro Glu Gln Ile Arg Phe Phe Gly Val Pro Val Glu Val Pro
 130 135 140

Leu Lys Lys Glu Lys Gly Phe Gln Leu Ser Leu Glu Asp Val Lys Glu
 145 150 155 160

Lys Val Thr Glu Arg Thr Lys Ala Ile Val Ile Asn Ser Pro Asn Asn
 165 170 175

Pro Thr Gly Ala Val Tyr Glu Glu Glu Leu Lys Ile Ala Glu
 180 185 190

Phe Cys Val Glu Arg Gly Ile Phe Ile Ile Ser Asp Glu Cys Tyr Glu
 195 200 205

Tyr Phe Val Tyr Gly Asp Ala Lys Phe Val Ser Pro Ala Ser Phe Ser
 210 215 220

Asp Glu Val Lys Asn Ile Thr Phe Thr Val Asn Ala Phe Ser Lys Ser
 225 230 235 240

Tyr Ser Met Thr Gly Trp Arg Ile Gly Tyr Val Ala Cys Pro Glu Glu
 245 250 255

Tyr Ala Lys Val Ile Ala Ser Leu Asn Ser Gln Ser Val Ser Asn Val
260 265 270

Thr Thr Phe Ala Gln Tyr Gly Ala Leu Glu Ala Leu Lys Asn Pro Lys
275 280 285

Ser Lys Asp Phe Val Asn Glu Met Arg Asn Ala Phe Glu Arg Arg Arg
290 295 300

Asp Thr Ala Val Glu Glu Leu Ser Lys Ile Pro Gly Met Asp Val Val
305 310 315 320

Lys Pro Glu Gly Ala Phe Tyr Ile Phe Pro Asp Phe Ser Ala Tyr Ala
325 330 335

Glu Lys Leu Gly Gly Asp Val Lys Leu Ser Glu Phe Leu Leu Glu Lys
340 345 350

Ala Lys Val Ala Val Val Pro Gly Ser Ala Phe Gly Ala Pro Gly Phe
355 360 365

Leu Arg Leu Ser Tyr Ala Leu Ser Glu Glu Arg Leu Val Glu Gly Ile
370 375 380

Arg Arg Ile Lys Lys Ala Leu Glu Glu Ile
385 390 394

What Is Claimed Is:

1. An isolated polynucleotide comprising a member selected from the group consisting of:
 - (a) a polynucleotide having at least a 70% identity to a polynucleotide encoding an enzyme comprising amino acid sequences set forth in SEQ ID NOS:25-32, 35 and 40;
 - (b) a polynucleotide which is complementary to the polynucleotide of (a); and
 - (c) a polynucleotide comprising at least 15 consecutive bases of the polynucleotide of (a) or (b).
2. The polynucleotide of Claim 1 wherein the polynucleotide is DNA.
3. The polynucleotide of Claim 1 wherein the polynucleotide is RNA.
4. The polynucleotide of Claim 2 which encodes an enzyme comprising amino acids 1 to 414 of SEQ ID NO:25.
5. The polynucleotide of Claim 2 which encodes an enzyme comprising amino acids 1 to 373 of SEQ ID NO:26.
6. The polynucleotide of Claim 2 which encodes an enzyme comprising amino acids 1 to 453 of SEQ ID NO:27.
7. The polynucleotide of Claim 2 which encodes an enzyme comprising amino acids 1 to 343 of SEQ ID NO:28.
8. The polynucleotide of Claim 2 which encodes an enzyme comprising amino acids 1 to 398 of SEQ ID NO:29.

9. The polynucleotide of Claim 2 which encodes an enzyme comprising amino acids 1 to 592 of SEQ ID NO:30.

10. The polynucleotide of Claim 2 which encodes an enzyme comprising amino acids 1 to 354 of SEQ ID NO:31.

11. The polynucleotide of Claim 2 which encodes an enzyme comprising amino acids 1 to 303 of SEQ ID NO:32.

12. The polynucleotide of Claim 2 which encodes an enzyme comprising amino acids 1 to 363 of SEQ ID NO:36.

13. The polynucleotide of Claim 2 which encodes an enzyme comprising amino acids 1 to 394 of SEQ ID NO:40.

14. An isolated polynucleotide comprising a member selected from the group consisting of:

(a) a polynucleotide having at least a 70% identity to a polynucleotide encoding an enzyme expressed by the DNA contained in ATCC Deposit No. _____;

(b) a polynucleotide complementary to the polynucleotide of (a); and

(c) a polynucleotide comprising at least 15 consecutive bases of the polynucleotide of (a) and (b).

15. A vector comprising the DNA of Claim 2.

16. A host cell comprising the vector of Claim 13.

17. A process for producing a polypeptide comprising: expressing from the host cell of Claim 14 a polypeptide encoded by said DNA.

18. A process for producing a cell comprising: transforming or transfecting the cell with the vector of Claim 14 such that the cell expresses the polypeptide encoded by the DNA contained in the vector.

19. An enzyme comprising a member selected from the group consisting of an enzyme comprising an amino acid sequence which is at least 70% identical to the amino acid sequence set forth in SEQ ID NOS:25-32, 36 and 40.

20. A method for transferring an amino group from an amino acid to an α -keto acid comprising:

contacting an amino acid in the presence of an α -keto acid with an enzyme selected from the group consisting of an enzyme having the amino acid sequence set forth in SEQ ID NOS:25-32, 36 and 40.

FIGURE 1

ATG ATT GAA GAC CCT ATG GAC TGG GCT TTT CCG AGG ATA AAG AGA CTG Met Ile Glu Asp Pro Met Asp Trp Ala Phe Pro Arg Ile Lys Arg Leu	48
5 10 15	
CCT CAG TAT GTC TTC TCT CTC GTT AAC GAA CTC AAG TAC AAG CTA AGG Pro Gln Tyr Val Phe Ser Leu Val Asn Glu Leu Lys Tyr Lys Leu Arg	96
20 25 30	
CGT GAA GGC GAA GAT GTA GTG GAT CTT GGT ATG GGC AAT CCT AAC ATG Arg Glu Gly Glu Asp Val Val Asp Leu Gly Met Gly Asn Pro Asn Met	144
35 40 45	
CCT CCA GCA AAG CAC ATA ATA GAT AAA CTC TGC GAA GTG GCT CAA AAG Pro Pro Ala Lys His Ile Ile Asp Lys Leu Cys Glu Val Ala Gln Lys	192
50 55 60	
CCG AAC GTT CAC GGA TAT TCT GCG TCA AGG GGC ATA CCA AGA CTG AGA Pro Asn Val His Gly Tyr Ser Ala Ser Arg Gly Ile Pro Arg Leu Arg	240
65 70 75 80	
AAG GCT ATA TGT AAC TTC TAC GAA GAA AGG TAC GGA GTG AAA CTC GAC Lys Ala Ile Cys Asn Phe Tyr Glu Glu Arg Tyr Gly Val Lys Leu Asp	288
85 90 95	
CCT GAG AGG GAG GCT ATA CTA ACA ATC GGT GCA AAG GAA GGG TAT TCT Pro Glu Arg Glu Ala Ile Leu Thr Ile Gly Ala Lys Glu Gly Tyr Ser	336
100 105 110	
CAT TTG ATG CTT GCG ATG ATA TCT CCG GGT GAT ACG GTA ATA GTT CCT His Leu Met Leu Ala Met Ile Ser Pro Gly Asp Thr Val Ile Val Pro	384
115 120 125	
AAT CCC ACC TAT CCT ATT CAC TAT TAC GCT CCC ATA ATT GCA GGA GGG Asn Pro Thr Tyr Pro Ile His Tyr Tyr Ala Pro Ile Ile Ala Gly Gly	432
130 135 140	
GAA GTT CAC TCA ATA CCC CTT AAC TTC TCG GAC GAT CAA GAT CAT CAG Glu Val His Ser Ile Pro Leu Asn Phe Ser Asp Asp Gln Asp His Gln	480
145 150 155 160	
GAA GAG TTT TTA AGG AGG CTT TAC GAG ATA GTA AAA ACC GCG ATG CCA Glu Glu Phe Leu Arg Arg Leu Tyr Glu Ile Val Lys Thr Ala Met Pro	528
165 170 175	
AAA CCC AAG GCT GTC GTC ATA AGC TTT CCT CAC AAT CCA ACG ACC ATA Lys Pro Lys Ala Val Val Ile Ser Phe Pro His Asn Pro Thr Thr Ile	576
180 185 190	
ACG GTA GAA AAG GAC TTT TTT AAA GAA ATA GTT AAG TTT GCA AAG GAA Thr Val Glu Lys Asp Phe Phe Lys Glu Ile Val Lys Phe Ala Lys Glu	624
195 200 205	
CAC GGT CTC TGG ATA ATA CAC GAT TTT GCG TAT GCG GAT ATA GCC TTT His Gly Leu Trp Ile Ile His Asp Phe Ala Tyr Ala Asp Ile Ala Phe	672
210 215 220	
GAC GGT TAC AAG CCC CCC TCA ATA CTC GAA ATA GAA GGT GCT AAA GAC Asp Gly Tyr Lys Pro Pro Ser Ile Leu Glu Ile Glu Gly Ala Lys Asp	720
225 230 235 240	

GTT GCG GTT GAG CTC TAC TCC ATG TCA AAG GGC TTT TCA ATG GCG GGC Val Ala Val Glu Leu Tyr Ser Met Ser Lys Gly Phe Ser Met Ala Gly 245 250 255	768
TGG AGG GTA GCC TTT GTC GTT GGA AAC GAA ATA CTC ATA AAA AAC CTT Trp Arg Val Ala Phe Val Val Gly Asn Glu Ile Leu Ile Lys Asn Leu 260 265 270	816
GCA CAC CTC AAA AGC TAC TTG GAT TAC GGT ATA TTT ACT CCC ATA CAG Ala His Leu Lys Ser Tyr Leu Asp Tyr Gly Ile Phe Thr Pro Ile Gln 275 280 285	864
GTG GCC TCT ATT ATC GCA TTA GAG AGC CCC TAC GAA ATC GTG GAA AAA Val Ala Ser Ile Ile Ala Leu Glu Ser Pro Tyr Glu Ile Val Glu Lys 290 295 300	912
ACC GCA AAG GTT TAC CAA AAA AGA AGA GAC GTT CTG GTG GAA GGG TTA Thr Ala Lys Val Tyr Gln Lys Arg Arg Asp Val Leu Val Glu Gly Leu 305 310 315 320	960
AAC AGG CTC GGC TGG AAA GTA AAA AAA CCT AAG GCT ACC ATG TTC GTC Asn Arg Leu Gly Trp Lys Val Lys Lys Pro Lys Ala Thr Met Phe Val 325 330 335	1008
TGG GCA AAG ATT CCC GAA TGG ATA AAT ATG AAC TCT CTG GAC TTT TCC Trp Ala Lys Ile Pro Glu Trp Ile Asn Met Asn Ser Leu Asp Phe Ser 340 345 350	1056
TTG TTC CTC CTA AAA GAG GCG AAG GTT GCG GTA TCC CCG GGT GTG GGC Leu Phe Leu Leu Lys Glu Ala Lys Val Ala Val Ser Pro Gly Val Gly 355 360 365	1104
TTT GGT CAG TAC GGA GAG GGG TAC GTA AGG TTT GCA CTT GTA GAA AAT Phe Gly Gln Tyr Gly Glu Gly Tyr Val Arg Phe Ala Leu Val Glu Asn 370 375 380	1152
GAA CAC AGG ATC AGA CAG GCT ATA AGG GGA ATA AGG AAA GCC TTC AGA Glu His Arg Ile Arg Gln Ala Ile Arg Gly Ile Arg Lys Ala Phe Arg 385 390 395 400	1200
AAA CTC CAG AAG GAG AGG AAA CTT GAA CCT GAG AGA AGT GCT TAA Lys Leu Gln Lys Glu Arg Lys Leu Glu Pro Glu Arg Ser Ala End 405 410 414	1245

FIGURE 2

ATG GAC AGG CTT GAA AAA GTA TCA CCC TTC ATA GTA ATG GAT ATC CTA Met Asp Arg Leu Glu Lys Val Ser Pro Phe Ile Val Met Asp Ile Leu 5 10 15	48
GCT CAG GCC CAG AAG TAC GAA GAC GTA GTA CAC ATG GAG ATA GGA GAG Ala Gln Ala Gln Lys Tyr Glu Asp Val Val His Met Glu Ile Gly Glu 20 25 30	96
CCC GAT TTA GAA CCG TCT CCC AAG GTA ATG GAA GCT CTG GAA CGT GCG Pro Asp Leu Glu Pro Ser Pro Lys Val Met Glu Ala Leu Glu Arg Ala 35 40 45	144
GTG AAG GAA AAG ACG TTC TTC TAC ACC CCT GCT CTG GGA CTC TGG GAA Val Lys Glu Lys Thr Phe Phe Tyr Thr Pro Ala Leu Gly Leu Trp Glu 50 55 60	192
CTC AGG GAA AGG ATA TCG GAG TTT TAC AGG AAA AAG TAC AGC GTT GAA Leu Arg Glu Arg Ile Ser Glu Phe Tyr Arg Lys Lys Tyr Ser Val Glu 65 70 75 80	240
GTT TCT CCA GAG AGA GTC ATC GTA ACT ACC GGA ACT TCG GGA GCG TTT Val Ser Pro Glu Arg Val Ile Val Thr Thr Gly Thr Ser Gly Ala Phe 85 90 95	288
CTC GTA GCC TAC GCC GTA ACA CTA AAT GCG GGA GAG AAG ATA ATC CTC Leu Val Ala Tyr Ala Val Thr Leu Asn Ala Gly Glu Lys Ile Ile Leu 100 105 110	336
CCA GAC CCC TCT TAC CCC TGT TAC AAA AAC TTT GCC TAC CTC TTA GAC Pro Asp Pro Ser Tyr Pro Cys Tyr Lys Asn Phe Ala Tyr Leu Leu Asp 115 120 125	384
GCT CAG CCG GTT TTC GTA AAC GTT GAC AAG GAA ACG AAT TAC GAA GTA Ala Gln Pro Val Phe Val Asn Val Asp Lys Glu Thr Asn Tyr Glu Val 130 135 140	432
AGG AAA GAG ATG ATA GAA GAC ATT GAT GCG AAA GCC CTT CAC ATT TCC Arg Lys Glu Met Ile Glu Asp Ile Asp Ala Lys Ala Leu His Ile Ser 145 150 155 160	480
TCG CCT CAA AAC CCT ACG GGC ACA CTC TAC TCA CCT GAA ACC CTG AAG Ser Pro Gln Asn Pro Thr Gly Thr Leu Tyr Ser Pro Glu Thr Leu Lys 165 170 175	528
GAA CTT GCG GAG TAC TGC GAA GAG AAG GGT ATG TAC TTC ATA TCC GAC Glu Leu Ala Glu Tyr Cys Glu Glu Lys Gly Met Tyr Phe Ile Ser Asp 180 185 190	576
GAG ATT TAC CAC GGA CTC GTT TAC GAA GGT AGG GAG CAC ACA GCA CTT Glu Ile Tyr His Gly Leu Val Tyr Glu Gly Arg Glu His Thr Ala Leu 195 200 205	624
GAG TTC TCT GAC AGG GCT ATT GTC ATA AAC GGG TTT TCT AAG TAC TTC Glu Phe Ser Asp Arg Ala Ile Val Ile Asn Gly Phe Ser Lys Tyr Phe 210 215 220	672
TGT ATG CCA GGT TTC AGG ATA GGG TGG ATG ATA GTT CCG GAA GAA CTC Cys Met Pro Gly Phe Arg Ile Gly Trp Met Ile Val Pro Glu Glu Leu 225 230 235 240	720

GTG AGA AAG GCG GAA ATA GTA ATT CAG AAC GTA TTT ATA TCT GCC CCG Val Arg Lys Ala Glu Ile Val Ile Gln Asn Val Phe Ile Ser Ala Pro 245 250 255	768
ACG CTC AGT CAG TAC GCC GCC CTT GAG GCT TTT GAT TAC GAG TAT TTG Thr Leu Ser Gln Tyr Ala Ala Leu Glu Ala Phe Asp Tyr Glu Tyr Leu 260 265 270	816
GAG AAG GTA AGA AAA ACC TTT GAA GAG AGG AGG AAC TTC CTT TAT GGG Glu Lys Val Arg Lys Thr Phe Glu Glu Arg Arg Asn Phe Leu Tyr Gly 275 280 285	864
GAA CTG AAA AAA CTC TTC AAG ATA GAC GCG AAA CCT CAG GGA GCT TTT Glu Leu Lys Lys Leu Phe Lys Ile Asp Ala Lys Pro Gln Gly Ala Phe 290 295 300	912
TAC GTA TGG GCA AAC ATA AGT GAT TAC TCC ACA GAT AGC TAC GAA TTT Tyr Val Trp Ala Asn Ile Ser Asp Tyr Ser Thr Asp Ser Tyr Glu Phe 305 310 315 320	960
GCT TTA AAA CTT TTA AGG GAG GCG AGG GTG GCG GTA ACG CCC GGG GTG Ala Leu Lys Leu Leu Arg Glu Ala Arg Val Ala Val Thr Pro Gly Val 325 330 335	1008
GAC TTT GGA AAA AAC AAA ACG AAG GAG TAT ATA AGG TTT GCT TAT ACG Asp Phe Gly Lys Asn Lys Thr Lys Glu Tyr Ile Arg Phe Ala Tyr Thr 340 345 350	1056
AGA AAG ATA GAA GAA CTT AAG GAG GGC GTT GAA AGG ATA AAG AAG TTC Arg Lys Ile Glu Glu Leu Lys Glu Gly Val Glu Arg Ile Lys Lys Phe 355 360 365	1104
TTA GAG AAG CTT AGC TGA Leu Glu Lys Leu Ser End 370	1122

FIGURE 3

ATG TGG GAA TTA GAC CCT AAA ACG CTC GAA AAG TGG GAC AAG GAG TAC Met Trp Glu Leu Asp Pro Lys Thr Leu Glu Lys Trp Asp Lys Glu Tyr 5 10 15	48
TTC TGG CAT CCA TTT ACC CAG ATG AAA GTC TAC AGA GAA GAA AAC Phe Trp His Pro Phe Thr Gln Met Lys Val Tyr Arg Glu Glu Glu Asn 20 25 30	96
CTG ATA TTT GAA CGC GGA GAA GGC GTT TAC CTG TGG GAC ATA TAC GGC Leu Ile Phe Glu Arg Gly Glu Gly Val Tyr Leu Trp Asp Ile Tyr Gly 35 40 45	144
AGG AAG TAT ATA GAT GCC ATA TCT TCC CTC TGG TGC AAC GTC CAC GGA Arg Lys Tyr Ile Asp Ala Ile Ser Ser Leu Trp Cys Asn Val His Gly 50 55 60	192
CAT AAC CAC CCT AAA CTG AAC GCA GTT ATG AAA CAG CTC TGT AAG His Asn His Pro Lys Leu Asn Asn Ala Val Met Lys Gln Leu Cys Lys 65 70 75 80	240
GTA GCT CAC ACA ACT ACT CTG GGA AGT TCC AAC GTT CCC GCC ATA CTC Val Ala His Thr Thr Leu Gly Ser Ser Asn Val Pro Ala Ile Leu 85 90 95	288
CTT GCA AAG AAG CTT GTA GAA ATT TCT CCT GAA GGA TTA AAC AAG GTC Leu Ala Lys Lys Leu Val Glu Ile Ser Pro Glu Gly Leu Asn Lys Val 100 105 110	336
TTT TAC TCC GAA GAC GGT GCG GAA GCA GTA GAG ATA GCG ATA AAG ATG Phe Tyr Ser Glu Asp Gly Ala Glu Ala Val Glu Ile Ala Ile Lys Met 115 120 125	384
GCT TAT CAC TAC TGG AAG AAC AAG GGA GTT AAA GGG AAA AAC GTT TTC Ala Tyr His Tyr Trp Lys Asn Lys Gly Val Lys Gly Lys Asn Val Phe 130 135 140	432
ATA ACG CTT TCC GAA GCC TAC CAC GGG GAT ACT GTA GGA GCG GTT AGC Ile Thr Leu Ser Glu Ala Tyr His Gly Asp Thr Val Gly Ala Val Ser 145 150 155 160	480
GTA GGG GGT ATA GAA CTC TTC CAC GGA ACT TAT AAA GAT CTC CTT TTC Val Gly Gly Ile Glu Leu Phe His Gly Thr Tyr Lys Asp Leu Leu Phe 165 170 175	528
AAG ACT ATA AAA CTC CCA TCT CCT TAC CTG TAC TGC AAG GAA AAG TAC Lys Thr Ile Lys Leu Pro Ser Pro Tyr Leu Tyr Cys Lys Glu Lys Tyr 180 185 190	576
GGG GAA CTC TGC CCT GAG TGC ACG GCA GAT TTA TTA AAA CAA CTG GAA Gly Glu Leu Cys Pro Glu Cys Thr Ala Asp Leu Leu Lys Gln Leu Glu 195 200 205	624
GAT ATC CTG AAG TCG CGG GAA GAT ATC GTT GCG GTC ATT ATG GAA GCG Asp Ile Leu Lys Ser Arg Glu Asp Ile Val Ala Val Ile Met Glu Ala 210 215 220	672
GGA ATT CAG GCA GCC GCG GGA ATG CTC CCC TTC CCT CCG GGA TTT TTG Gly Ile Gln Ala Ala Ala Gly Met Leu Pro Phe Pro Pro Gly Phe Leu 225 230 235 240	720

AAA GGC GTA AGG GAG CTT ACG AAG AAA TAC GAC ACT TTA ATG ATA GTT Lys Gly Val Arg Glu Leu Thr Lys Lys Tyr Asp Thr Leu Met Ile Val 245 250 255	768
GAC GAG GTT GCC ACG GGA TTT GGC AGG ACG GGA ACG ATG TTT TAC TGT Asp Glu Val Ala Thr Gly Phe Gly Arg Thr Gly Thr Met Phe Tyr Cys 260 265 270	816
GAG CAG GAA GGA GTC AGT CCG GAC TTT ATG TGT CTA GGT AAG GGT ATA Glu Gln Glu Gly Val Ser Pro Asp Phe Met Cys Leu Gly Lys Gly Ile 275 280 285	864
ACC GGA GGG TAC CTC CCG CTT GCT GCG ACA CTC ACA ACG GAC GAG GTG Thr Gly Tyr Leu Pro Leu Ala Ala Thr Leu Thr Thr Asp Glu Val 290 295 300	912
TTC AAT GCC TTT TTA GGT GAG TTC GGG GAG GCA AAG CAC TTT TAC CAC Phe Asn Ala Phe Leu Gly Glu Phe Gly Glu Ala Lys His Phe Tyr His 305 310 315 320	960
GGG CAC ACC TAC ACT GGA AAT AAC CTC GCC TGT TCC GTT GCA CTC GCA Gly His Thr Tyr Thr Gly Asn Asn Leu Ala Cys Ser Val Ala Leu Ala 325 330 335	1008
AAC TTA GAA GTT TTT GAG GAA GAA AGA ACT TTA GAG AAG CTC CAA CCA Asn Leu Glu Val Phe Glu Glu Arg Thr Leu Glu Lys Leu Gln Pro 340 345 350	1056
AAG ATA AAG CTT TTA AAG GAA AGG CTT CAG GAG TTC TGG GAA CTC AAG Lys Ile Lys Leu Leu Lys Glu Arg Leu Gln Glu Phe Trp Glu Leu Lys 355 360 365	1104
CAC GTT GGA GAT GTT AGA CAG CTA GGT TTT ATG GCT GGA ATA GAG CTG His Val Gly Asp Val Arg Gln Leu Gly Phe Met Ala Gly Ile Glu Leu 370 375 380	1152
GTG AAG GAC AAA GAA AAG GGA GAA CCT TTC CCT TAC GGT GAA AGG ACG Val Lys Asp Lys Glu Lys Gly Glu Pro Phe Pro Tyr Gly Glu Arg Thr 385 390 395 400	1200
GGA TTT AAG GTG GCT TAC AAG TGC AGG GAA AAA GGG GTG TTT TTG AGA Gly Phe Lys Val Ala Tyr Lys Cys Arg Glu Lys Gly Val Phe Leu Arg 405 410 415	1245
CCG CTC GGA GAC GTT ATG GTA TTG ATG ATG CCT CTT GTA ATA GAG GAA Pro Leu Gly Asp Val Met Val Leu Met Met Pro Leu Val Ile Glu Glu 420 425 430	1293
GAC GAA ATG AAC TAC GTT ATT GAT ACA CTT AAA TGG GCA ATT AAA GAG Asp Glu Met Asn Tyr Val Ile Asp Thr Leu Lys Trp Ala Ile Lys Glu 435 440 445	1341
CTT GAA AAA GAG GTG TAG Leu Glu Lys Glu Val End 450	1359

FIGURE 4

ATG ACA TAC TTA ATG AAC AAT TAC GCA AGG TTG CCC GTC AAG TTT GTC Met Thr Tyr Leu Met Asn Asn Tyr Ala Arg Leu Pro Val Lys Phe Val	48
5 10 15	
AGG GGA AAA GGT GTT TAC CTG TAC GAT GAG GAA GGA AAG GAG TAT CTT Arg Gly Lys Gly Val Tyr Leu Tyr Asp Glu Glu Gly Lys Glu Tyr Leu	96
20 25 30	
GAC TTT GTC TCC GGT ATA GGC GTC AAC TCC CTC GGT CAC GCT TAC CCA Asp Phe Val Ser Gly Ile Gly Val Asn Ser Leu Gly His Ala Tyr Pro	144
35 40 45	
AAA CTC ACA GAA GCT CTA AAA GAA CAG GTT GAG AAA CTC CTC CAC GTT Lys Leu Thr Glu Ala Leu Lys Glu Gln Val Glu Lys Leu Leu His Val	192
50 55 60	
TCA AAT CTT TAC GAA AAC CCG TGG CAG GAA GAA CTG GCT CAC AAA CTT Ser Asn Leu Tyr Glu Asn Pro Trp Gln Glu Leu Ala His Lys Leu	240
65 70 75 80	
GTA AAA CAC TTC TGG ACA GAA GGG AAG GTA TTT TTC GCA AAC AGC GGA Val Lys His Phe Trp Thr Glu Gly Lys Val Phe Phe Ala Asn Ser Gly	288
85 90 95	
ACG GAA AGT GTA GAG GCG GCT ATA AAG CTC GCA AGG AAG TAC TGG AGG Thr Glu Ser Val Glu Ala Ala Ile Lys Leu Ala Arg Lys Tyr Trp Arg	336
100 105 110	
GAT AAA GGA AAG AAC AAG TGG AAG TTT ATA TCC TTT GAA AAC TCT TTC Asp Lys Gly Lys Asn Lys Trp Lys Phe Ile Ser Phe Glu Asn Ser Phe	384
115 120 125	
CAC GGG AGA ACC TAC GGT AGC CTC TCC GCA ACG GGA CAG CCA AAG TTC His Gly Arg Thr Tyr Gly Ser Leu Ser Ala Thr Gly Gln Pro Lys Phe	432
130 135 140	
CAC AAA GGC TTT GAA CCT CTA GTT CCT GGA TTT TCT TAC GCA AAG CTG His Lys Gly Phe Glu Pro Leu Val Pro Gly Phe Ser Tyr Ala Lys Leu	480
145 150 155 160	
AAC GAT ATA GAC AGC GTT TAC AAA CTC CTA GAC GAG GAA ACC GCG GGG Asn Asp Ile Asp Ser Val Tyr Lys Leu Leu Asp Glu Glu Thr Ala Gly	528
165 170 175	
ATA ATT ATT GAA GTT ATA CAA GGA GAG GGC GGA GTA AAC GAG GCG AGT Ile Ile Ile Glu Val Ile Gln Gly Glu Gly Val Asn Glu Ala Ser	576
180 185 190	
GAG GAT TTT CTA AGT AAA CTC CAG GAA ATT TGT AAA GAA AAA GAT GTG Glu Asp Phe Leu Ser Lys Leu Gln Glu Ile Cys Lys Glu Lys Asp Val	624
195 200 205	
CTC TTA ATT ATA GAC GAA GTG CAA ACG GGA ATA GGA AGG ACC GGG GAA Leu Leu Ile Ile Asp Glu Val Gln Thr Gly Ile Gly Arg Thr Gly Glu	672
210 215 220	
TTC TAC GCA TAT CAA CAC TTC AAT CTA AAA CCG GAC GTA ATT GCG CTT Phe Tyr Ala Tyr Gln His Phe Asn Leu Lys Pro Asp Val Ile Ala Leu	720
225 230 235 240	

GCG AAG GGA CTC GGA GGA GGT GTG CCA ATA GGT GCC ATC CTT GCA AGG Ala Lys Gly Leu Gly Gly Val Pro Ile Gly Ala Ile Leu Ala Arg 245 250 255	768
GAA GAA GTG GCC CAG AGC TTT ACT CCC GGC TCC CAC GGC TCT ACC TTC Glu Glu Val Ala Gln Ser Phe Thr Pro Gly Ser His Gly Ser Thr Phe 260 265 270	816
GGA GGA AAC CCC TTA GCC TGC AGG GCG GGA ACA GTG GTA GTA GAT GAA Gly Gly Asn Pro Leu Ala Cys Arg Ala Gly Thr Val Val Val Asp Glu 275 280 285	864
GTT GAA AAA CTC CTG CCT CAC GTA AGG GAA GTG GGG AAT TAC TTC AAA Val Glu Lys Leu Leu Pro His Val Arg Glu Val Gly Asn Tyr Phe Lys 290 295 300	912
GAA AAA CTG AAG GAA CTC GGC AAA GGA AAG GTA AAG GGA AGA GGA TTG Glu Lys Leu Lys Glu Leu Gly Lys Gly Lys Val Lys Gly Arg Gly Leu 305 310 315 320	960
ATG CTC GGT CTT GAA CTT GAA AGA GAG TGT AAA GAT TAC GTT CTC AAG Met Leu Gly Leu Glu Leu Arg Glu Cys Lys Asp Tyr Val Leu Lys 325 330 335	1008
GCT CTT GAA AGG GAC TTC TCA TAA Ala Leu Glu Arg Asp Phe Ser End 340	1032

FIGURE 5

ATG CGG AAA CTG GCC GAG CGG GCG CAG AAA CTG AGC CCC TCT CCC ACC Met Arg Lys Leu Ala Glu Arg Ala Gln Lys Leu Ser Pro Ser Pro Thr 5 10 15	48
CTC TCG GTG GAC ACC AAG GCC AAG GAG CTT TTG CGG CAG GGG GAA AGG Leu Ser Val Asp Thr Lys Ala Lys Glu Leu Leu Arg Gln Gly Glu Arg 20 25 30	96
GTC ATC AAT TTC GGG GCG GGG GAG CCG GAC TTC GAT ACA CCG GAA CAC Val Ile Asn Phe Gly Ala Gly Glu Pro Asp Phe Asp Thr Pro Glu His 35 40 45	144
ATC AAG GAA GCG GCG AAG CGA GCT TTA GAT CAG GGC TTC ACC AAG TAC Ile Lys Glu Ala Ala Lys Arg Ala Leu Asp Gln Gly Phe Thr Lys Tyr 50 55 60	192
ACG CCG GTG GCT GGG ATC TTA CCT CTT CGG GAG GCC ATA TGC GAG AAG Thr Pro Val Ala Gly Ile Leu Pro Leu Arg Glu Ala Ile Cys Glu Lys 65 70 75 80	240
CTT TAC CGC GAC AAT CAA CTG GAA TAC AGC CCG AAT GAG ATC GTG GTC Leu Tyr Arg Asp Asn Gln Leu Glu Tyr Ser Pro Asn Glu Ile Val Val 85 90 95	288
TCC TGT GGC GCC AAG CAT TCT ATT TTC AAC GCT CTG CAG GTC CTC CTG Ser Cys Gly Ala Lys His Ser Ile Phe Asn Ala Leu Gln Val Leu Leu 100 105 110	336
GAC CCG GGG GAC GAG GTG ATA ATC CCC GTC CCC TAC TGG ACT TCC TAT Asp Pro Gly Asp Glu Val Ile Ile Pro Val Pro Tyr Trp Thr Ser Tyr 115 120 125	384
CCG GAG CAG GTG AAG CTG GCG GGA GGG GTG CCG GTT TTC GTC CCC ACC Pro Glu Gln Val Lys Leu Ala Gly Gly Val Pro Val Phe Val Pro Thr 130 135 140	432
TCT CCC GAG AAC GAC TTC AAG CTC AGG CCG GAA GAT CTA CGT GCG GCT Ser Pro Glu Asn Asp Phe Lys Leu Arg Pro Glu Asp Leu Arg Ala Ala 145 150 155 160	480
GTA ACC CCG CGC ACC CGC CTT TTG ATC CTC AAT TCC CCG GCC AAC CCC Val Thr Pro Arg Thr Arg Leu Leu Ile Leu Asn Ser Pro Ala Asn Pro 165 170 175	528
ACA GGC ACC GTT TAC CGC CGG GAG GAA CTT ATC GGC TTA GCG GAG GTA Thr Gly Thr Val Tyr Arg Arg Glu Glu Leu Ile Gly Leu Ala Glu Val 180 185 190	576
GCC CTG GAG GCC GAC CTA TGG ATC TTG TCG GAC GAG ATC TAC GAA AAG Ala Leu Glu Ala Asp Leu Trp Ile Leu Ser Asp Glu Ile Tyr Glu Lys 195 200 205	624
CTG ATC TAC GAC GGG ATG GAG CAC GTG AGC ATA GCC GCG CTC GAC CCG Leu Ile Tyr Asp Gly Met Glu His Val Ser Ile Ala Ala Leu Asp Pro 210 215 220	672
GAG GTC AAA AAG CGC ACG ATT GTG GTA AAC GGT GTT TCC AAG GCT TAC Glu Val Lys Lys Arg Thr Ile Val Val Asn Gly Val Ser Lys Ala Tyr 225 230 235 240	720

GCC ATG ACC GGT TGG CGC ATA GGT TAT GCT GCC GCT CCC CGG CCG ATA Ala Met Thr Gly Trp Arg Ile Gly Tyr Ala Ala Ala Pro Arg Pro Ile 245 250 255	768
GCC CAG GCC ATG ACC AAC CTC CAA AGC CAC AGT ACC TCT AAC CCC ACT Ala Gln Ala Met Thr Asn Leu Gln Ser His Ser Thr Ser Asn Pro Thr 260 265 270	816
TCC GTA GCC CAG GCG GCG CTG GCC GCT CTG AAG GGG CCA CAA GAG Ser Val Ala Gln Ala Ala Leu Ala Ala Leu Lys Gly Pro Gln Glu 275 280 285	864
CCG GTG GAG AAC ATG CGC CGG GCT TTT CAA AAG CGG CGG GAT TTC ATC Pro Val Glu Asn Met Arg Arg Ala Phe Gln Lys Arg Arg Asp Phe Ile 290 295 300	912
TGG CAG TAC CTA AAC TCC TTA CCC GGA GTG CGC TGC CCC AAA CCT TTA Trp Gln Tyr Leu Asn Ser Leu Pro Gly Val Arg Cys Pro Lys Pro Leu 305 310 315 320	960
GGG GCC TTT TAC GTC TTT CCA GAA GTT GAG CGG GCT TTT GGG CCG CCG Gly Ala Phe Tyr Val Phe Pro Glu Val Glu Arg Ala Phe Gly Pro Pro 325 330 335	1008
TCT AAA AGG ACG GGA AAT ACT ACC GCT AGC GAC CTG GCC CTT TTC CTC Ser Lys Arg Thr Gly Asn Thr Ala Ser Asp Leu Ala Leu Phe Leu 340 345 350	1056
CTG GAA GAG ATA AAA GTG GCC ACC GTG GCT GGG GCT GCC TTT GGG GAC Leu Glu Glu Ile Lys Val Ala Thr Val Ala Gly Ala Ala Phe Gly Asp 355 360 365	1104
GAT CGC TAC CTG CGC TTT TCC TAC GCC CTG CGG CTG GAA GAT ATC GAA Asp Arg Tyr Leu Arg Phe Ser Tyr Ala Leu Arg Leu Glu Asp Ile Glu 370 375 380	1152
GAG GGG ATG CAA CGG TTT AAA GAA TTG ATC GAA GCG GCA CTT TAA Glu Gly Met Gln Arg Phe Lys Glu Leu Ile Glu Ala Ala Leu End 385 390 395	1197

FIGURE 6

ATG TGC GGG ATA GTC GGA TAC GTA GGG AGG GAT TTA GCC CTT CCT ATA Met Cys Gly Ile Val Gly Tyr Val Gly Arg Asp Leu Ala Leu Pro Ile 5 10 15	48
GTC CTC GGA GCT CTT GAG AGA CTC GAA TAC AGG GGT TAC GAC TCC GCG Val Leu Gly Ala Leu Glu Arg Leu Glu Tyr Arg Gly Tyr Asp Ser Ala 20 25 30	96
GGA GTT GCC CTT ATA GAA GAC GGG AAA CTC ATA GTT GAA AAG AAG AAG Gly Val Ala Leu Glu Asp Gly Lys Leu Ile Val Glu Lys Lys Lys 35 40 45	144
GGA AAG ATA AGG GAA CTC GTT AAA GCG CTA TGG GGA AAG GAT TAC AAG Gly Lys Ile Arg Glu Leu Val Lys Ala Leu Trp Gly Lys Asp Tyr Lys 50 55 60	192
GCT AAA ACG GGT ATA GGT CAC ACA CGC TGG GCA ACC CAC GGA AAG CCC Ala Lys Thr Gly Ile Gly His Thr Arg Trp Ala Thr His Gly Lys Pro 65 70 75 80	240
ACG GAC GAG AAC GCC CAC CCC CAC ACC GAC GAA AAA GGT GAG TTT GCA Thr Asp Glu Asn Ala His Pro His Thr Asp Glu Lys Gly Glu Phe Ala 85 90 95	288
GTA GTT CAC AAC GGG ATA ATA GAA AAC TAC TTA GAA CTA AAA GAG GAA Val Val His Asn Gly Ile Ile Glu Asn Tyr Leu Glu Leu Lys Glu Glu 100 105 110	336
CTA AAG AAG GAA GGT GTA AAG TTC AGG TCC GAA ACA GAC ACA GAA GTT Leu Lys Lys Glu Gly Val Lys Phe Arg Ser Glu Thr Asp Thr Glu Val 115 120 125	384
ATA GCC CAC CTC ATA GCG AAG AAC TAC AGG GGG GAC TTA CTG GAG GCC Ile Ala His Leu Ile Ala Lys Asn Tyr Arg Gly Asp Leu Leu Glu Ala 130 135 140	432
GTT TTA AAA ACC GTA AAG AAA TTA AAG GGT GCT TTT GCC TTT GCG GTT Val Leu Lys Thr Val Lys Lys Leu Lys Gly Ala Phe Ala Phe Ala Val 145 150 155 160	480
ATA ACG GTT CAC GAA CCA AAC AGA CTA ATA GGA GTG AAG CAG GGG AGT Ile Thr Val His Glu Pro Asn Arg Leu Ile Gly Val Lys Gln Gly Ser 165 170 175	528
CCT TTA ATC GTC GGA CTC GGA GAA GGA AAC TTC CTC GCT TCA GAT Pro Leu Ile Val Gly Leu Gly Glu Gly Glu Asn Phe Leu Ala Ser Asp 180 185 190	576
ATT CCC GCA ATA CTT CCT TAC ACG AAA AAG ATT ATT GTT CTT GAT GAC Ile Pro Ala Ile Leu Pro Tyr Thr Lys Lys Ile Ile Val Leu Asp Asp 195 200 205	624
GGG GAA ATA GCG GAC CTG ACT CCC GAC ACT GTG AAC ATT TAC AAC TTT Gly Glu Ile Ala Asp Leu Thr Pro Asp Thr Val Asn Ile Tyr Asn Phe 210 215 220	672
GAG GGA GAG CCC GTT TCA AAG GAA GTA ATG ATT ACG CCC TGG GAT CTT Glu Gly Glu Pro Val Ser Lys Glu Val Met Ile Thr Pro Trp Asp Leu 225 230 235 240	720

GTT TCT GCG GAA AAG GGT GGT TTT AAA CAC TTC ATG CTA AAA GAG ATA Val Ser Ala Glu Lys Gly Gly Phe Lys His Phe Met Leu Lys Glu Ile 245 250 255	768
TAC GAA CAG CCC AAA GCC ATA AAC GAC ACA CTC AAG GGT TTC CTC TCA Tyr Glu Gln Pro Lys Ala Ile Asn Asp Thr Leu Lys Gly Phe Leu Ser 260 265 270	816
ACC GAA GAC GCA ATA CCC TTT AAG TTA AAA GAC TTC AGA AGG GTT TTA Thr Glu Asp Ala Ile Pro Phe Lys Leu Lys Asp Phe Arg Arg Val Leu 275 280 285	864
ATA ATA GCG TGC GGG ACC TCT TAC CAC GCG GGC TTC GTC GGA AAG TAC Ile Ile Ala Cys Gly Thr Ser Tyr His Ala Gly Phe Val Gly Lys Tyr 290 295 300	912
TGG ATA GAG AGA TTT GCA GGT GTT CCC ACA GAG GTA ATT TAC GCT TCG Trp Ile Glu Arg Phe Ala Gly Val Pro Thr Glu Val Ile Tyr Ala Ser 305 310 315 320	960
GAA TTC AGG TAT GCG GAC GTT CCC GTT TCG GAC AAG GAT ATC GTT ATC Glu Phe Arg Tyr Ala Asp Val Pro Val Ser Asp Lys Asp Ile Val Ile 325 330 335	1008
GGA ATT TCC CAG TCA GGA GAG ACC GCT GAC ACA AAG TTT GCC CTT CAG Gly Ile Ser Gln Ser Gly Glu Thr Ala Asp Thr Lys Phe Ala Leu Gln 340 345 350	1056
TCC GCA AAG GAA AAG GGA GCC TTT ACC GTG GGA CTC GTA AAC GTA GTG Ser Ala Lys Glu Lys Gly Ala Phe Thr Val Gly Leu Val Asn Val Val 355 360 365	1104
GGA AGT GCC ATA GAC AGG GAG TCG GAC TTT TCC CTT CAC ACA CAT GCG Gly Ser Ala Ile Asp Arg Glu Ser Asp Phe Ser Leu His Thr His Ala 370 375 380	1152
GGA CCC GAA ATA GGC GTG GCG GCT ACA AAG ACC TTC ACC GCA CAG TTC Gly Pro Glu Ile Gly Val Ala Ala Thr Lys Thr Phe Thr Ala Gln Phe 385 390 395 400	1200
ACC GCA CTC TAC GCC CTT TCG GTA AGG GAA AGT GAG GAG AGG GAA AAT Thr Ala Leu Tyr Ala Leu Ser Val Arg Glu Ser Glu Glu Arg Glu Asn 405 410 415	1248
CTA ATA AGA CTC CTT GAA AAG GTT CCA TCA CTC GTT GAA CAA ACA CTG Leu Ile Arg Leu Leu Glu Lys Val Pro Ser Leu Val Glu Gln Thr Leu 420 425 430	1296
AAC ACC GCA GAA GAA GTG GAG AAG GTA GCG GAA AAG TAC ATG AAA AAG Asn Thr Ala Glu Glu Val Glu Lys Val Ala Glu Lys Tyr Met Lys Lys 435 440 445	1344
AAA AAC ATG CTT TAC CTC GGA AGG TAC TTA AAT TAC CCC ATA GCG CTG Lys Asn Met Leu Tyr Leu Gly Arg Tyr Leu Asn Tyr Pro Ile Ala Leu 450 455 460	1392
GAG GGA GCT CTT AAA CTT AAA GAA ATT TCT TAC ATA CAC GCG GAA GGT Glu Gly Ala Leu Lys Leu Lys Glu Ile Ser Tyr Ile His Ala Glu Gly 465 470 475 480	1440
TAT CCC GCA GGG GAG ATG AAG CAC GGT CCC ATA GCC CTC ATA GAC GAA Tyr Pro Ala Gly Glu Met Lys His Gly Pro Ile Ala Leu Ile Asp Glu 485 490 495	1488

AAC ATG CCG GTT GTG GTA ATC GCA CCG AAA GAC AGG GTT TAC GAG AAG Asn Met Pro Val Val Val Ile Ala Pro Lys Asp Arg Val Tyr Glu Lys 500 505 510	1536
ATA CTC TCA AAC GTA GAA GAG GTT CTC GCA AGA AAG GGA AGG GTT ATT Ile Leu Ser Asn Val Glu Glu Val Leu Ala Arg Lys Gly Arg Val Ile 515 520 525	1584
TCT GTA GGC TTT AAA GGA GAC GAA ACT CTC AAA AGC AAA TCC GAG AGC Ser Val Gly Phe Lys Gly Asp Glu Thr Leu Lys Ser Lys Ser Glu Ser 530 535 540	1632
GTT ATG GAA ATC CCG AAG GCA GAA GAA CCG ATA ACT CCT TTC TTG ACG Val Met Glu Ile Pro Lys Ala Glu Glu Pro Ile Thr Pro Phe Leu Thr 545 550 555 560	1680
GTA ATA CCC CTG CAA CTC TTT GCC TAC TTT ATA GCG AGC AAA CTG GGA Val Ile Pro Leu Gln Leu Phe Ala Tyr Phe Ile Ala Ser Lys Leu Gly 565 570 575	1728
580	
CTG GAT GTG GAT CAG CCG AGA AAT CTC GCC AAA ACG GTC ACG GTG GAA Leu Asp Val Asp Gln Pro Arg Asn Leu Ala Lys Thr Val Thr Val Glu 580 585 590	1776
TAA	1779
End	

FIGURE 7

ATG ATA CCC CAG AGG ATT AAG GAA CTT GAA GCT TAC AAG ACG GAG GTC Met Ile Pro Gln Arg Ile Lys Glu Leu Glu Ala Tyr Lys Thr Glu Val 5 10 15	48
ACT CCC GCC TCC GTC AGG CTT TCC TCT AAC GAA TTC CCC TAC GAC TTT Thr Pro Ala Ser Val Arg Leu Ser Ser Asn Glu Phe Pro Tyr Asp Phe 20 25 30	96
CCC GAG GAG ATA AAA CAA AGG GCC TTA GAA GAA TTA AAA AAG GTT CCC Pro Glu Ile Lys Gln Arg Ala Leu Glu Glu Leu Lys Lys Val Pro 35 40 45	144
TTG AAC AAA TAC CCA GAC CCC GAA GCG AAA GAG TTA AAA GCG GTT CTT Leu Asn Lys Tyr Pro Asp Pro Glu Ala Lys Glu Leu Lys Ala Val Leu 50 55 60	192
GCG GAT TTT TTC GGC GTT AAG GAA GAA AAT TTA GTT CTC GGT AAC GGT Ala Asp Phe Phe Gly Val Lys Glu Glu Asn Leu Val Leu Gly Asn Gly 65 70 75 80	240
TCG GAC GAA CTC ATA TAC TAC CTC TCA ATA GCT ATA GGT GAA CTT TAC Ser Asp Glu Leu Ile Tyr Tyr Leu Ser Ile Ala Ile Gly Glu Leu Tyr 85 90 95	288
ATA CCC GTT TAC ATA CCT GTT CCC ACC TTT CCC ATG TAC GAG ATA AGT Ile Pro Val Tyr Ile Pro Val Pro Thr Phe Pro Met Tyr Glu Ile Ser 100 105 110	336
GCG AAA GTT CTC GGA AGA CCC CTC GTA AAG GTT CAA CTG GAC GAA AAC Ala Lys Val Leu Gly Arg Pro Leu Val Lys Val Gln Leu Asp Glu Asn 115 120 125	384
TTT GAT ATA GAC TTA GAA AGA AGT ATT GAA TTA ATA GAG AAA GAA AAA Phe Asp Ile Asp Leu Glu Arg Ser Ile Glu Leu Ile Glu Lys Glu Lys 130 135 140	432
CCC GTT CTC GGG TAC TTT GCT TAC CCA AAC AAC CCC ACG GGA AAC CTC Pro Val Leu Gly Tyr Phe Ala Tyr Pro Asn Asn Pro Thr Gly Asn Leu 145 150 155 160	480
TTT TCC AGG GGA AAG ATT GAG GAG ATA AGA AAC AGG GGT GTT TTC TGT Phe Ser Arg Gly Lys Ile Glu Glu Ile Arg Asn Arg Gly Val Phe Cys 165 170 175	528
GTA ATA GAC GAA GCC TAC TAT CAT TAC TCC GGA GAA ACC TTT CTG GAA Val Ile Asp Glu Ala Tyr Tyr His Tyr Ser Gly Glu Thr Phe Leu Glu 180 185 190	576
GAC GCG CTC AAA AGG GAA GAT ACG GTA GTT TTG AGG ACA CTT TCA AAA Asp Ala Leu Lys Arg Glu Asp Thr Val Val Leu Arg Thr Leu Ser Lys 195 200 205	624
ATC GGT ATG GCG AGT TTA AGG GTA GGG ATT TTA ATA GGG AAG GGG GAA Ile Gly Met Ala Ser Leu Arg Val Gly Ile Leu Ile Gly Lys Gly Glu 210 215 220	672
ATC GTC TCA GAA ATT AAC AAG GTG AGA CTC CCC TTC AAC GTG ACC TAC Ile Val Ser Glu Ile Asn Lys Val Arg Leu Pro Phe Asn Val Thr Tyr 225 230 235 240	720

CCC TCT CAG GTG ATG GCA AAA GTT CTC CTC ACG GAG GGA AGA GAA TTC Pro Ser Gln Val Met Ala Lys Val Leu Leu Thr Glu Gly Arg Glu Phe 245 250 255	768
CTA ATG GAA AAG ATA CAG GAG GTT GTA ACA GAG CGA GAA AGG ATG TAC Leu Met Glu Lys Ile Gln Glu Val Val Thr Glu Arg Glu Arg Met Tyr 260 265 270	816
GAC GAA ATG AAG AAA ATA GAA GGA GTT GAG GTT TTT CCG AGT AAG GCT Asp Glu Met Lys Lys Ile Glu Gly Val Glu Val Phe Pro Ser Lys Ala 275 280 285	864
AAC TTC TTG CTT TTC AGA ACG CCT TAC CCC GCC CAC GAG GTT TAT CAG Asn Phe Leu Leu Phe Arg Thr Pro Tyr Pro Ala His Glu Val Tyr Gln 290 295 300	912
GAG CTA CTG AAA AGG GAT GTC CTC GTC AGG AAC GTA TCT TAC ATG GAA Glu Leu Leu Lys Arg Asp Val Leu Val Arg Asn Val Ser Tyr Met Glu 305 310 315 320	960
GGA CTC CAA AAG TGC CTC AGG GTA AGC GTA GGG AAA CCG GAA GAA AAC Gly Leu Gln Lys Cys Leu Arg Val Ser Val Gly Lys Pro Glu Glu Asn 325 330 335	1008
AAC AAG TTT CTG GAA GCA CTG GAG GAG AGT ATA AAA TCC CTT TCA AGC Asn Lys Phe Leu Glu Ala Leu Glu Ser Ile Lys Ser Leu Ser Ser 340 345 350	1056
TCT CTT TAA Ser Leu End	1065

FIGURE 8

ATG AAG CCG TAC GCT AAA TAT ATC TGG CTT GAC GGC AGA ATA CTT AAG Met Lys Pro Tyr Ala Lys Tyr Ile Trp Leu Asp Gly Arg Ile Leu Lys 5 10 15	48
TGG GAA GAC GCG AAA ATA CAC GTG TTG ACT CAC GCG CTT CAC TAC GGA Trp Glu Asp Ala Lys Ile His Val Leu Thr His Ala Leu His Tyr Gly 20 25 30	96
ACC TCT ATA TTC GAG GGA ATA AGA GGG TAT TGG AAC GGC GAT AAT TTG Thr Ser Ile Phe Glu Gly Ile Arg Gly Tyr Trp Asn Gly Asp Asn Leu 35 40 45	144
CTC GTC TTT AGG TTA GAA GAA CAC ATC GAC CGC ATG TAC AGA TCG GCT Leu Val Phe Arg Leu Glu His Ile Asp Arg Met Tyr Arg Ser Ala 50 55 60	192
AAG ATA CTA GGC ATA AAT ATT CCG TAT ACA AGA GAG GAA GTC CGC CAA Lys Ile Leu Gly Ile Asn Ile Pro Tyr Thr Arg Glu Glu Val Arg Gln 65 70 75 80	240
GCT GTA CTA GAG ACC ATA AAG GCT AAT AAC TTC CGA GAG GAT GTC TAC Ala Val Leu Glu Thr Ile Lys Ala Asn Phe Arg Glu Asp Val Tyr 85 90 95	288
ATA AGA CCT GTG GCG TTT GTC GCC TCG CAG ACG GTG ACG CTT GAC ATA Ile Arg Pro Val Ala Phe Val Ala Ser Gln Thr Val Thr Leu Asp Ile 100 105 110	336
AGA AAT TTG GAA GTC TCC CTC GCG GTT ATT GTA TTC CCA TTT GGC AAA Arg Asn Leu Glu Val Ser Leu Ala Val Ile Val Phe Pro Phe Gly Lys 115 120 125	384
TAC CTC TCG CCC AAC GGC ATT AAG GCA ACG ATT GTA AGC TGG CGT AGA Tyr Leu Ser Pro Asn Gly Ile Lys Ala Thr Ile Val Ser Trp Arg Arg 130 135 140	432
GTA CAT AAT ACA ATG CTC CCT GTG ATG GCA AAA ATC GGC GGT ATA TAT Val His Asn Thr Met Leu Pro Val Met Ala Lys Ile Gly Gly Ile Tyr 145 150 155 160	480
GTA AAC TCT GTA CTT GCG CTT GTA GAG GCT AGA AGC AGG GGA TTT GAC Val Asn Ser Val Leu Ala Leu Val Glu Ala Arg Ser Arg Gly Phe Asp 165 170 175	528
GAG GCT TTA TTA ATG GAC GTT AAC GGT TAT GTT GAG GGT TCT GGA Glu Ala Leu Leu Met Asp Val Asn Gly Tyr Val Val Glu Gly Ser Gly 180 185 190	576
GAG AAT ATT TTC ATT GTC AGA GGT GGA AGG CTT TTC ACG CCG CCA GTC Glu Asn Ile Phe Ile Val Arg Gly Gly Arg Leu Phe Thr Pro Pro Val 195 200 205	624
CAC GAA TCT ATC CTC GAG GGA ATT ACG AGG GAT ACG GTA ATA AAG CTC His Glu Ser Ile Leu Glu Gly Ile Thr Arg Asp Thr Val Ile Lys Leu 210 215 220	672
AGC GGG GAT GTG GGA CTT CGG GTG GAG GAA AAG CCT ATT ACG AGG GAG Ser Gly Asp Val Gly Leu Arg Val Glu Glu Lys Pro Ile Thr Arg Glu 225 230 235 240	720

GAG GTG TAT ACA GCA GCC GAC GAG GTG TTT TTA GTA GGA ACC GCC GCA GAG	768	
Glu Val Tyr Thr Ala Asp Glu Val Phe Leu Val Gly Thr Ala Ala Glu		
245	250	255
ATA ACG CCA GTG GTG GAG GTT GAC GGC AGA ACA ATC GGC ACA GGC AAG	816	
Ile Thr Pro Val Val Glu Val Asp Gly Arg Thr Ile Gly Thr Gly Lys		
260	265	270
CCG GGC CCC ATT ACG ACA AAA ATA GCT GAG CTG TAC TCA AAC GTC GTG	864	
Pro Gly Pro Ile Thr Thr Lys Ile Ala Glu Leu Tyr Ser Asn Val Val		
275	280	285
AGA GGC AAA GTA GAG AAA TAC TTA AAT TGG ATC ACT CCT GTG TAT TAG	912	
Arg Gly Lys Val Glu Lys Tyr Leu Asn Trp Ile Thr Pro Val Tyr End		
290	295	300

FIGURE 9

Ammonifex degensii histidinol phosphate aminotransferase

1 ATG GCA GTC AAA GTG CGG CCT GAG CTC AGC CAG GTG GAG ATC TAC CGT CCC GGC AAA CCC 60
 1 Met Ala Val Lys Val Arg Pro Glu Leu Ser Gin Val Glu Ile Tyr Arg Pro Gly Lys Pro 20

 61 ATC GAA GAG GTA AAG AAG GAG CTG GGG CTG GAG GAG GTA GTC AAG CTG GCC TCC AAC GAG 120
 21 Ile Glu Glu Val Lys Glu Leu Gly Leu Glu Glu Val Val Lys Leu Ala Ser Asn Glu 40

 121 AAC CCT CTG GGA CCT TCT CCC AAG GCC GTG GCG GCG CTG GAG GGA CTG GAC CAC TGG CAC 180
 41 Asn Pro Leu Gly Pro Ser Pro Lys Ala Val Ala Ala Leu Glu Gly Leu Asp His Trp His 60

 181 CTT TAC CCA GAA GGC TCA AGC TAT GAG CTA CGG CAG GCG CTG GGT AAG AAA CTG GAG ATA 240
 61 Leu Tyr Pro Glu Gly Ser Ser Tyr Glu Leu Arg Gin Ala Leu Gly Lys Leu Glu Ile 80

 241 GAC CCG GAC AGC ATC ATC GTG GGT TGC GGC TCA AGC GAA GTC ATC CAG ATG CTC TCT TTG 300
 81 Asp Pro Asp Ser Ile Ile Val Gly Cys Gly Ser Ser Glu Val Ile Gin Met Leu Ser Leu 100

 301 GCC CTG CTG GCG CCC GGC GAC GAG GTG GTC ATC CCT GTG CCT ACC TTT CCC CGC TAT GAG 360
 101 Ala Leu Leu Ala Pro Glu Asp Glu Val Val Ile Pro Val Pro Thr Phe Pro Arg Tyr Glu 120

 361 CCC CTG GCA CGG CTC ATG GGG GCT AAT CCC GTA AAA GTT CCC TTG AAG GAC TAC CGC ATC 420
 121 Pro Leu Ala Arg Leu Met Gly Ala Asn Pro Val Lys Val Pro Leu Lys Asp Tyr Arg Ile 140

 421 GAT GTG GAG GCA GTG GCC CGA GCC CTT TCC CCC CGT ACC AAG CTG GTC TAC CTA TGC AAC 480
 141 Asp Val Glu Ala Val Ala Arg Ala Leu Ser Pro Arg Thr Lys Leu Val Tyr Leu Cys Asn 160

 481 CCC AAC AAC CCC ACC GGG ACC ATC GTC ACC CGG GAG GTG GAG TGG TTC TTG GAA AAG 540
 161 Pro Asn Asn Pro Thr Gly Thr Ile Val Thr Arg Glu Val Glu Trp Phe Leu Glu Lys 180

 541 GCG GGG GAG GGG GTT CTC ACC GTG CTG GAC GAG GCC TAC TGC GAG TAC GTG ACC AGC CCC 600
 181 Ala Gly Glu Gly Val Leu Thr Val Leu Asp Glu Ala Tyr Cys Glu Tyr Val Thr Ser Pro 200

 601 GCC TAC CCT GAT GGG CTC GAT TTC CTG CGC CGG GGC TAC AAT GTG GTG GTG CTG CGC ACC 660
 201 Ala Tyr Pro Asp Gly Leu Asp Phe Leu Arg Arg Gly Tyr Asn Val Val Leu Arg Thr 220

 661 TTC TCC AAG ATC TAC GGG CTG GCC GGG CTG CGC ATA GGG TAC GGT GTG GCG GAC AGG GAG 720
 221 Phe Ser Lys Ile Tyr Gly Leu Ala Gly Leu Arg Ile Gly Tyr Val Ala Asp Arg Glu 240

 721 CTG GTG GCG GAA CTG CAC CGG GTG CGG GAG CCT TTC AAT GTC AGT TCC GCT GCT CAG ATA 780
 241 Leu Val Ala Glu Leu His Arg Val Arg Glu Pro Phe Asn Val Ser Ser Ala Ala Glu Ile 260

 781 GCC GCC CTG GCC GCC CTG GAA GAC GAA GAG TTC GTG GCG CTT TCG CGC CAG GTC AAC GAA 840
 261 Ala Ala Leu Ala Leu Glu Asp Glu Glu Phe Val Ala Leu Ser Arg Gin Val Asn Glu 280

 841 GAA GGG AAG GTT TTT CTC TAC CGA GAA CTG GAG AGG CGG GGG ATC GCC TAC GTG CCC ACC 900
 281 Glu Gly Lys Val Phe Leu Tyr Arg Glu Leu Glu Arg Arg Gly Ile Ala Tyr Val Pro Thr 300

 901 GAG GCC AAC TTC CTA CTC TTC GAT GCC GGT CGG GAC GAG CAG GAA GAA GTA TTT CGC CGG ATG 960
 301 Glu Ala Asn Phe Leu Leu Phe Asp Ala Gly Arg Asp Glu Glu Val Phe Arg Arg Met 320

 961 CTG CGC CAG GGA GTG ATC ATC CGG GNC GGG GTG GGT TAT CCC ACC CAC TTA AGG GTG ACC 1020
 321 Leu Arg Glu Gly Val Ile Ile Arg Xxx Gly Val Gly Tyr Pro Thr His Leu Arg Val Thr 340

 1021 ATC GGC ACC TTG GAA CAG AAC CAG CGC TTC CTG GAA GCT TTG GAT AAG GCT CTA GAG CTT 1080
 341 Ile Glu Thr Leu Glu Glu Asn Glu Arg Phe Leu Glu Ala Leu Asp Lys Ala Leu Glu Leu 360

 1081 AGG GGG GTT TAA 1092
 361 Arg Gly Val End 364

FIGURE 10

Aquifex aspartate aminotransferase

1 ATG AGA AAA GGA CTT GCA AGT AGG GTA AGT CAC CTA AAA CCT TCC CCC ACG CTG ACC ATA 60
 Met Arg Lys Gly Leu Ala Ser Arg Val Ser His Leu Lys Pro Ser Pro Thr Leu Thr Ile
 61 ACC GCA AAA GCA AAA GAA TTA AGG GCT AAA GGA GTG GAC GTT ATA GGT TTT GGA GCG GGA 120
 Thr Ala Lys Ala Lys Glu Leu Arg Ala Lys Gly Val Asp Val Ile Gly Phe Gly Ala Gly
 121 GAA CCT GAC TTC GAC ACA CCC GAC TTC ATA AAG GAA GCC TGT ATA AGG GCT TTA AGG GAA 180
 Glu Pro Asp Phe Asp Thr Pro Asp Phe Ile Lys Glu Ala Cys Ile Arg Ala Leu Arg Glu
 181 GGA AAG ACC AAG TAC GCT CCC TCC GCG GGA ATA CCA GAG CTC AGA GAA GCT ATA GCT GAA 240
 Gly Lys Thr Lys Tyr Ala Pro Ser Ala Gly Ile Pro Glu Leu Arg Glu Ala Ile Ala Glu
 241 AAA CTA CTG AAA GAA AAC AAA GTT GAG TAC AAA CCT TCA GAG ATA GTC GTT TCC GCA GGA 300
 Lys Leu Leu Lys Glu Asn Lys Val Glu Tyr Lys Pro Ser Glu Ile Val Val Ser Ala Gly
 301 GCG AAA ATG GTT CTC TTC CTC ATA TTC ATG GCT ATA CTG GAC GAA GGA GAC GAG GTT TTA 360
 Ala Lys Met Val Leu Phe Leu Ile Phe Met Ala Ile Leu Asp Glu Gly Asp Glu Val Leu
 361 CTA CCT AGC CCT TAC TGG GTA ACT TAC CCC GAA CAG ATA AGG TTC TTC GGA GGG GTT CCC 420
 Leu Pro Ser Pro Tyr Trp Val Thr Tyr Pro Glu Gln Ile Arg Phe Phe Gly Gly Val Pro
 421 GTT GAG GTT CCT CTA AAG AAA GAG AAA GGA TTT CAA TTA AGT CTG GAA GAT GTG AAA GAA 480
 Val Glu Val Pro Leu Lys Lys Glu Lys Gly Phe Gln Leu Ser Leu Glu Asp Val Lys Glu
 481 AAG GTT ACG GAG AGA ACA AAA GCT ATA GTC ATA AAC TCT CCG AAC AAC CCC ACT GGT GCT 540
 Lys Val Thr Glu Arg Thr Lys Ala Ile Val Ile Asn Ser Pro Asn Asn Pro Thr Gly Ala
 541 GTT TAC GAA GAG GAG GAA CTT AAG AAA ATA GCG GAG TTT TGC GTG GAG AGG GGC ATT TTC 600
 Val Tyr Glu Glu Glu Leu Lys Lys Ile Ala Glu Phe Cys Val Glu Arg Gly Ile Phe
 601 ATA ATT TCC GAT GAG TGC TAT GAG TAC TTC GTT GGT GAT GCA AAA TTT GTT AGC CCT 660
 Ile Ile Ser Asp Glu Cys Tyr Glu Tyr Phe Val Tyr Gly Asp Ala Lys Phe Val Ser Pro
 661 GCC TCT TTC TCG GAT GAA GTA AAG AAC ATA ACC TTC ACG GTA AAC GCC TTT TCG AAG AGC 720
 Ala Ser Phe Ser Asp Glu Val Lys Asn Ile Thr Phe Thr Val Asn Ala Phe Ser Lys Ser
 721 TAT TCC ATG ACT GGT TGG CGA ATA GGT TAT GTA GCG TGC CCC GAA GAG TAC GCA AAA GTG 780
 Tyr Ser Met Thr Gly Trp Arg Ile Gly Tyr Val Ala Cys Pro Glu Glu Tyr Ala Lys Val
 781 ATA GCG ACT CTT AAC AGC CAG ACT GTT TCC AAC GTC ACT ACC TTT GCC CAG TAT GGA GCT 840
 Ile Ala Ser Leu Asn Ser Gln Ser Val Ser Asn Val Thr Thr Phe Ala Gln Tyr Gly Ala
 841 CTT GAG GCC TTG AAA AAT CCA AAG TCT AAA GAT TTT GTA AAC GAA ATG AGA AAT GCT TTT 900
 Leu Glu Ala Leu Lys Asn Pro Lys Ser Lys Asp Phe Val Asn Glu Met Arg Asn Ala Phe
 901 GAA AGG AGA AGG GAT AGC GCT GTA GAA GAG CTT TCT AAA ATT CCA GGT ATG GAT GTG GTA 960
 Glu Arg Arg Asp Thr Ala Val Glu Glu Leu Ser Lys Ile Pro Gly Met Asp Val Val
 961 AAA CCC GAA GGT GCC TTT TAC ATA TTT CCG GAC TTC TCC GCT TAC GCT GAG AAA CTG GGT 1020
 Lys Pro Glu Gly Ala Phe Tyr Ile Phe Pro Asp Phe Ser Ala Tyr Ala Glu Lys Leu Glu
 1021 GGT GAT GTG AAA CTC TCG GAG TTC CTT CTG GAA AAG GCT AAG GTT GCG GTG GTT CCC GGT 1080
 Gly Asp Val Lys Leu Ser Glu Phe Leu Glu Lys Ala Lys Val Ala Val Val Pro Gly
 1081 TCG GCC TTC GGA GCT CCC GGA TTT TTG AGG CTT TCT TAC GCC CTT TCC GAG GAA AGA CTC 1140
 Ser Ala Phe Gly Ala Pro Gly Phe Leu Arg Leu Ser Tyr Ala Leu Ser Glu Glu Arg Leu
 1141 GTT GAG GGT ATA AGG AGA ATA AAG AAA GCC CTT GAA GAG ATC TAA 1185
 Val Glu Gly Ile Arg Arg Ile Lys Lys Ala Leu Glu Glu Ile End

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/01094

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12N 9/10

US CL : 435/193

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/193; 536/23.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

aps,capplus, biosis, embase
search terms: aminotransferase or transaminase, aquifex, ammonifex, pyrobaculum

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WETMUR et al. Cloning, sequencing, and expression of RecA proteins from three distantly related thermophilic eubacteria. J. Biol. Chem. 14 October 1994, Vol. 269, No. 41, pages 25928-25935.	1-20
A	BROWN et al. Root of the universal tree of life based on ancient aminoacyl-tRNA synthetase gene duplications. Proc. Natl. Acad. Sci., USA. March 1995, Vol. 92, No. 7, pages 2441-2445.	1-20
A	VOLKL et al. Genomic and cDNA sequence tags of the hyperthermophilic archaeon Pyrobaculum aerophilum. Nucleic Acids Res. 1996, Vol. 24, No. 22, 4373-4378.	1-20

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

17 MARCH 1997

Date of mailing of the international search report

04 APR 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

ELIZABETH SLOBODYANSKY

Facsimile No. (703) 305-3230

Telephone No. 3080196

Jab
fcv